Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-12-347793.txt : 20120809 0001193125-12-347793.hdr.sgml : 20120809 20120809165008 ACCESSION NUMBER: 0001193125-12-347793 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20120630 FILED AS OF DATE: 20120809 DATE AS OF CHANGE: 20120809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NABI BIOPHARMACEUTICALS CENTRAL INDEX KEY: 0000072444 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 591212264 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35285 FILM NUMBER: 121021027 BUSINESS ADDRESS: STREET 1: 12270 WILKINS AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20852 BUSINESS PHONE: 301-770-3099 MAIL ADDRESS: STREET 1: 12270 WILKINS AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20852 FORMER COMPANY: FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS DATE OF NAME CHANGE: 20020304 FORMER COMPANY: FORMER CONFORMED NAME: NABI /DE/ DATE OF NAME CHANGE: 19960405 FORMER COMPANY: FORMER CONFORMED NAME: NORTH AMERICAN BIOLOGICALS INC DATE OF NAME CHANGE: 19920703 10-Q 1 d351633d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2012

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 000-04829

Nabi Biopharmaceuticals

(Exact name of registrant as specified in its charter)

Delaware

59-1212264

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

12270 Wilkins Avenue, Rockville, MD 20852

(Address of principal executive offices, including zip code)

(301) 770-3099

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer, large accelerated filer” and “small reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares outstanding of the registrant’s common stock, par value $.10 per share, at August 3, 2012, was 28,328,389 shares.

Nabi Biopharmaceuticals

INDEX


		Page No.
PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements		3
	- Condensed Consolidated Balance Sheets as of June 30, 2012, and December 31, 2011		3
	- Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2012, and June 25, 2011		4
	- Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2012, and June 25, 2011		5
	- Notes to Condensed Consolidated Financial Statements		6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		18
Item 4.	Controls and Procedures		18

PART II.	OTHER INFORMATION		18
Item 1.	Legal Proceedings		18
Item 6.	Exhibits		18
	Signatures		19
	Exhibit Index		20
	Certifications		21

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Nabi Biopharmaceuticals

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands)


	June 30, 2012			December 31, 2011
ASSETS
Current assets:
Cash and cash equivalents	$	92,649		$	94,310
Marketable securities		—			2,079
Receivables		—			995
Prepaid expenses and other current assets		301			497

Total current assets		92,950			97,881
Property and equipment, net		—			84

Total assets	$	92,950		$	97,965

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	75		$	146
Accrued expenses and other current liabilities		1,435			1,918
Deferred revenue		2,526			2,526
Liabilities of discontinued operations		—			1,662

Total current liabilities		4,036			6,252
Deferred revenue		31,579			32,842

Total liabilities		35,615			39,094

Stockholders’ equity:
Convertible preferred stock		—			—
Common stock		6,357			6,359
Capital in excess of par value		374,792			373,157
Treasury stock		(92,567	)		(92,567	)
Accumulated deficit		(231,247	)		(228,078	)

Total stockholders’ equity		57,335			58,871

Total liabilities and stockholders’ equity	$	92,950		$	97,965

See accompanying notes to condensed consolidated financial statements.

Nabi Biopharmaceuticals

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share amounts)


	For the Three Months Ended						For the Six Months Ended
	June 30,			June 25,			June 30,			June 25,
	2012			2011			2012			2011
Revenue:
Revenue	$	631		$	3,744		$	1,263		$	12,917
Operating expenses:
Cost of services		—			549			—			1,174
Research and development expenses		1,330			6,456			2,848			11,791
General and administrative expenses		2,176			1,426			3,453			2,768

Total operating costs		3,506			8,431			6,301			15,733

Operating loss		(2,875	)		(4,687	)		(5,038	)		(2,816	)
Interest income		33			50			65			122
Other income (expense), net		109			38			142			75

Loss from continuing operations before income taxes		(2,733	)		(4,599	)		(4,831	)		(2,619	)
Benefit from income taxes		—			—			671			—

Loss from continuing operations		(2,733	)		(4,599	)		(4,160	)		(2,619	)
Income from discontinued operations, net of tax provision		—			—			991			—

Net loss	$	(2,733	)	$	(4,599	)	$	(3,169	)	$	(2,619	)

Basic income (loss) per share:
Continuing operations	$	(0.06	)	$	(0.11	)	$	(0.10	)	$	(0.06	)
Discontinued operations	$	—		$	—		$	0.02		$	—
Diluted income (loss) per share:
Continuing operations	$	(0.06	)	$	(0.11	)	$	(0.10	)	$	(0.06	)
Discontinued operations	$	—		$	—		$	0.02		$	—
Basic weighted-average shares outstanding		42,664			42,307			42,578			42,221

Diluted weighted-average shares outstanding		42,664			42,307			42,578			42,221

See accompanying notes to condensed consolidated financial statements.

Nabi Biopharmaceuticals

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)


	For the Six Months Ended
	June 30,			June 25,
	2012			2011
Cash flow from operating activities:
Net loss	$	(3,169	)	$	(2,619	)
Income from discontinued operations, net of tax provision		991			—

Net loss from continuing operations		(4,160	)		(2,619	)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities from continuing operations:
Depreciation and amortization		34			110
Non-cash intra-period tax allocation		(671	)		—
Share-based compensation		1,634			1,215
Loss on sale of property and equipment		—			29
Changes in assets and liabilities:
Receivables		995			304
Prepaid expenses and other assets		196			(417	)
Accounts payable, accrued expenses and other liabilities		(505	)		(1,119	)
Deferred revenue		(1,263	)		(6,534	)

Net cash used in operating activities		(3,740	)		(9,031	)

Cash flow from investing activities:
Proceeds from sales and maturities of marketable securities		2,079			52,035
Purchases of marketable securities		—			(10,632	)
Proceeds from sales of property and equipment		—			158
Capital expenditures		—			(1	)

Net cash provided by investing activities		2,079			41,560

Cash flow from financing activities:
Proceeds from issuances of common stock for employee benefit plans		—			525

Net cash provided by financing activities		—			525

Net increase (decrease) in cash and cash equivalents		(1,661	)		33,054
Cash and cash equivalents at beginning of period		94,310			53,564

Cash and cash equivalents at end of period	$	92,649		$	86,618

See accompanying notes to condensed consolidated financial statements.

Nabi Biopharmaceuticals

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 COMPANY OVERVIEW

We are a biopharmaceutical company that has focused on the development of vaccines addressing unmet medical needs, including nicotine addiction. We have been incorporated in Delaware since 1969 and our operations are located in Rockville, Maryland. Our sole remaining product currently in development is NicVAX^® [Nicotine Conjugate Vaccine], an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. We suffered a significant setback in 2011 when NicVAX did not achieve the primary endpoint in two Phase III efficacy trials conducted in the U.S. The only remaining trial of NicVAX is the Phase IIb trial in combination with Pfizer’s varenicline being conducted in the Netherlands. If the results of the remaining trial, which are expected before year-end 2012, are positive, we believe the potential residual value of NicVAX will be enhanced. As of June 30, 2012, our remaining assets include the following: (i) $92.6 million of cash and cash equivalents, (ii) the potential residual value of NicVAX as well as any next-generation nicotine vaccine which was licensed to GlaxoSmithKline Biologicals S.A. (GSK) in 2010, (iii) the potential royalty from Phoslyra which was sold to Fresenius USA Manufacturing, Inc. (Fresenius) in 2006, and (iv) the potential value of our net operating losses (NOLs).

Merger Agreement with Biota Holdings Limited. On April 22, 2012, we entered into a merger implementation agreement (Merger Agreement) with Biota Holdings Limited, a Melbourne, Australia company (Biota), pursuant to which, among other things, Nabi and Biota will undertake a business combination under Australian corporate law such that each ordinary share of Biota capital stock will be exchanged for newly issued shares of Nabi common stock, and Biota will become a wholly-owned subsidiary of Nabi (the Merger). In connection with the Merger, Nabi will change its name to “Biota Pharmaceuticals, Inc.” but will remain listed on the NASDAQ Stock Market as its sole stock exchange listing and be headquartered in the United States.

Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger:

•

Each Biota share outstanding immediately prior to the effective time will be transferred to Nabi in exchange for 0.669212231 Nabi shares (as such amount may be adjusted pursuant to the terms of the Merger Agreement, including an adjustment for the shares purchased pursuant to the tender offer that we just completed). Immediately after the closing of the Merger, the Nabi shares issued to former Biota stockholders will represent approximately 74% of Nabi’s outstanding common stock, and the shares of common stock held by current Nabi stockholders will represent approximately 26% of Nabi’s outstanding common stock;

•

The board of directors of Nabi will consist of six Biota directors and two Nabi directors; and

•

Biota’s current Chief Executive Officer and Chief Financial Officer are expected to serve as the Chief Executive Officer and Chief Financial Officer, respectively, of Nabi until the appointment of a new U.S.-based management team.

Prior to the closing of the Merger Agreement, subject to the terms and conditions of the Merger Agreement:

•

Nabi intends to return to Nabi’s stockholders excess cash above $54 million (which is required to be delivered to the combined company), after satisfying and reserving for outstanding liabilities, through a dividend, return of capital or repurchase of outstanding Nabi shares through an issuer tender offer approved by the Board of Directors of Nabi, or a combination thereof. We currently estimate the amount of cash to be returned to Nabi stockholders to be in the range of $25 to $29 million, including the $ 24.4 million that we paid to stockholders who tendered their shares to us in our recently completed tender offer on July 30, 2012; and

•

Nabi plans to distribute to its stockholders contingent value rights providing certain payment rights arising from cash received by Nabi from a future sale, transfer, license or similar transaction involving our NicVAX program assets.

Consummation of the Merger is subject to customary conditions for a business combination of this type under Australian and Delaware corporate law, including, among others, (i) approval of the Merger by the stockholders of Biota in accordance with applicable Australian law, (ii) the affirmative vote of the holders of a majority of the issued and outstanding Nabi shares at a meeting of stockholders approving amendments to the certificate of incorporation of Nabi to (a) increase the number of authorized Nabi Shares to 200,000,000, principally to allow for the issuance of additional Nabi Shares to pay the Merger consideration, and (b) change the name of Nabi to “Biota Pharmaceuticals, Inc.,” and (iii) the affirmative vote of the holders of a majority of the votes cast at the Nabi stockholder meeting approving issuance of new Nabi shares to Biota stockholders in the Merger, as required by the rules of the NASDAQ Stock Market.

Each party’s obligation to consummate the Merger is subject to certain other conditions, including approval of the Merger by the Supreme Court of Victoria, Australia, the expiration or early termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and certain other competition laws, the absence of any injunction, restraint or governmental restriction making illegal or restraining the consummation of the transactions contemplated by the Merger Agreement, the accuracy of the other party’s representations and warranties contained in the Merger Agreement that are qualified as to materiality, the accuracy in all material respects of the other party’s representations and warranties contained in the Merger Agreement that are not qualified as to materiality, the other party’s performance in all material respects of all obligations to be performed by it under the Merger Agreement, and the absence of any effect, event, occurrence or matter that has had or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the other party of the nature specified in the Merger Agreement. In addition, Biota’s obligation to consummate the Merger is subject to receiving a certificate from Nabi showing that Nabi has a closing net cash balance of no less than $54 million, calculated in accordance with the terms of the Merger Agreement, and the appointment of specified Biota directors to the Nabi board of directors effective as of the closing of the Merger. The parties expect to close the Merger in the third quarter of 2012 subject to satisfaction of these and other closing conditions.

Tender Offer. On July 30, 2012 we completed a “modified Dutch auction” tender offer for our common stock at a price per share not less than $1.58 and not greater than $1.72 and purchased 14,547,996 shares of our common stock for approximately $24.4 million at an average costs per share of approximately $1.68. We funded the share purchases in the tender offer using available cash on hand.

In response to a preliminary proxy solicitation by Mangrove Partners indicating that they intend to oppose the merger with Biota, Nabi filed an 8-K in which our Board of Directors affirmed its belief that the Merger Agreement with Biota is in the best interest of shareholders.

NicVAX Agreement with GSK. In March 2010, we closed an exclusive worldwide option and licensing agreement with GSK for NicVAX as well as for the development of follow-on nicotine addiction vaccines. Upon closing, we received a $40 million initial payment. Under the terms of the agreement, we granted to GSK (i) an option to obtain an exclusive worldwide license to develop, commercialize and manufacture NicVAX as it currently exists, as well as certain potential alternative forms of NicVAX together with an adjuvant other than a GSK proprietary adjuvant and/or with different presentation, dosage or administration (NicVAX Alternatives), and (ii) an exclusive worldwide license to develop, commercialize and manufacture certain future generation candidate vaccines for the prevention or treatment of nicotine addiction based on our NicVAX intellectual property (other than NicVAX and NicVAX Alternatives). GSK has informed us that it does not intend to exercise the NicVAX option due to the failure of the Phase III trials to achieve their primary end points. However, GSK has not indicated that it has terminated the development of the future generation nicotine vaccine.

candidates. GSK also will pay us royalty payments on annual net sales of future generation candidates, beginning at 5% and potentially increasing on incremental sales to as high as 7%, with the increase depending on whether annual net sales of future generation candidates meet or exceed specified annual sales targets in any calendar year ranging from $300 million to $600 million. The probability of us receiving future contingent milestones or royalties is uncertain as it is based on the achievement of various success-based development and regulatory approvals contingent upon the occurrence of various future events, the occurrence of most of which have a high degree of uncertainty.

PentaStaph Sale to GSK. In November 2009, we sold our PentaStaph product candidate and related assets to GSK under an Asset Purchase Agreement for a total consideration of $46 million including a $20 million up-front payment and $26 million payable upon achievement of certain milestones, all of which we have received. We completed our work to help develop PentaStaph under contract with GSK during the second quarter of 2011.

PhosLo. In 2006, we sold certain assets related to our PhosLo operations to Fresenius. Under the sale agreement, we are entitled to additional contingent milestone payments of $2.5 million upon approval of a new indication for PhosLo and royalties of up to $65.0 million on annual sales of Phoslyra, a new formulation of PhosLo, over a base amount of $32 million for 10 years after the November 14, 2006 closing date. To date, annual sales of Phoslyra have not exceeded the base amount, and we have not recognized any royalty revenue from those sales.

NOTE 2 BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2011, has been derived from audited consolidated financial statements as of that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission.

Principles of consolidation: The condensed consolidated financial statements include the accounts of Nabi Biopharmaceuticals and our wholly-owned subsidiaries (referred to as “Nabi,” the “Company,” “us,” or “we” throughout this report). All significant inter-company accounts and transactions are eliminated in consolidation. All of our wholly-owned subsidiaries are dormant or are otherwise non-operative.

Accounting estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period, including such amounts related to discontinued operations. Actual results could differ from those estimates.

Fiscal year periods: Historically, our fiscal year ended on the last Saturday of December. Consequently, we periodically had a 53-week fiscal year. In 2012, we amended our By-Laws to change our fiscal year end to a calendar basis; this prospective change did not have a material impact on our financial condition and results of operations for any periods presented.

Financial instruments: The carrying amounts of financial instruments including cash equivalents, marketable securities, accounts receivable and accounts payable approximated fair value as of June 30, 2012 and December 31, 2011, because of the relatively short-term maturity of these instruments.

Cash, cash equivalents and marketable securities: Cash equivalents consist of investments in low risk, highly liquid securities with original maturities of 90 days or less. Marketable securities consist of low risk fixed income investment instruments such as government obligations, government agency and Federal Deposit Insurance Corporation backed notes with maturities typically less than eighteen months. Marketable securities are classified as available-for-sale and recorded at fair value; unrealized gains and losses on those securities are reflected in other comprehensive income (loss). We assess the risk of impairment related to securities held in our investment portfolio on a regular basis and noted no “permanent” or “other than temporary” impairment during the first six months of 2012. Our investment policies and procedures are reviewed periodically by management and our audit committee to minimize credit risk.

Concentration of credit risk: Financial instruments that potentially subject us to credit and liquidity risk consist primarily of cash, marketable securities and receivables. The Company maintains cash deposits at major financial institutions with high credit quality. The Company’s operating accounts exceeded the Federal Deposit Insurance Corporation limits of $250,000. Cash equivalents primarily consist of short-term money market funds, which are deposited with reputable financial institutions. At June 30, 2012, the Company’s marketable investments consist primarily of United States government agency securities as well as corporate debt securities and commercial paper. The Company’s investment policy limits investments to only investment-grade securities with the objective to preserve principal and maintain sufficient liquidity to meet operational objectives.

Revenue recognition: Our revenue generating arrangements may include multiple elements and deliverables, including licenses, options, research and development activities, participation on joint steering committees and contract manufacturing, among other elements. When we determine that an element has stand-alone value to our customer, we allocate a portion of the total contract price to that element based on its relative selling price, determined pursuant to a selling price hierarchy, and recognize revenue for that element according to its characteristics. Revenue consists of license fees, milestone payments, and payments for contractual services.

License fees received that do not have stand-alone value are initially recorded as deferred revenue, and are subsequently recognized as revenue ratably over the period of our participation on joint steering committees. The joint steering committee established in connection with our option and license agreement with GSK related to NicVAX is currently expected to operate for 190 months from the date of the agreement (or through December 2025). Our efforts under the joint steering committee established in connection with our asset purchase agreement with GSK related to PentaStaph were completed in the second quarter of 2011.

For milestones that are deemed substantive, we recognize the contingent revenue when: (i) the milestones have been achieved; (ii) no further performance obligations with respect to the milestones exist; and (iii) collection is reasonably assured. A milestone is considered substantive if all of the following conditions are met: (i) the milestone is nonrefundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone appears reasonable in relation to the effort expended with the other milestones in the arrangement and the related risk associated with achievement of the milestone. If a milestone is deemed not to be substantive, the Company would recognize the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment will be deferred and recognized as revenue as the Company completes its performance obligations.

Payments for contractual services are recognized as revenue when earned, typically when the services are rendered.

We analyze cost reimbursable grants and contracts to determine whether we should report such reimbursements as revenue or as an offset to research and development expenses incurred.

Collaborative arrangements: We are an active participant with exposure to significant risks and rewards of commercialization relating to the development of NicVAX and future generation nicotine vaccines based on NicVAX technology. For costs incurred and revenues generated from third parties where we are deemed to be the principal participant, we recognize revenues and costs using the gross basis of accounting; otherwise we use the net basis of accounting.

Research and development expenses: Research and development costs are expensed as incurred; advanced payments are deferred and subsequently expensed over the period of performance. Research and development expenses include direct labor costs as well as the costs of contractors and other direct and indirect expenses (including an allocation of the costs of facilities). We expense amounts payable to third parties under collaborative product development agreements at the earlier of the milestone achievement or as payments become contractually due. In the first six months of 2011 we recorded approximately $0.3 million of cost reimbursements from government grants as an offset to research and development expenses (none during 2012).

Income (loss) per share: Basic income (loss) per share is computed by dividing consolidated net income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of stock options. The dilutive impact of dilutive potential common shares resulting from stock options is determined by applying the treasury stock method. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the three- and six month periods ended June 30, 2012 and June 25, 2011. The Company’s unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator.

A total of approximately 3.7 million potentially dilutive shares related to stock options have been excluded in the calculation of diluted net loss per share for the three- and six month periods ended June 30, 2012 and a total of approximately 4.6 million potentially dilutive shares for the three- and six periods ended June 25, 2011, as their inclusion would be anti-dilutive.

Share-based compensation: We expense the estimated fair value of share-based awards made in exchange for employee services over the requisite employee service period. Share-based compensation cost for stock options is determined at the grant date using an option pricing model; share-based compensation cost for restricted stock is determined at the grant date based on the closing price of our common stock on that date. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period.

Income taxes: We account for income taxes using the asset and liability approach, which requires, among other things, recognition of future tax benefits and liabilities measured at enacted rates attributable to temporary differences between financial statement and income tax bases of assets and liabilities and to tax net operating loss carryforwards to the extent that realization of these benefits is more likely than not. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year. We periodically evaluate the realizability of our net deferred tax assets; a valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. We recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits, and our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. We consider discontinued operations for purposes of determining the amount of tax benefits that result from a loss from continuing operations.

Segment information: We currently operate in a single business segment.

Recent accounting standards: In June 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2011-05, Presentation of Comprehensive Income. ASU 2011-05 revises the manner in which entities present comprehensive income in their financial statements. The new guidance removes the presentation options in Accounting Standards Codification 220 and requires entities to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements. ASU 2011-05 did not change the items that must be reported in other comprehensive income. The Company adopted the provisions of ASU 2011-05 in the first quarter of 2012. As the Company’s net loss was the same as comprehensive loss, the Company did not include a statement of comprehensive loss.

New accounting pronouncements: We have evaluated all Accounting Standards Updates through the date the financial statements were issued and believe the adoption of these will not have a material impact to our results of operations or financial position.

NOTE 3 AVAILABLE FOR SALE INVESTMENTS

The amortized cost, gross unrealized gains and losses and estimated fair value of available-for-sale marketable securities by security classification as of December 31, 2011 (none at June 30, 2012), were as follows:


December 31, 2011 (In thousands)	Amortized Costs		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Values
Government-sponsored securities	$	993	$	—	$	—	$	993
Corporate debt securities		1,086		—		—		1,086

Total securities	$	2,079	$	—	$	—	$	2,079

During the six months ended June 30, 2012 and June 25, 2011 we had no realized gains (losses) on sales of available-for-sale marketable securities. Gains and losses on available-for-sale marketable securities are based on the specific identification method. The contractual maturities of all of our available-for-sale investments as of December 31, 2011 were less than 12 months.

NOTE 4 DISCONTINUED OPERATIONS

During 2006, we assessed our pricing programs under Medicare/Medicaid and other governmental pricing programs for the period from 2002 through the second quarter of 2006. In connection with the 2006 review, we identified additional liabilities related to discontinued operations for possible overbilling under Medicare/Medicaid and other governmental pricing programs. The estimated liability related to these programs was approximately $1.7 million at December 31, 2011. In the first quarter 2012, we undertook an assessment of the remaining liabilities and concluded that these remaining liabilities should be eliminated after determining that any remaining obligations related to the programs were not material.

NOTE 5 INCOME TAXES

We file income tax returns in the U.S., with various states and foreign jurisdictions, and are subject to tax audits in all jurisdictions for which we file tax returns. Tax audits by their very nature are often complex and can require several years to complete. As of June 30, 2012, we recorded a valuation allowance against all of our deferred tax assets.

Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. We establish accruals for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These accruals are established when we believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjust these accruals in light of changing facts and circumstances, such as the outcome of a tax audit.

Under the tax statute of limitations applicable to the Internal Revenue Code, we are no longer subject to U.S. federal income tax examinations by the Internal Revenue Service for years before 2005. However, because we are carrying forward income tax attributes, such as net operating losses and tax credits from 2002 and earlier tax years, these attributes can still be audited when used on returns filed in the future. Under the statutes of limitation applicable to most state income tax laws, we are no longer subject to state income tax examinations by tax authorities for years before 2005 in states in which we have filed income tax returns. Certain states may take the position that we are subject to income tax in such states even though we have not filed income tax returns in such states and, depending on the varying state income tax statutes and administrative practices, the statute of limitations in such states may extend to years before 2005. We are subject to foreign tax examinations by tax authorities for all years of operation.

NOTE 6 FAIR VALUE DISCLOSURES

We follow a three-tier fair value hierarchy which prioritizes the inputs used in measuring the fair value of our assets and liabilities. These tiers include (i) Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; (ii) Level 2, defined as observable inputs other than Level 1 prices such as quoted prices for similar assets, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and (iii) Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. All cash and cash equivalents, as well as available-for-sale marketable securities, are recorded at fair value at June 30, 2012 and December 31, 2011. The inputs used in measuring the fair value of these instruments are considered to be Level 1 and Level 2 in accordance with the three-tier fair value hierarchy.

The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy and the fair values are based on period-end statements supplied by the various banks and brokers. The majority of our funds were deposited in institutional money market mutual funds with the remainder held in regular interest bearing and non-interest bearing depository accounts with commercial banks.

The inputs used in measuring the fair value of our available-for-sale marketable securities at December 31, 2011 (none at June 30, 2012) are considered to be Level 2 in accordance with the three-tier fair value hierarchy. These securities are valued using a multi-dimensional pricing model that includes a variety of inputs, including quoted prices for similar assets and liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. To assess the fair value of these securities, we obtain fair values from an independent third-party valuation service provider. As we are responsible for the determination of fair value, we review the values provided by the independent third-party valuation service provider for reasonableness, which could include reviewing other publicly available information.


December 31, 2011			Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In thousands)	Total		Level 1		Level 2		Level 3
Government-sponsored securities	$	993	$	—	$	993	$	—
Corporate debt securities		1,086		721		365		—

Total	$	2,079	$	721	$	1,358	$	—

NOTE 7 TREASURY STOCK

On July 30, 2012 we completed a “modified Dutch auction” tender offer for our common stock at a price per share not less than $1.58 and not greater than $1.72, and purchased 14,547,996 shares of our common stock for approximately $24.4 million at an average cost per share of approximately $1.68.

NOTE 8 SHARE BASED COMPENSATION

A summary of option activity under our stock compensation plans as of June 30, 2012, and the changes during the first six months of 2012 is presented below:


Options	Number of Options
Outstanding at December 31, 2011		4,053,652
Granted		1,000
Exercised		—
Forfeited		(64,198	)
Expired		(325,253	)

Outstanding at June 30, 2012		3,665,201

Exercisable at June 30, 2012		3,121,084

We granted options to purchase 1,000 shares at an exercise price of $1.89 during the first six months of 2012, with an average fair value at the date of grant of $0.96. The grant becomes exercisable between one and three years after the date of grant. We estimate the fair value of each stock option on the date of grant using the Black-Scholes option-pricing formula and amortize expense over the option’s vesting period using the straight-line attribution approach.

A summary of our restricted stock awards as of June 30, 2012 and the changes during the first six months of 2012 is presented below:


Awards	Number of Awards
Nonvested at December 31, 2011		405,977
Granted		—
Vested		(193,503	)
Forfeited		(16,220	)

Nonvested at June 30, 2012		196,254

Share-based compensation expense for the three months ended June 30, 2012 and June 25, 2011 was $0.7 million and $0.6 million, respectively. Share-based compensation expense for the six months ended June 30, 2012 and June 25, 2011 was $1.6 million and $1.2 million, respectively.

NOTE 9 LICENSES AND ROYALTY ARRANGEMENTS

We have entered into licenses and royalty agreements for our products in development.

PentaStaph: In November 2009, we sold our PentaStaph product candidate and related assets to GSK under an Asset Purchase Agreement for a total consideration of $46 million including a $20 million up-front payment and $26 million payable upon achievement of certain milestones, all of which we have received. We completed our work to help develop PentaStaph under contract with GSK during the second quarter of 2011.

NicVAX: In March 2010, we closed an exclusive worldwide option and licensing agreement with GSK for NicVAX as well as for the development of follow-on nicotine addiction vaccines. Upon closing, we received a $40 million initial payment. Under the terms of the agreement, we granted to GSK (i) an option to obtain an exclusive worldwide license to develop, commercialize and manufacture NicVAX as it currently exists, as well as certain potential alternative forms of NicVAX together with an adjuvant other than a GSK proprietary adjuvant and/or with different presentation, dosage or administration (NicVAX Alternatives), and (ii) an exclusive worldwide license to develop, commercialize and manufacture certain future generation candidate vaccines for the prevention or treatment of nicotine addiction based on our NicVAX intellectual property (other than NicVAX and NicVAX Alternatives).

GSK has informed us that it does not intend to exercise the NicVAX option due to the failure of the Phase III trials to achieve their primary end points. However, GSK has not indicated that it terminated the development of the future generation nicotine vaccine.

Notwithstanding the failure to achieve the primary endpoint in our two Phase III trials, if the future generation nicotine vaccine being developed by GSK is successful, GSK will pay us up to $290 million in contingent milestone payments as follows: (i) up to $47 million based on Phase II and Phase III clinical trial-related milestones, (ii) up to $34 million based on obtaining regulatory approval in certain major market countries, and (iii) up to a total of $209 million based on tiered annual sales of future generation candidates. GSK also will pay us royalty payments on annual net sales of future generation candidates, beginning at 5% and potentially increasing on incremental sales to as high as 7%, with the increase depending on whether annual net sales of future generation candidates meet or exceed specified annual sales targets in any calendar year ranging from $300 million to $600 million. We believe all future milestones under the NicVAX agreement to be substantive as they are at risk until achieved. The probability of us receiving future contingent milestones or royalties is uncertain as it is based on the achievement of various success-based development and regulatory approvals contingent upon the occurrence of various future events, the occurrence of most of which have a high degree of uncertainty of occurring.

Revenue under the NicVAX agreement consists of license fees, milestone payments, and payments for contractual services. License fees received are initially recorded as deferred revenue, and are subsequently recognized as revenue ratably over the period of our participation on joint steering committees. The joint steering committee related to the NicVAX agreement is currently expected to operate for 190 months from the date of the agreement (or through December 2025).

NOTE 10 NOL RIGHTS AGREEMENT

On August 25, 2011, our Board of Directors adopted a stockholder Rights Agreement with American Stock Transfer & Trust Company, LLC, as rights agent, in an effort to prevent an "ownership change" under Section 382 from occurring and thereby protect the value of our net operating losses. Under the Rights Agreement, the Board of Directors declared a non-taxable dividend of one preferred share purchase right for each outstanding share of common stock to be distributed to stockholders of record on August 25, 2011. Concurrent with the signing of the Merger Agreement with Biota, Nabi and the rights agent amended the Rights Agreement to terminate the rights under the Rights Agreement.

NOTE 11 COMMITMENTS AND CONTINGENCIES

We have agreements with our employees that include certain cash payments and equity-based award modifications in the event of a termination of employment or a change in control of the Company.

We are parties to legal proceedings that we believe to be ordinary, routine litigation incidental to the business of present or former operations. It is management’s opinion, based on the advice of counsel, that the ultimate resolution of such litigation will not have a material adverse effect on our financial condition, results of operations or cash flows.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD LOOKING STATEMENTS

Statements in this quarterly report that are not strictly historical are forward-looking statements and include statements about potential strategic transactions, products in development, results and analyses of clinical trials and studies, research and development expenses, cash expenditures, licensure applications and approvals, alliances and partnerships, among other matters. You can identify these forward-looking statements because they involve our expectations, intentions, beliefs, plans, projections, anticipations, or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to successfully complete the proposed merger between Nabi and Biota or any other strategic transaction; realize any value for NicVAX in light of our two failed Phase III clinical trials; obtain a successful result in a remaining clinical trial for NicVAX or realize any value from a successful result; have GSK successfully develop and commercialize any future generation candidate nicotine vaccine; terminate existing NicVAX contract manufacturing and development agreements without significant penalties; collect any further milestones and royalty payments under the PhosLo agreement; maintain sufficient patent protection; avoid products liability claims; maintain sufficient insurance; and use our net operating loss carry forwards. Some of these factors are more fully discussed, as are other factors, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission, as amended by our Quarterly Report of Form 10-Q for the quarter ended March 31, 2012 filed with the Securities Exchange Commission. We do not undertake to update any of these forward-looking statements or to announce the results of any revisions to these forward-looking statements except as required by law.

The following is a discussion and analysis of the major factors contributing to our financial condition and results of operations for the three and six months ended June 30, 2012 and June 25, 2011. The discussion and analysis should be read in conjunction with the condensed consolidated financial statements and notes thereto.

OVERVIEW

Our sole remaining product currently in development is NicVAX^® [Nicotine Conjugate Vaccine], an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. We suffered a significant setback in 2011 when NicVAX did not achieve the primary endpoint in two Phase III efficacy trials conducted in the U.S. The only remaining trial of NicVAX is the Phase IIb trial in combination with Pfizer’s varenicline being conducted in the Netherlands. If the results of the remaining trial, which are expected before year-end 2012, are positive, we believe the potential residual value of NicVAX will be enhanced. As of June 30, 2012, our remaining assets include the following: (i) $92.6 million of cash and cash equivalents, (ii) the potential residual value of NicVAX as well as any next-generation nicotine vaccine which was licensed to GlaxoSmithKline Biologicals S.A. (GSK) in 2010, (iii) the potential royalty from Phoslyra which was sold to Fresenius USA Manufacturing, Inc. (Fresenius) in 2006, and (iv) the potential value of our net operating losses (NOLs).

Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger:

•

The board of directors of Nabi will consist of six Biota directors and two Nabi directors; and

•

Prior to the closing of the Merger Agreement, subject to the terms and conditions of the Merger Agreement:

•

Nabi intends to return to Nabi’s stockholders excess cash above $54 million (which is required to be delivered to the combined company), after satisfying and reserving for outstanding liabilities, through a dividend, return of capital or repurchase of outstanding Nabi shares through an issuer tender offer approved by the Board of Directors of Nabi, or a combination thereof. We currently estimate the amount of cash to be returned to Nabi stockholders to be in the range of $25 to $29 million, including the $24.4 million that we paid to stockholders who tendered their shares to us in our recently completed tender offer on July 30, 2012; and

•

to 200,000,000, principally to allow for the issuance of additional Nabi Shares to pay the Merger consideration, and (b) change the name of Nabi to “Biota Pharmaceuticals, Inc.” , and (iii) the affirmative vote of the holders of a majority of the votes cast at the Nabi stockholer meeting approving issuance of new Nabi shares to Biota stockholders in the Merger, as required by the rules of the NASDAQ Stock Market.

Tender Offer. On July 30, 2012 we completed a “modified Dutch auction” tender offer for our common stock at a price per share not less than $1.58 and not greater than $1.72 and purchased 14,547,996 shares of our common stock for approximately $ 24.4 million at an average cost per share of approximately $1.68. We funded the share purchases in the tender offer using available cash on hand.

The probability of us receiving future contingent milestones or royalties is uncertain as it is based on the achievement of various success-based development and regulatory approvals contingent upon the occurrence of various future events, the occurrence of most of which have a high degree of uncertainty.

FOR THE THREE MONTHS ENDED JUNE 30, 2012 AND JUNE 25, 2011

Revenue. Revenue reflects (i) the amortization of the initial upfront payment received under our PentaStaph and NicVAX agreements, (ii) the completion of substantive milestones included in those agreements, and (iii) services provided to GSK. Total revenue in the second quarter of 2012 of $0.6 million related solely to amortization of the initial upfront payment under our NicVAX agreement. Total revenue in the second quarter of 2011 of $3.7 million included $3.2 million of deferred revenue amortization from the PentaStaph and NicVAX agreements, and $0.5 million for services under the PentaStaph and NicVAX agreements. The decrease in revenue from 2011 to 2012 reflects the completion of activity under the PentaStaph agreement as well as completion of services provided to GSK.

Cost of services. We had no cost of services for the second quarter of 2012 compared to $0.5 million for the second quarter of 2011, all of which was related to services provided to GSK. All such services were completed in 2011.

Research and development expenses. Research and development expenses were $1.3 million and $6.5 million for the second quarter of 2012 and 2011, respectively. The decrease is due to a reduction in NicVAX-related clinical trials and manufacturing activities in 2012 as compared to 2011, as all but one trial was completed in 2011. Research and development expenses, prior to the completion of the proposed Merger, are expected to continue at current levels.

General and administrative expenses. General and administrative expenses, net of an allocation of a portion of these expenses to cost of services, were $2.2 million for the second quarter of 2012 compared to $1.4 million for the second quarter of 2011. The increase is primarily due to legal and other transaction-related costs incurred in connection with the proposed Merger.

FOR THE SIX MONTHS ENDED JUNE 30, 2012 AND JUNE 25, 2011

Revenue. Revenue reflects (i) the amortization of the initial upfront payment received under our PentaStaph and NicVAX agreements, (ii) the completion of substantive milestones included in those agreements, and (iii) services provided to GSK. Total revenue in the second quarter of 2012 of $1.3 million related solely to amortization of the initial upfront payment under our NicVAX agreement. Total revenue in the second quarter of 2011 of $12.9 million included $6.5 million of deferred revenue amortization from the PentaStaph and NicVAX agreements, $5.0 million for a completed PentaStaph milestone, and $1.4 million for services under the PentaStaph and NicVAX agreements. The decrease in revenue from 2011 to 2012 reflects the completion of activity under the PentaStaph agreement as well as completion of services provided to GSK.

Cost of services. We had no cost of services in the first six months of 2012 compared to cost of services of $1.2 million for the first six months of 2011, all of which was related to services provided to GSK. All such services were completed in 2011.

Research and development expenses. Research and development expenses were $2.8 million for the first half of 2012, compared to $11.8 million for the first half of 2011. The decrease is due to a reduction in NicVAX-related clinical trials and manufacturing activities in 2012 as compared to 2011, as all but one trial was completed in 2011.

General and administrative expenses. General and administrative expenses, net of an allocation of a portion of these expenses to cost of services, were $3.5 million for the first half of 2012, compared to $2.8 million for the first half 2011. The increase is primarily due to legal and other transaction-related costs incurred in connection with the proposed Merger.

Income from Discontinued Operations. Income from discontinued operations for the first half of 2012 of approximately $1.7 million ($1.0 million net of provision for income taxes) resulted from the reduction of our estimated liabilities related to pricing programs under Medicare/Medicaid and other governmental pricing programs.

LIQUIDITY AND CAPITAL RESOURCES

Our cash, cash equivalents and marketable securities at June 30, 2012 totaled $92.6 million compared to $96.4 million on December 31, 2011. The decline is the result of our net cash used in operations during 2012.

Cash used in operating activities from continuing operations was $3.7 million and $9.0 million for the periods ended June 30, 2012 and June 25, 2011, respectively. The decrease in cash used is primarily due to reduced NicVAX-related clinical trials and manufacturing activities in 2012 as compared to 2011 and overall reduction in most operating costs.

We believe cash, cash equivalents and marketable securities on hand at June 30, 2012 will be sufficient to meet our anticipated cash requirements for operations for at least the next 12 months.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Note 2 to our condensed consolidated financial statements includes a discussion of our significant accounting policies. A summary of the more significant policies follows:

License fees received are initially recorded as deferred revenue, and are subsequently recognized as revenue ratably over the period of our participation on joint steering committees. The joint steering committee related to the NicVAX agreement is currently expected to operate for 190 months from the date of the agreement (or through December 2025). Our efforts under the joint steering committee related to the PentaStaph agreement were completed in the second quarter of 2011.

Payments for contractual services are recognized as revenue when earned, typically when the services are rendered.

We analyze cost reimbursable grants and contracts to determine whether we should report such reimbursements as revenue or as an offset to research and development expenses incurred.

Research and development expenses: Research and development costs are expensed as incurred; advanced payments are deferred and subsequently expensed over the period of performance. Research and development expenses include direct labor costs as well as the costs of contractors and other direct and indirect expenses (including an allocation of the costs of facilities). We expense amounts payable to third parties under collaborative product development agreements at the earlier of the milestone achievement or as payments become contractually due. In the second quarter 2011 we recorded approximately $0.3 million of cost reimbursements from government grants as an offset to research and development expenses (none in 2012).

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes to our market risk as described in Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2011.

Item 4. Controls and Procedures

Our Chief Executive Officer currently serves as acting Chief Financial Officer.

Evaluation of Disclosure Controls and Procedures

An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Accounting Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Accounting Officer concluded that these disclosure controls and procedures were effective.

Changes in Internal Controls Over Financial Reporting

There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met, and therefore, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. We do not expect that our disclosure controls and procedures or our internal control over financial reporting are able to prevent with certainty all errors and all fraud.

PART II OTHER INFORMATION

Item 1. Legal Proceedings

Item 6. Exhibits



31		Rule 13a-14(a)/15d-14(a) Certification.

32		Section 1350 Certification.

101*		The following materials from the Nabi Biopharmaceuticals Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2012 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets as of June 30, 2012 and December 31, 2011, (ii) the Condensed Consolidated Statement of Operations for the Three and Six Months Ended June 30, 2012 and June 25, 2011, (iii) the Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2012 and June 25,2011 and (iv) related notes.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Nabi Biopharmaceuticals

Date: August 9, 2012	By:	/s/ Raafat E.F. Fahim, Ph.D.

		Raafat E.F. Fahim, Ph.D.
		President, Chief Executive Officer and acting Chief Financial Officer

	By:	/s/ Ronald B. Kocak

		Ronald B. Kocak
		Corporate Controller and Chief Accounting Officer

EXHIBIT INDEX


Exhibit		Description

31		Rule 13a-14(a)/15d-14(a) Certification.

32		Section 1350 Certification.

101*		The following materials from the Nabi Biopharmaceuticals Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2012 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets as of June 30, 2012 and December 31, 2011, (ii) the Condensed Consolidated Statement of Operations for the Three and Six Months Ended June 30, 2012 and June 25, 2011, (iii) the Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2012 and June 25,2011 and (iv) related notes.

EX-31 2 d351633dex31.htm EX-31 EX-31

Exhibit 31

CERTIFICATIONS

Rule 13a-14(a)/15d-14(a) Certification

I, Raafat E.F. Fahim, Ph.D., certify that:

1.	I have reviewed this report on Form 10-Q of Nabi Biopharmaceuticals;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which could adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 9, 2012	By:	/s/ Raafat E.F. Fahim, Ph.D.
		Raafat E.F. Fahim, Ph.D.
		President, Chief Executive Officer and acting Chief Financial Officer

EX-32 3 d351633dex32.htm EX-32 EX-32

Exhibit 32

SECTION 1350 CERTIFICATION

The undersigned officer of Nabi Biopharmaceuticals, or the Company, hereby certifies that, as of the date of this statement, the Company’s report on Form 10-Q for the quarter ended June 30, 2012, or the Report, fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that, to the best of his knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of June 30, 2012 and the results of operations of the Company for the six months ended June 30, 2012.

The purpose of this certification is solely to comply with Title 18, Chapter 63, Section 1350 of the United States Code, as amended by Section 906 of the Sarbanes-Oxley Act of 2002. This statement is not “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Act or any other federal or state law or regulation.


Date: August 9, 2012	By:	/s/ Raafat E.F. Fahim, Ph.D.
		Raafat E.F. Fahim, Ph.D.
		President, Chief Executive Officer and acting Chief Financial Officer

EX-101.INS 4 nabi-20120630.xml XBRL INSTANCE DOCUMENT 0000072444 2011-12-01 2011-12-31 0000072444 us-gaap:PreferredStockMember 2012-01-01 2012-06-30 0000072444 2011-06-25 0000072444 2010-12-25 0000072444 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2012-06-30 0000072444 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2012-06-30 0000072444 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2012-06-30 0000072444 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2012-06-30 0000072444 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2012-06-30 0000072444 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2012-06-30 0000072444 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2011-12-31 0000072444 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2011-12-31 0000072444 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2011-12-31 0000072444 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2011-12-31 0000072444 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2011-12-31 0000072444 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2012-06-30 0000072444 us-gaap:CorporateDebtSecuritiesMember 2012-06-30 0000072444 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2011-12-31 0000072444 us-gaap:CorporateDebtSecuritiesMember 2011-12-31 0000072444 us-gaap:FairValueInputsLevel3Member 2012-06-30 0000072444 us-gaap:FairValueInputsLevel2Member 2012-06-30 0000072444 us-gaap:FairValueInputsLevel1Member 2012-06-30 0000072444 us-gaap:FairValueInputsLevel3Member 2011-12-31 0000072444 us-gaap:FairValueInputsLevel2Member 2011-12-31 0000072444 us-gaap:FairValueInputsLevel1Member 2011-12-31 0000072444 2012-04-01 2012-06-30 0000072444 2011-03-27 2011-06-25 0000072444 2011-01-01 2011-06-25 0000072444 us-gaap:MinimumMember 2012-07-31 0000072444 us-gaap:MaximumMember 2012-07-31 0000072444 nabi:NicvaxMember 2012-06-30 0000072444 2010-12-26 2011-06-25 0000072444 us-gaap:SubsidiariesMember 2012-06-30 0000072444 us-gaap:ParentMember 2012-06-30 0000072444 2011-12-31 0000072444 nabi:NicvaxMember 2010-03-01 2010-03-31 0000072444 2012-06-30 0000072444 nabi:NicvaxMember 2012-01-01 2012-06-30 0000072444 nabi:NicvaxMember nabi:DevelopNextGenerationMember 2012-01-01 2012-06-30 0000072444 nabi:PentastaphMember 2009-11-01 2009-11-30 0000072444 nabi:NicvaxMember us-gaap:MinimumMember 2012-01-01 2012-06-30 0000072444 nabi:NicvaxMember us-gaap:MaximumMember 2012-01-01 2012-06-30 0000072444 us-gaap:MinimumMember 2012-01-01 2012-06-30 0000072444 us-gaap:MaximumMember 2012-01-01 2012-06-30 0000072444 2012-07-01 2012-07-31 0000072444 nabi:PhosloMember 2006-01-01 2006-12-31 0000072444 2012-08-03 0000072444 2012-01-01 2012-06-30 iso4217:USD xbrli:shares xbrli:pure nabi:Clinical_trial xbrli:shares iso4217:USD

NOTE 1 COMPANY OVERVIEW We are a biopharmaceutical company that has focused on the development of vaccines addressing unmet medical needs, including nicotine addiction. We have been incorporated in Delaware since 1969 and our operations are located in Rockville, Maryland. Our sole remaining product currently in development is NicVAX ® [Nicotine Conjugate Vaccine], an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. We suffered a significant setback in 2011 when NicVAX did not achieve the primary endpoint in two Phase III efficacy trials conducted in the U.S. The only remaining trial of NicVAX is the Phase IIb trial in combination with Pfizer’s varenicline being conducted in the Netherlands. If the results of the remaining trial, which are expected before year-end 2012, are positive, we believe the potential residual value of NicVAX will be enhanced. As of June 30, 2012, our remaining assets include the following: (i) $92.6 million of cash and cash equivalents, (ii) the potential residual value of NicVAX as well as any next-generation nicotine vaccine which was licensed to GlaxoSmithKline Biologicals S.A. (GSK) in 2010, (iii) the potential royalty from Phoslyra which was sold to Fresenius USA Manufacturing, Inc. (Fresenius) in 2006, and (iv) the potential value of our net operating losses (NOLs). Merger Agreement with Biota Holdings Limited. On April 22, 2012, we entered into a merger implementation agreement (Merger Agreement) with Biota Holdings Limited, a Melbourne, Australia company (Biota), pursuant to which, among other things, Nabi and Biota will undertake a business combination under Australian corporate law such that each ordinary share of Biota capital stock will be exchanged for newly issued shares of Nabi common stock, and Biota will become a wholly-owned subsidiary of Nabi (the Merger). In connection with the Merger, Nabi will change its name to “Biota Pharmaceuticals, Inc.” but will remain listed on the NASDAQ Stock Market as its sole stock exchange listing and be headquartered in the United States. Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger:   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%"> </td> <td width="2%" valign="top" align="left">•</td> <td width="1%" valign="top"> </td> <td align="left" valign="top"> Each Biota share outstanding immediately prior to the effective time will be transferred to Nabi in exchange for 0.669212231 Nabi shares (as such amount may be adjusted pursuant to the terms of the Merger Agreement, including an adjustment for the shares purchased pursuant to the tender offer that we just completed). Immediately after the closing of the Merger, the Nabi shares issued to former Biota stockholders will represent approximately 74% of Nabi’s outstanding common stock, and the shares of common stock held by current Nabi stockholders will represent approximately 26% of Nabi’s outstanding common stock; </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%"> </td> <td width="2%" valign="top" align="left">•</td> <td width="1%" valign="top"> </td> <td align="left" valign="top"> The board of directors of Nabi will consist of six Biota directors and two Nabi directors; and </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%"> </td> <td width="2%" valign="top" align="left">•</td> <td width="1%" valign="top"> </td> <td align="left" valign="top"> Biota’s current Chief Executive Officer and Chief Financial Officer are expected to serve as the Chief Executive Officer and Chief Financial Officer, respectively, of Nabi until the appointment of a new U.S.-based management team. </td> </tr> </table> Prior to the closing of the Merger Agreement, subject to the terms and conditions of the Merger Agreement:   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%"> </td> <td width="2%" valign="top" align="left">•</td> <td width="1%" valign="top"> </td> <td align="left" valign="top"> Nabi intends to return to Nabi’s stockholders excess cash above $54 million (which is required to be delivered to the combined company), after satisfying and reserving for outstanding liabilities, through a dividend, return of capital or repurchase of outstanding Nabi shares through an issuer tender offer approved by the Board of Directors of Nabi, or a combination thereof. We currently estimate the amount of cash to be returned to Nabi stockholders to be in the range of $25 to $29 million, including the $ 24.4 million that we paid to stockholders who tendered their shares to us in our recently completed tender offer on July 30, 2012; and </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%"> </td> <td width="2%" valign="top" align="left">•</td> <td width="1%" valign="top"> </td> <td align="left" valign="top"> Nabi plans to distribute to its stockholders contingent value rights providing certain payment rights arising from cash received by Nabi from a future sale, transfer, license or similar transaction involving our NicVAX program assets. </td> </tr> </table>   Consummation of the Merger is subject to customary conditions for a business combination of this type under Australian and Delaware corporate law, including, among others, (i) approval of the Merger by the stockholders of Biota in accordance with applicable Australian law, (ii) the affirmative vote of the holders of a majority of the issued and outstanding Nabi shares at a meeting of stockholders approving amendments to the certificate of incorporation of Nabi to (a) increase the number of authorized Nabi Shares to 200,000,000, principally to allow for the issuance of additional Nabi Shares to pay the Merger consideration, and (b) change the name of Nabi to “Biota Pharmaceuticals, Inc.,” and (iii) the affirmative vote of the holders of a majority of the votes cast at the Nabi stockholder meeting approving issuance of new Nabi shares to Biota stockholders in the Merger, as required by the rules of the NASDAQ Stock Market. Each party’s obligation to consummate the Merger is subject to certain other conditions, including approval of the Merger by the Supreme Court of Victoria, Australia, the expiration or early termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and certain other competition laws, the absence of any injunction, restraint or governmental restriction making illegal or restraining the consummation of the transactions contemplated by the Merger Agreement, the accuracy of the other party’s representations and warranties contained in the Merger Agreement that are qualified as to materiality, the accuracy in all material respects of the other party’s representations and warranties contained in the Merger Agreement that are not qualified as to materiality, the other party’s performance in all material respects of all obligations to be performed by it under the Merger Agreement, and the absence of any effect, event, occurrence or matter that has had or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the other party of the nature specified in the Merger Agreement. In addition, Biota’s obligation to consummate the Merger is subject to receiving a certificate from Nabi showing that Nabi has a closing net cash balance of no less than $54 million, calculated in accordance with the terms of the Merger Agreement, and the appointment of specified Biota directors to the Nabi board of directors effective as of the closing of the Merger. The parties expect to close the Merger in the third quarter of 2012 subject to satisfaction of these and other closing conditions. Tender Offer. On July 30, 2012 we completed a “modified Dutch auction” tender offer for our common stock at a price per share not less than $1.58 and not greater than $1.72 and purchased 14,547,996 shares of our common stock for approximately $24.4 million at an average costs per share of approximately $1.68. We funded the share purchases in the tender offer using available cash on hand. In response to a preliminary proxy solicitation by Mangrove Partners indicating that they intend to oppose the merger with Biota, Nabi filed an 8-K in which our Board of Directors affirmed its belief that the Merger Agreement with Biota is in the best interest of shareholders. NicVAX Agreement with GSK. In March 2010, we closed an exclusive worldwide option and licensing agreement with GSK for NicVAX as well as for the development of follow-on nicotine addiction vaccines. Upon closing, we received a $40 million initial payment. Under the terms of the agreement, we granted to GSK (i) an option to obtain an exclusive worldwide license to develop, commercialize and manufacture NicVAX as it currently exists, as well as certain potential alternative forms of NicVAX together with an adjuvant other than a GSK proprietary adjuvant and/or with different presentation, dosage or administration (NicVAX Alternatives), and (ii) an exclusive worldwide license to develop, commercialize and manufacture certain future generation candidate vaccines for the prevention or treatment of nicotine addiction based on our NicVAX intellectual property (other than NicVAX and NicVAX Alternatives). GSK has informed us that it does not intend to exercise the NicVAX option due to the failure of the Phase III trials to achieve their primary end points. However, GSK has not indicated that it has terminated the development of the future generation nicotine vaccine. Notwithstanding the failure to achieve the primary endpoint in our two Phase III trials, if the future generation nicotine vaccine being developed by GSK is successful, GSK will pay us up to a total of $290 million in contingent milestone payments as follows: (i) up to $47 million based on Phase II and Phase III clinical trial-related milestones, (ii) up to $34 million based on obtaining regulatory approval in certain major market countries, and (iii) up to a total of $209 million based on tiered annual sales of future generation candidates. GSK also will pay us royalty payments on annual net sales of future generation candidates, beginning at 5% and potentially increasing on incremental sales to as high as 7%, with the increase depending on whether annual net sales of future generation candidates meet or exceed specified annual sales targets in any calendar year ranging from $300 million to $600 million. The probability of us receiving future contingent milestones or royalties is uncertain as it is based on the achievement of various success-based development and regulatory approvals contingent upon the occurrence of various future events, the occurrence of most of which have a high degree of uncertainty. PentaStaph Sale to GSK. In November 2009, we sold our PentaStaph product candidate and related assets to GSK under an Asset Purchase Agreement for a total consideration of $46 million including a $20 million up-front payment and $26 million payable upon achievement of certain milestones, all of which we have received. We completed our work to help develop PentaStaph under contract with GSK during the second quarter of 2011. PhosLo. In 2006, we sold certain assets related to our PhosLo operations to Fresenius. Under the sale agreement, we are entitled to additional contingent milestone payments of $2.5 million upon approval of a new indication for PhosLo and royalties of up to $65.0 million on annual sales of Phoslyra, a new formulation of PhosLo, over a base amount of $32 million for 10 years after the November 14, 2006 closing date. To date, annual sales of Phoslyra have not exceeded the base amount, and we have not recognized any royalty revenue from those sales.

NOTE 2 BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2011, has been derived from audited consolidated financial statements as of that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission. Principles of consolidation: The condensed consolidated financial statements include the accounts of Nabi Biopharmaceuticals and our wholly-owned subsidiaries (referred to as “Nabi,” the “Company,” “us,” or “we” throughout this report). All significant inter-company accounts and transactions are eliminated in consolidation. All of our wholly-owned subsidiaries are dormant or are otherwise non-operative. Accounting estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period, including such amounts related to discontinued operations. Actual results could differ from those estimates. Fiscal year periods: Historically, our fiscal year ended on the last Saturday of December. Consequently, we periodically had a 53-week fiscal year. In 2012, we amended our By-Laws to change our fiscal year end to a calendar basis; this prospective change did not have a material impact on our financial condition and results of operations for any periods presented. Financial instruments: The carrying amounts of financial instruments including cash equivalents, marketable securities, accounts receivable and accounts payable approximated fair value as of June 30, 2012 and December 31, 2011, because of the relatively short-term maturity of these instruments. Cash, cash equivalents and marketable securities: Cash equivalents consist of investments in low risk, highly liquid securities with original maturities of 90 days or less. Marketable securities consist of low risk fixed income investment instruments such as government obligations, government agency and Federal Deposit Insurance Corporation backed notes with maturities typically less than eighteen months. Marketable securities are classified as available-for-sale and recorded at fair value; unrealized gains and losses on those securities are reflected in other comprehensive income (loss). We assess the risk of impairment related to securities held in our investment portfolio on a regular basis and noted no “permanent” or “other than temporary” impairment during the first six months of 2012. Our investment policies and procedures are reviewed periodically by management and our audit committee to minimize credit risk.   Concentration of credit risk: Financial instruments that potentially subject us to credit and liquidity risk consist primarily of cash, marketable securities and receivables. The Company maintains cash deposits at major financial institutions with high credit quality. The Company’s operating accounts exceeded the Federal Deposit Insurance Corporation limits of $250,000. Cash equivalents primarily consist of short-term money market funds, which are deposited with reputable financial institutions. At June 30, 2012, the Company’s marketable investments consist primarily of United States government agency securities as well as corporate debt securities and commercial paper. The Company’s investment policy limits investments to only investment-grade securities with the objective to preserve principal and maintain sufficient liquidity to meet operational objectives. Revenue recognition: Our revenue generating arrangements may include multiple elements and deliverables, including licenses, options, research and development activities, participation on joint steering committees and contract manufacturing, among other elements. When we determine that an element has stand-alone value to our customer, we allocate a portion of the total contract price to that element based on its relative selling price, determined pursuant to a selling price hierarchy, and recognize revenue for that element according to its characteristics. Revenue consists of license fees, milestone payments, and payments for contractual services. License fees received that do not have stand-alone value are initially recorded as deferred revenue, and are subsequently recognized as revenue ratably over the period of our participation on joint steering committees. The joint steering committee established in connection with our option and license agreement with GSK related to NicVAX is currently expected to operate for 190 months from the date of the agreement (or through December 2025). Our efforts under the joint steering committee established in connection with our asset purchase agreement with GSK related to PentaStaph were completed in the second quarter of 2011. For milestones that are deemed substantive, we recognize the contingent revenue when: (i) the milestones have been achieved; (ii) no further performance obligations with respect to the milestones exist; and (iii) collection is reasonably assured. A milestone is considered substantive if all of the following conditions are met: (i) the milestone is nonrefundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone appears reasonable in relation to the effort expended with the other milestones in the arrangement and the related risk associated with achievement of the milestone. If a milestone is deemed not to be substantive, the Company would recognize the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment will be deferred and recognized as revenue as the Company completes its performance obligations. Payments for contractual services are recognized as revenue when earned, typically when the services are rendered. We analyze cost reimbursable grants and contracts to determine whether we should report such reimbursements as revenue or as an offset to research and development expenses incurred. Collaborative arrangements: We are an active participant with exposure to significant risks and rewards of commercialization relating to the development of NicVAX and future generation nicotine vaccines based on NicVAX technology. For costs incurred and revenues generated from third parties where we are deemed to be the principal participant, we recognize revenues and costs using the gross basis of accounting; otherwise we use the net basis of accounting. Research and development expenses: Research and development costs are expensed as incurred; advanced payments are deferred and subsequently expensed over the period of performance. Research and development expenses include direct labor costs as well as the costs of contractors and other direct and indirect expenses (including an allocation of the costs of facilities). We expense amounts payable to third parties under collaborative product development agreements at the earlier of the milestone achievement or as payments become contractually due. In the first six months of 2011 we recorded approximately $0.3 million of cost reimbursements from government grants as an offset to research and development expenses (none during 2012). Income (loss) per share: Basic income (loss) per share is computed by dividing consolidated net income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of stock options. The dilutive impact of dilutive potential common shares resulting from stock options is determined by applying the treasury stock method. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the three- and six month periods ended June 30, 2012 and June 25, 2011. The Company’s unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator. A total of approximately 3.7 million potentially dilutive shares related to stock options have been excluded in the calculation of diluted net loss per share for the three- and six month periods ended June 30, 2012 and a total of approximately 4.6 million potentially dilutive shares for the three- and six periods ended June 25, 2011, as their inclusion would be anti-dilutive.   Share-based compensation: We expense the estimated fair value of share-based awards made in exchange for employee services over the requisite employee service period. Share-based compensation cost for stock options is determined at the grant date using an option pricing model; share-based compensation cost for restricted stock is determined at the grant date based on the closing price of our common stock on that date. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period. Income taxes: We account for income taxes using the asset and liability approach, which requires, among other things, recognition of future tax benefits and liabilities measured at enacted rates attributable to temporary differences between financial statement and income tax bases of assets and liabilities and to tax net operating loss carryforwards to the extent that realization of these benefits is more likely than not. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year. We periodically evaluate the realizability of our net deferred tax assets; a valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. We recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits, and our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. We consider discontinued operations for purposes of determining the amount of tax benefits that result from a loss from continuing operations. Segment information: We currently operate in a single business segment. Recent accounting standards: In June 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2011-05, Presentation of Comprehensive Income. ASU 2011-05 revises the manner in which entities present comprehensive income in their financial statements. The new guidance removes the presentation options in Accounting Standards Codification 220 and requires entities to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements. ASU 2011-05 did not change the items that must be reported in other comprehensive income. The Company adopted the provisions of ASU 2011-05 in the first quarter of 2012. As the Company’s net loss was the same as comprehensive loss, the Company did not include a statement of comprehensive loss. New accounting pronouncements: We have evaluated all Accounting Standards Updates through the date the financial statements were issued and believe the adoption of these will not have a material impact to our results of operations or financial position.

NOTE 3 AVAILABLE FOR SALE INVESTMENTS The amortized cost, gross unrealized gains and losses and estimated fair value of available-for-sale marketable securities by security classification as of December 31, 2011 (none at June 30, 2012), were as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="50%"> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> December 31, 2011 (In thousands) </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Amortized Costs</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Gross Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Gross Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Estimated Fair Values</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Government-sponsored securities </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">993</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">993</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Corporate debt securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,086</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,086</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total securities </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,079</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,079</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> During the six months ended June 30, 2012 and June 25, 2011 we had no realized gains (losses) on sales of available-for-sale marketable securities. Gains and losses on available-for-sale marketable securities are based on the specific identification method. The contractual maturities of all of our available-for-sale investments as of December 31, 2011 were less than 12 months.

NOTE 4 DISCONTINUED OPERATIONS During 2006, we assessed our pricing programs under Medicare/Medicaid and other governmental pricing programs for the period from 2002 through the second quarter of 2006. In connection with the 2006 review, we identified additional liabilities related to discontinued operations for possible overbilling under Medicare/Medicaid and other governmental pricing programs. The estimated liability related to these programs was approximately $1.7 million at December 31, 2011. In the first quarter 2012, we undertook an assessment of the remaining liabilities and concluded that these remaining liabilities should be eliminated after determining that any remaining obligations related to the programs were not material.

NOTE 5 INCOME TAXES We file income tax returns in the U.S., with various states and foreign jurisdictions, and are subject to tax audits in all jurisdictions for which we file tax returns. Tax audits by their very nature are often complex and can require several years to complete. As of June 30, 2012, we recorded a valuation allowance against all of our deferred tax assets.   Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. We establish accruals for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These accruals are established when we believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjust these accruals in light of changing facts and circumstances, such as the outcome of a tax audit. Under the tax statute of limitations applicable to the Internal Revenue Code, we are no longer subject to U.S. federal income tax examinations by the Internal Revenue Service for years before 2005. However, because we are carrying forward income tax attributes, such as net operating losses and tax credits from 2002 and earlier tax years, these attributes can still be audited when used on returns filed in the future. Under the statutes of limitation applicable to most state income tax laws, we are no longer subject to state income tax examinations by tax authorities for years before 2005 in states in which we have filed income tax returns. Certain states may take the position that we are subject to income tax in such states even though we have not filed income tax returns in such states and, depending on the varying state income tax statutes and administrative practices, the statute of limitations in such states may extend to years before 2005. We are subject to foreign tax examinations by tax authorities for all years of operation.

NOTE 6 FAIR VALUE DISCLOSURES We follow a three-tier fair value hierarchy which prioritizes the inputs used in measuring the fair value of our assets and liabilities. These tiers include (i) Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; (ii) Level 2, defined as observable inputs other than Level 1 prices such as quoted prices for similar assets, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and (iii) Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. All cash and cash equivalents, as well as available-for-sale marketable securities, are recorded at fair value at June 30, 2012 and December 31, 2011. The inputs used in measuring the fair value of these instruments are considered to be Level 1 and Level 2 in accordance with the three-tier fair value hierarchy. The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy and the fair values are based on period-end statements supplied by the various banks and brokers. The majority of our funds were deposited in institutional money market mutual funds with the remainder held in regular interest bearing and non-interest bearing depository accounts with commercial banks. The inputs used in measuring the fair value of our available-for-sale marketable securities at December 31, 2011 (none at June 30, 2012) are considered to be Level 2 in accordance with the three-tier fair value hierarchy. These securities are valued using a multi-dimensional pricing model that includes a variety of inputs, including quoted prices for similar assets and liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. To assess the fair value of these securities, we obtain fair values from an independent third-party valuation service provider. As we are responsible for the determination of fair value, we review the values provided by the independent third-party valuation service provider for reasonableness, which could include reviewing other publicly available information.   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="46%"> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom">December 31, 2011</td> <td valign="bottom"> </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Quoted Prices in Active Markets for Identical Assets</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Significant Other Observable Inputs</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Significant Unobservable Inputs</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> (In thousands) </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Total</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Level 1</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Level 2</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Level 3</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Government-sponsored securities </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">993</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">993</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Corporate debt securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,086</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">721</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">365</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,079</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">721</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,358</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

NOTE 7 TREASURY STOCK On July 30, 2012 we completed a “modified Dutch auction” tender offer for our common stock at a price per share not less than $1.58 and not greater than $1.72, and purchased 14,547,996 shares of our common stock for approximately $24.4 million at an average cost per share of approximately $1.68.

NOTE 8 SHARE BASED COMPENSATION A summary of option activity under our stock compensation plans as of June 30, 2012, and the changes during the first six months of 2012 is presented below:   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="80%"> </td> <td valign="bottom" width="11%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> Options </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Number of Options</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,053,652</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Exercised </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Forfeited </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(64,198</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Expired </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(325,253</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Outstanding at June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,665,201</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Exercisable at June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,121,084</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table> We granted options to purchase 1,000 shares at an exercise price of $1.89 during the first six months of 2012, with an average fair value at the date of grant of $0.96. The grant becomes exercisable between one and three years after the date of grant. We estimate the fair value of each stock option on the date of grant using the Black-Scholes option-pricing formula and amortize expense over the option’s vesting period using the straight-line attribution approach. A summary of our restricted stock awards as of June 30, 2012 and the changes during the first six months of 2012 is presented below:   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="80%"> </td> <td valign="bottom" width="12%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> Awards </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Number of Awards</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Nonvested at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">405,977</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Vested </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(193,503</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr> <td valign="top"> Forfeited </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(16,220</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Nonvested at June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">196,254</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> Share-based compensation expense for the three months ended June 30, 2012 and June 25, 2011 was $0.7 million and $0.6 million, respectively. Share-based compensation expense for the six months ended June 30, 2012 and June 25, 2011 was $1.6 million and $1.2 million, respectively.

NOTE 9 LICENSES AND ROYALTY ARRANGEMENTS We have entered into licenses and royalty agreements for our products in development. PentaStaph: In November 2009, we sold our PentaStaph product candidate and related assets to GSK under an Asset Purchase Agreement for a total consideration of $46 million including a $20 million up-front payment and $26 million payable upon achievement of certain milestones, all of which we have received. We completed our work to help develop PentaStaph under contract with GSK during the second quarter of 2011. NicVAX: In March 2010, we closed an exclusive worldwide option and licensing agreement with GSK for NicVAX as well as for the development of follow-on nicotine addiction vaccines. Upon closing, we received a $40 million initial payment. Under the terms of the agreement, we granted to GSK (i) an option to obtain an exclusive worldwide license to develop, commercialize and manufacture NicVAX as it currently exists, as well as certain potential alternative forms of NicVAX together with an adjuvant other than a GSK proprietary adjuvant and/or with different presentation, dosage or administration (NicVAX Alternatives), and (ii) an exclusive worldwide license to develop, commercialize and manufacture certain future generation candidate vaccines for the prevention or treatment of nicotine addiction based on our NicVAX intellectual property (other than NicVAX and NicVAX Alternatives).   GSK has informed us that it does not intend to exercise the NicVAX option due to the failure of the Phase III trials to achieve their primary end points. However, GSK has not indicated that it terminated the development of the future generation nicotine vaccine. Notwithstanding the failure to achieve the primary endpoint in our two Phase III trials, if the future generation nicotine vaccine being developed by GSK is successful, GSK will pay us up to $290 million in contingent milestone payments as follows: (i) up to $47 million based on Phase II and Phase III clinical trial-related milestones, (ii) up to $34 million based on obtaining regulatory approval in certain major market countries, and (iii) up to a total of $209 million based on tiered annual sales of future generation candidates. GSK also will pay us royalty payments on annual net sales of future generation candidates, beginning at 5% and potentially increasing on incremental sales to as high as 7%, with the increase depending on whether annual net sales of future generation candidates meet or exceed specified annual sales targets in any calendar year ranging from $300 million to $600 million. We believe all future milestones under the NicVAX agreement to be substantive as they are at risk until achieved. The probability of us receiving future contingent milestones or royalties is uncertain as it is based on the achievement of various success-based development and regulatory approvals contingent upon the occurrence of various future events, the occurrence of most of which have a high degree of uncertainty of occurring. Revenue under the NicVAX agreement consists of license fees, milestone payments, and payments for contractual services. License fees received are initially recorded as deferred revenue, and are subsequently recognized as revenue ratably over the period of our participation on joint steering committees. The joint steering committee related to the NicVAX agreement is currently expected to operate for 190 months from the date of the agreement (or through December 2025).   NOTE 10 NOL RIGHTS AGREEMENT On August 25, 2011, our Board of Directors adopted a stockholder Rights Agreement with American Stock Transfer & Trust Company, LLC, as rights agent, in an effort to prevent an "ownership change" under Section 382 from occurring and thereby protect the value of our net operating losses. Under the Rights Agreement, the Board of Directors declared a non-taxable dividend of one preferred share purchase right for each outstanding share of common stock to be distributed to stockholders of record on August 25, 2011. Concurrent with the signing of the Merger Agreement with Biota, Nabi and the rights agent amended the Rights Agreement to terminate the rights under the Rights Agreement.

NOTE 11 COMMITMENTS AND CONTINGENCIES We have agreements with our employees that include certain cash payments and equity-based award modifications in the event of a termination of employment or a change in control of the Company. We are parties to legal proceedings that we believe to be ordinary, routine litigation incidental to the business of present or former operations. It is management’s opinion, based on the advice of counsel, that the ultimate resolution of such litigation will not have a material adverse effect on our financial condition, results of operations or cash flows.

Revenue recognition: Our revenue generating arrangements may include multiple elements and deliverables, including licenses, options, research and development activities, participation on joint steering committees and contract manufacturing, among other elements. When we determine that an element has stand-alone value to our customer, we allocate a portion of the total contract price to that element based on its relative selling price, determined pursuant to a selling price hierarchy, and recognize revenue for that element according to its characteristics. Revenue consists of license fees, milestone payments, and payments for contractual services. License fees received that do not have stand-alone value are initially recorded as deferred revenue, and are subsequently recognized as revenue ratably over the period of our participation on joint steering committees. The joint steering committee established in connection with our option and license agreement with GSK related to NicVAX is currently expected to operate for 190 months from the date of the agreement (or through December 2025). Our efforts under the joint steering committee established in connection with our asset purchase agreement with GSK related to PentaStaph were completed in the second quarter of 2011. For milestones that are deemed substantive, we recognize the contingent revenue when: (i) the milestones have been achieved; (ii) no further performance obligations with respect to the milestones exist; and (iii) collection is reasonably assured. A milestone is considered substantive if all of the following conditions are met: (i) the milestone is nonrefundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone appears reasonable in relation to the effort expended with the other milestones in the arrangement and the related risk associated with achievement of the milestone. If a milestone is deemed not to be substantive, the Company would recognize the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment will be deferred and recognized as revenue as the Company completes its performance obligations. Payments for contractual services are recognized as revenue when earned, typically when the services are rendered. We analyze cost reimbursable grants and contracts to determine whether we should report such reimbursements as revenue or as an offset to research and development expenses incurred.

<table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="50%"> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> December 31, 2011 (In thousands) </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Amortized Costs</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Gross Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Gross Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Estimated Fair Values</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Government-sponsored securities </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">993</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">993</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Corporate debt securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,086</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,086</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total securities </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,079</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,079</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

<table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="46%"> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom">December 31, 2011</td> <td valign="bottom"> </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Quoted Prices in Active Markets for Identical Assets</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Significant Other Observable Inputs</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Significant Unobservable Inputs</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> (In thousands) </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Total</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Level 1</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Level 2</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Level 3</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Government-sponsored securities </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">993</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">993</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Corporate debt securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,086</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">721</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">365</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,079</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">721</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,358</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

<table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="80%"> </td> <td valign="bottom" width="12%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> Awards </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Number of Awards</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Nonvested at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">405,977</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Vested </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(193,503</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr> <td valign="top"> Forfeited </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(16,220</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Nonvested at June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">196,254</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

false --12-31 Q2 2012 2012-06-30 10-Q 0000072444 28328389 Accelerated Filer NABI BIOPHARMACEUTICALS 2500000 24400000 600000000 300000000 600000000 300000000 32000000 46000000 26000000 290000000 40000000 through December 2025 through December 2025 20000000 29000000 25000000 250000 40000000 P190M P190M Less than 90 days 54000000 34000000 34000000 47000000 47000000 209000000 209000000 less than 12 months P18M 65000000 54000000 2 2 P371D 0.07 0.05 0.07 0.05 0.26 0.74 P10Y 300000 0 200000000 P3Y P1Y 0.669212231 Under the Rights Agreement, the Board of Directors declared a non-taxable dividend of one preferred share purchase right for each outstanding share of common stock to be distributed to stockholders of record on August 25, 2011. Concurrent with the signing of the Merger Agreement with Biota, Nabi and the rights agent amended the Rights Agreement to terminate the rights under the Rights Agreement. 2011-08-25 1.72 1.58

146000

75000

373157000

374792000

1200000

600000

1600000

700000

4600000

3700000

97965000

92950000

97881000

92950000

2079000

721000

1358000

2079000

1086000

993000

2079000

1086000

993000

721000

365000

993000

53564000

86618000

94310000

92649000

92600000

33054000

-1661000

6359000

6357000

1174000

549000

2526000

32842000

31579000

110000

34000

2011-08-25

-29000

2768000

1426000

3453000

2176000

-2619000

-4599000

-4831000

-2733000

-2619000

-4599000

-4160000

-2733000

-0.06

-0.11

-0.10

-0.06

-0.11

-0.10

-0.06

991000

0.02

-671000

-6534000

-1263000

-1119000

-505000

417000

-196000

-304000

-995000

122000

50000

65000

33000

39094000

35615000

97965000

92950000

6252000

4036000

1662000

1700000

2079000

525000

41560000

2079000

-9031000

-3740000

-2619000

-4599000

-3169000

-2733000

15733000

8431000

6301000

3506000

-2816000

-4687000

-5038000

-2875000

1918000

1435000

-671000

75000

38000

142000

109000

10632000

1000

497000

301000

525000

52035000

2079000

158000

84000

995000

11791000

6456000

2848000

1330000

-228078000

-231247000

12917000

3744000

1263000

631000

1215000

1634000

16220

405977

196254

193503

3121084

325253

64198

1000

0.96

4053652

3665201

1.89

58871000

57335000

1.68

14547996

92567000

24400000

42221

42307

42578

42664

42221

42307

42578

42664

EX-101.SCH 5 nabi-20120630.xsd XBRL TAXONOMY EXTENSION SCHEMA 0604 - Disclosure - Discounted Operations (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0207 - Disclosure - Treasury Stock link:presentationLink link:calculationLink link:definitionLink 0204 - Disclosure - Discounted Operations link:presentationLink link:calculationLink link:definitionLink 0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0201 - Disclosure - Company Overview link:presentationLink link:calculationLink link:definitionLink 0202 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0203 - Disclosure - Available for Sale Investments link:presentationLink link:calculationLink link:definitionLink 0211 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0205 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0206 - Disclosure - Fair Value Disclosures link:presentationLink link:calculationLink link:definitionLink 0208 - Disclosure - Share Based Compensation link:presentationLink link:calculationLink link:definitionLink 0210 - Disclosure - NOL Rights Agreement link:presentationLink link:calculationLink link:definitionLink 0209 - Disclosure - Licenses and Royalty Arrangements link:presentationLink link:calculationLink link:definitionLink 0402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0503 - Disclosure - Available for Sale Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0506 - Disclosure - Fair Value Disclosures (Tables) link:presentationLink link:calculationLink link:definitionLink 0508 - Disclosure - Share Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0601 - Disclosure - Company Overview (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0602 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06031 - Disclosure - Available for Sale Investments (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0603 - Disclosure - Available for Sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0606 - Disclosure - Fair Value Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 0607 - Disclosure - Treasury Stock (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06082 - Disclosure - Share Based Compensation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0608 - Disclosure - Share Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 06081 - Disclosure - Share Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 0610 - Disclosure - NOL Rights Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 0609 - Disclosure - Licenses and Royalty Arrangements (Details Textual) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 nabi-20120630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 nabi-20120630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 nabi-20120630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and entity information. Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Condensed Consolidated Balance Sheets [Abstract] Assets [Abstract] ASSETS Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Marketable Securities, Current Marketable securities Receivables, Net, Current Receivables Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Assets, Total Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Accounts Payable, Current Accounts payable Other Accrued Liabilities, Current Accrued expenses and other current liabilities Deferred Revenue, Current Deferred revenue Liabilities of Disposal Group, Including Discontinued Operation, Current Liabilities of discontinued operations Liabilities, Current Total current liabilities Deferred Revenue, Noncurrent Deferred revenue Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value Convertible preferred stock Common Stock, Value, Issued Common stock Additional Paid in Capital, Common Stock Capital in excess of par value Treasury Stock, Value Treasury stock Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity Liabilities and Stockholders Equity Total liabilities and stockholders' equity Condensed Consolidated Statements of Operations [Abstract] Revenues [Abstract] Revenue: Revenues Revenue Operating Expenses [Abstract] Operating expenses: Cost of services Cost of Services Research and Development Expense Research and development expenses General and Administrative Expense General and administrative expenses Total operating costs Operating Expenses Operating loss Operating Income (Loss) Investment Income, Interest Interest income Other Nonoperating Income (Expense) Other income (expense), net Loss from continuing operations before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Cumulative Effects of Changes in Accounting Principles, Noncontrolling Interest Income Tax Expense (Benefit) Benefit from income taxes Loss from continuing operations Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest Net loss from continuing operations Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income from discontinued operations, net of tax provision Net loss Net Income (Loss) Attributable to Parent Net loss Basic income (loss) per share: Earnings Per Share, Basic [Abstract] Income (Loss) from Continuing Operations, Per Basic Share Continuing operations Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share Discontinued operations Diluted income (loss) per share: Earnings Per Share, Diluted [Abstract] Income (Loss) from Continuing Operations, Per Diluted Share Continuing operations Income (Loss) from Discontinued Operations, Net of Tax, Per Diluted Share Discontinued operations Basic weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Basic Diluted weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted Condensed Consolidated Statements of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flow from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss from continuing operations to net cash used in operating activities from continuing operations: Depreciation, Depletion and Amortization Depreciation and amortization Share-based Compensation Share-based compensation Gain (Loss) on Sale of Property Plant Equipment Loss on sale of property and equipment Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Receivables Receivables Increase (Decrease) in Prepaid, Deferred Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flow from investing activities: Proceeds from sales of maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flow from financing activities: Proceeds from Issuance of Common Stock Proceeds from issuances of common stock for employee benefit plans Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in cash and cash equivalents Company Overview [Abstract] Company overview. Nature of Operations [Text Block] Company Overview Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Basis of Presentation and Summary of Significant Accounting Policies Available for Sale Investments [Abstract] Available for Sale Securities [Text Block] Available for Sale Investments Commitments and Contingencies [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Income Taxes [Abstract] Income Tax Disclosure [Text Block] Income Taxes Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Disclosures Treasury Stock [Abstract] Treasury stock. Treasury Stock [Text Block] Treasury Stock Share Based Compensation [Abstract] Disclosure of Compensation Related Costs Share Based Payments [Text Block] Share Based Compensation NOL Rights Agreement [Abstract] NOL rights agreement. NOL Rights Agreement [Text Block] NOL Rights Agreement NOL rights agreement. Licenses and Royalty Arrangements [Abstract] Licenses and royalty arrangements. Licenses and Revenue Arrangements [Text Block] Licenses and Royalty Arrangements Licenses and royalty arrangements. Principles of Consolidation and Presentation [Policy Text Block] Principles of consolidation and presentation Principles of consolidation and presentation. Accounting estimates Use of Estimates, Policy [Policy Text Block] Financial instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Cash, Cash Equivalents and Marketable Securities [Policy Text Block] Cash, cash equivalents and marketable securities Cash, cash equivalents and marketable securities. Collaborative arrangements Collaborative Arrangement, Accounting Policy [Policy Text Block] Revenue recognition Revenue Recognition, Policy [Policy Text Block] Research and development expenses Research and Development Expense, Policy [Policy Text Block] Share-based compensation Compensation Related Costs, Policy [Policy Text Block] Income taxes Income Tax, Policy [Policy Text Block] Income (loss) per share Earnings Per Share, Policy [Policy Text Block] Segment information Segment Reporting, Policy [Policy Text Block] Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Estimated Fair Value of Available-for-Sale Short-Term Investments by Security Classification Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block] Inputs used in measuring fair value of assets and liabilities Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of Option Activity Under Stock Compensation Plans Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Summary of Nonvested Restricted Stock Awards Company Overview [Table] Company overview. Range [Axis] Range [Domain] Range [Domain] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Arrangements by Product Name [Axis] Arrangements by product name. Arrangements by Product Name [Domain] Arrangements by product name. NicVAX [Member] NicVAX [Member] NicVAX. PentaStaph [Member] PentaStaph [Member] PentaStaph. Licensing Agreements, Type of Options Provided [Axis] Licensing agreements type of options provided. Licensing Agreements, Type of Options Provided [Domain] Licensing agreements type of options provided. Develop Next Generation [Member] Develop Next-Generation [Member] Develop next-generation. Company Overview [Line Items] Company overview. Development Arrangements Upfront Non Refundable Fee Received Initial payment received Development arrangements, upfront non-refundable fee received. Development Arrangements, Option Fee Received on Exercise of Options Option not exercised by GSK, maximum possible milestones Additional fee amount on exercise of options Development arrangements, option fee received on exercise of options. Development Arrangements, Upfront Payment Received Upfront payment received on the consideration amount Development arrangements, upfront payment received. Development Arrangements, Contingent Consideration, Potential Cash Payment Amount receivable upon achievement of milestones Development arrangements, contingent consideration, potential cash payment. Development Arrangements, Upfront Payment, Participation Period End date of NicVAX operating agreement Development arrangements, upfront payment, participation period. End date of GSK upfront payment recognition Reimbursements from Government Grants for Research and Development Expenses Reimbursements from government grants for research and development expenses Reimbursements from government grants for research and development expenses. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potential dilutive shares excluded in the calculation of diluted net income per share Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds Realized gains (losses) on sales of available-for-sale securities Schedule of Available-for-sale Securities [Table] Major Types of Debt and Equity Securities [Axis] Major Types of Debt And Equity Securities [Domain] U S Government Sponsored Enterprises Debt Securities [Member] Government-sponsored securities [Member] Corporate Debt Securities [Member] Corporate debt securities [Member] Schedule of Available-for-sale Securities [Line Items] Available-for-sale Securities, Amortized Cost Basis Amortized Costs Available-for-sale Securities, Gross Unrealized Gains Gross Unrealized Gains Available-for-sale Securities, Gross Unrealized Losses Gross Unrealized Losses Available-for-sale Securities, Fair Value Disclosure Estimated Fair Values Available-for-sale marketable securities Loss Contingency, Loss in Period Estimated amounts due under pricing programs Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Inputs Level1 [Member] Quoted Prices in Active Markets for Identical Assets, Level 1 [Member] Fair Value Inputs Level2 [Member] Significant Other Observable Inputs, Level 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets, Fair Value Disclosure Total Treasury Stock, Shares, Acquired Number of shares repurchased Treasury Stock, Value, Acquired, Cost Method Total value of shares repurchased Treasury Stock Acquired, Average Cost Per Share Average price paid per share for repurchase Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Granted Options granted to purchase Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Average grant date fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Exercise Period Share-based compensation arrangement by share-based payment award, options, grants in period, exercise period. Exercise period (in years) of options granted Outstanding at December 31, 2011 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at June 30, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable at June 30, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Nonvested at June 30, 2012 Nonvested at December 31, 2011 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited Stockholders Equity Note, Impact on Purchase Rights on Outstanding Securities Terms of the rights agreement Stockholders equity note, impact on purchase rights on outstanding securities Licenses and Royalty Arrangements [Table] Licenses and royalty arrangements. PhosLo [Member] PhosLo [Member] PhosLo. Licenses and Royalty Arrangements [Line Items] Licenses and royalty arrangements. Short-term Investments [Abstract] Estimated Fair Value of Available-for-Sale Short-Term Investments by Security Classification Company Overview (Textual) [Abstract] Company Overview (Textual) [Abstract] Company overview. Basis of Presentation and Summary of Significant Accounting Policies (Textual) [Abstract] Basis of Presentation and Summary of Significant Accounting Policies (Textual) [Abstract] Basis of presentation and summary of significant accounting policies. Available for Sale Investments (Textual) [Abstract] Available for Sale Investments (Textual) [Abstract] Available for sale investments. Treasury Stock (Textual) [Abstract] Treasury Stock (Textual) [Abstract] Treasury stock. Basis of Presentation and Summary of Significant Accounting Policies [Abstract] Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercise price of the options granted Development Arrangements Consideration Received Total consideration received for selling the assets of the vaccine products Development arrangements, consideration received. Assets, Current [Abstract] Current assets: Current liabilities: Liabilities, Current [Abstract] Company Overview (Additional Textual) [Abstract] Company overview. Company Overview (Additional Textual) [Abstract] Share Based Compensation (Textual) [Abstract] Share based compensation. Share Based Compensation (Textual) [Abstract] Share Based Compensation (Additional Textual) [Abstract] Share based compensation. Share Based Compensation (Additional Textual) [Abstract] NOL Rights Agreement (Textual) [Abstract] NOL Rights Agreement (Textual) [Abstract] NOL rights agreement. Licenses and Royalty Arrangements (Textual) [Abstract] Licenses and royalty arrangements. Licenses and Royalty Arrangements (Textual) [Abstract] Number of Phase Three Clinical Trials Number of phase III clinical trials Number of phase three clinical trials. Number of Weeks in Fiscal Year Number of weeks in fiscal year Number of weeks in fiscal year. EX-101.PRE 9 nabi-20120630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 R25.htm IDEA: XBRL DOCUMENT

Fair Value Disclosures (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Dec. 31, 2011
Inputs used in measuring fair value of assets and liabilities
Available-for-sale marketable securities	$ 0	$ 2,079
Total	0	2,079
Government-sponsored securities [Member]
Inputs used in measuring fair value of assets and liabilities
Available-for-sale marketable securities	0	993
Corporate debt securities [Member]
Inputs used in measuring fair value of assets and liabilities
Available-for-sale marketable securities	0	1,086
Quoted Prices in Active Markets for Identical Assets, Level 1 [Member]
Inputs used in measuring fair value of assets and liabilities
Total	0	721
Quoted Prices in Active Markets for Identical Assets, Level 1 [Member] \| Government-sponsored securities [Member]
Inputs used in measuring fair value of assets and liabilities
Available-for-sale marketable securities	0
Quoted Prices in Active Markets for Identical Assets, Level 1 [Member] \| Corporate debt securities [Member]
Inputs used in measuring fair value of assets and liabilities
Available-for-sale marketable securities	0	721
Significant Other Observable Inputs, Level 2 [Member]
Inputs used in measuring fair value of assets and liabilities
Total	0	1,358
Significant Other Observable Inputs, Level 2 [Member] \| Government-sponsored securities [Member]
Inputs used in measuring fair value of assets and liabilities
Available-for-sale marketable securities	0	993
Significant Other Observable Inputs, Level 2 [Member] \| Corporate debt securities [Member]
Inputs used in measuring fair value of assets and liabilities
Available-for-sale marketable securities	0	365
Significant Unobservable Inputs, Level 3 [Member]
Inputs used in measuring fair value of assets and liabilities
Total	0
Significant Unobservable Inputs, Level 3 [Member] \| Government-sponsored securities [Member]
Inputs used in measuring fair value of assets and liabilities
Available-for-sale marketable securities	0
Significant Unobservable Inputs, Level 3 [Member] \| Corporate debt securities [Member]
Inputs used in measuring fair value of assets and liabilities
Available-for-sale marketable securities	$ 0

- Definition

This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale.

+ References+ Details

XML 12 R9.htm IDEA: XBRL DOCUMENT

Income Taxes	6 Months Ended
Jun. 30, 2012
Income Taxes [Abstract]
Income Taxes	NOTE 5 INCOME TAXES We file income tax returns in the U.S., with various states and foreign jurisdictions, and are subject to tax audits in all jurisdictions for which we file tax returns. Tax audits by their very nature are often complex and can require several years to complete. As of June 30, 2012, we recorded a valuation allowance against all of our deferred tax assets. Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. We establish accruals for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These accruals are established when we believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjust these accruals in light of changing facts and circumstances, such as the outcome of a tax audit. Under the tax statute of limitations applicable to the Internal Revenue Code, we are no longer subject to U.S. federal income tax examinations by the Internal Revenue Service for years before 2005. However, because we are carrying forward income tax attributes, such as net operating losses and tax credits from 2002 and earlier tax years, these attributes can still be audited when used on returns filed in the future. Under the statutes of limitation applicable to most state income tax laws, we are no longer subject to state income tax examinations by tax authorities for years before 2005 in states in which we have filed income tax returns. Certain states may take the position that we are subject to income tax in such states even though we have not filed income tax returns in such states and, depending on the varying state income tax statutes and administrative practices, the statute of limitations in such states may extend to years before 2005. We are subject to foreign tax examinations by tax authorities for all years of operation.

Income Taxes

6 Months Ended

Jun. 30, 2012

Income Taxes [Abstract]

Income Taxes

NOTE 5 INCOME TAXES

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

EXCEL 13 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\U-&4X,C!E.5\R.#8S7S0R-CA?.6$S,U\P-6)D M96(Q9#1D-F,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;7!A;GE?3W9E#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I7;W)K#I7;W)K5]!#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%V M86EL86)L95]F;W)?4V%L95]);G9E#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-H87)E7T)A#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D-O;7!A;GE?3W9E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D)A#I7;W)K#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?1&ES8VQO#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-H87)E7T)A#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O M6%L='E?07)R86YG96UE,3PO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DY/3%]2:6=H='-?06=R965M96YT M7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I3='EL M97-H965T($A2968],T0B5V]R:W-H965T3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&4X,C!E.5\R.#8S7S0R M-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA,S-?,#5B9&5B,60T9#9C+U=O M'0O:'1M M;#L@8VAA2!);F9O2!296=I'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^2G5N(#,P+`T*"0DR,#$R/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^ M9F%L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^+2TQ,BTS,3QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&4X,C!E M.5\R.#8S7S0R-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA,S-?,#5B9&5B M,60T9#9C+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!A;F0@97%U M:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)FYB'0^)FYB'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'!E;G-E*2P@ M;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#D\&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA"!P'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\2!F:6YA;F-I;F<@86-T:79I=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&4X,C!E.5\R.#8S7S0R M-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA,S-?,#5B9&5B,60T9#9C+U=O M'0O:'1M M;#L@8VAA2!/=F5R=FEE=SPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T M9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#$@+2!U M6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP M<'@[<&%D9&EN9RUB;W1T;VTZ,'!X.SX\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/E=E(&%R92!A(&)I;W!H M87)M86-E=71I8V%L(&-O;7!A;GD@=&AA="!H87,@9F]C=7-E9"!O;B!T:&4@ M9&5V96QO<&UE;G0@;V8@=F%C8VEN97,@861D2!E;F1P;VEN="!I;B!T=V\@4&AA M'!E8W1E9"!B969O65A2!F7)A('=H:6-H('=A6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M&-H86YG960@9F]R(&YE=VQY(&ES2UO=VYE9"!S=6)S:61I87)Y(&]F($YA8FD@*'1H92!-97)G97(I M+B!);B!C;VYN96-T:6]N('=I=&@@=&AE($UE&-H M86YG92!L:7-T:6YG(&%N9"!B92!H96%D<75AF4Z-G!X.VUA M'0M86QI9VXZ(&QE9G0G(&)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!W:61T:#TS1#(E('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE M9G0^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P/@T* M("`@/'`@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@2!P2!B92!A9&IU2!A9G1E&EM871E;'D@-S0E(&]F($YA8FDF(S@R M,3<[2`R-B4@;V8@3F%B M:28C.#(Q-SMS(&]U='-T86YD:6YG(&-O;6UO;B!S=&]C:SL-"B`@(#PO9F]N M=#X\+W`^#0H@("`\+W1D/@T*("`@/"]T6QE/3-$)V)O M3IT:6UEF4],T0R/B8C.#(R-CL\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=VED=&@],T0Q)2!V86QI9VX],T1T;W`^ M/&9O;G0@"!":6]T82!D:7)E8W1O6QE/3-$)V)O3IT:6UEF4],T0R/B8C.#(R-CL\+V9O;G0^/"]T9#X@#0H@("`\=&0@=VED=&@] M,T0Q)2!V86QI9VX],T1T;W`^/&9O;G0@'!E8W1E9"!T;R!S97)V92!A6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$9F]N="US:7IE.C9P>#MM87)G:6XM=&]P.C!P>#MM87)G M:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/DYA8FD@:6YT96YD&-E0T*("`@97-T:6UA=&4@=&AE(&%M;W5N="!O9B!C87-H('1O(&)E(')E M='5R;F5D('1O($YA8FD@0T*("`@,S`L(#(P,3([ M(&%N9"`\+V9O;G0^/"]P/@T*("`@/"]T9#X-"B`@(#PO='(^#0H@("`\+W1A M8FQE/@T*("`@/'`@F4Z-G!X.VUA'0M86QI9VXZ M(&QE9G0G(&)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!W:61T:#TS1#(E('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@ MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P/@T*("`@/'`@86QI M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE M/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O M;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/D-O;G-U;6UA=&EO;B!O9B!T M:&4@365R9V5R(&ES('-U8FIE8W0-"B`@('1O(&-U2!C;VYD:71I M;VYS(&9O2!T:&4@2!T97)M:6YA=&EO;B!O9B!A;GD@ M87!P;&EC86)L92!W86ET:6YG('!E2!O9B!T:&4@;W1H97(@<&%R='DF(S@R,3<[2!I;B!A;&P@;6%T97)I86P@2!O9B!T:&4@;F%T=7)E('-P96-I9FEE9"!I M;B!T:&4@365R9V5R($%G6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA M6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@28C,38P.S,P+"`R,#$R('=E#0H@("!C;VUP;&5T960@82`F(S@R M,C`[;6]D:69I960@1'5T8V@@875C=&EO;B8C.#(R,3L@=&5N9&5R(&]F9F5R M(&9O&EM871E;'D@ M)#$N-C@N(%=E(&9U;F1E9"!T:&4@6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@'D@3IT:6UEF4],T0R/CQI/DYI8U9!6"!!9W)E96UE;G0@=VET:"!'4TLN M(#PO:3Y);B!-87)C:"`R,#$P+"!W92!C;&]S960@86X@97AC;'5S:79E('=O M6UE;G0N(%5N9&5R('1H92!T97)M2!E>&ES=',L(&%S('=E;&P@87,@8V5R=&%I;B!P;W1E M;G1I86P@86QT97)N871I=F4@9F]R;7,@;V8@3FEC5D%8('1O9V5T:&5R('=I M=&@@86X@861J=79A;G0@;W1H97(@=&AA;B!A($=32R!P2!A M9&IU=F%N="!A;F0O;W(@=VET:"!D:69F97)E;G0@<')E&-L=7-I=F4@=V]R;&1W:61E(&QI M8V5N2!E;F0@<&]I;G1S+B!(;W=E=F5R+"!'4TL@ M:&%S(&YO=`T*("`@:6YD:6-A=&5D('1H870@:70@:&%S('1E2!U M2!A<'!R;W9A;"!I;B!C97)T86EN(&UA:F]R(&UA6%L='D@<&%Y;65N=',@;VX@86YN=6%L(&YE="!S86QE2!O9B!U2X-"B`@(#PO M9F]N=#X\+W`^#0H@("`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`@4&AO7)A(&AA=F4@;F]T(&5X8V5E9&5D('1H92!B87-E(&%M M;W5N="P@86YD('=E(&AA=F4@;F]T(')E8V]G;FEZ960@86YY(')O>6%L='D@ M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&4X,C!E.5\R M.#8S7S0R-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA,S-?,#5B9&5B,60T M9#9C+U=O'0O:'1M;#L@8VAA2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R M/CPO'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ M+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E M9VEN($)L;V-K(%1A9V=E9"!.;W1E(#(@+2!U#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/DY/ M5$4@,B!"05-)4R!/1B!04D5314Y4051)3TX@04Y$(%-534U!4ED@3T8@4TE' M3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4R`\+V(^/"]F;VYT/CPO<#X- M"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP M<'@^/&9O;G0@2!I;F1I8V%T:79E(&]F M('1H92!R97-U;'1S('1H870@;6%Y(&]C8W5R(&9O65A2!I;F-L=61E9"!I;B!F:6YA;F-I86P@2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@:6X@=&AE(%5N:71E M9"!3=&%T97,@;V8@06UE2!T:&4@52Y3+B!3 M96-U&-H86YG90T*("`@0V]M;6ES#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/CQI/E!R:6YC:7!L97,@;V8@8V]N2UO=VYE9"!S=6)S:61I87)I97,@*')E9F5R6QE M/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2P@=V4-"B`@('!E2!H860@82`U,RUW965K(&9I2U,87=S('1O(&-H86YG M92!O=7(@9FES8V%L('EE87(@96YD('1O(&$@8V%L96YD87(@8F%S:7,[('1H M:7,@<')O6%B;&4@87!P3IT:6UEF4],T0R/CQI/D-A2!L:7%U:60@ M2!L M97-S('1H86X@96EG:'1E96X@;6]N=&AS+B!-87)K971A8FQE('-E8W5R:71I M97,@87)E(&-L87-S:69I960@87,@879A:6QA8FQE+69O28C.#(R,3L@:6UP86ER M;65N="!D=7)I;F<@=&AE(&9I`T*("`@;6]N=&AS(&]F(#(P,3(N M($]U6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P M.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/CQI/D-O;F-E;G1R871I;VX@;V8@8W)E9&ET(')I2!S=6)J96-T('5S('1O M(&-R961I="!A;F0-"B`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`@'!OF4@6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M'!E M;G-E9"!A6UE;G1S(&%R92!D M969E'!E;G-E M(&%M;W5N=',@<&%Y86)L92!T;R!T:&ER9"!P87)T:65S('5N9&5R(&-O;&QA M8F]R871I=F4@<')O9'5C="!D979E;&]P;65N="!A9W)E96UE;G1S(&%T('1H M92!E87)L:65R(&]F('1H92!M:6QE3IT M:6UEF4],T0R/CQI/DEN8V]M92`H;&]S2!T:&4@=V5I9VAT960M879E2!A<'!L>6EN9R!T:&4@ M=')E87-U&-L=61E3IT:6UEF4] M,T0R/D$@=&]T86P@;V8@87!P2`S+C&-L=61E9"!I;B!T:&4@8V%L8W5L M871I;VX@;V8@9&EL=71E9"!N970@;&]S"!M;VYT:"!P97)I;V1S(&5N9&5D($IU;F4F(S$V,#LS M,"P@,C`Q,B!A;F0@82!T;W1A;"!O9B!A<'!R;WAI;6%T96QY(#0N-B8C,38P M.VUI;&QI;VX@<&]T96YT:6%L;'D@9&EL=71I=F4@6QE/3-$9F]N="US:7IE.C%P M>#MM87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P M/@T*("`@/'`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`\+VD^5V4@ M:&%V92!E=F%L=6%T960@86QL($%C8V]U;G1I;F<@4W1A;F1A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\U-&4X,C!E.5\R.#8S7S0R-CA?.6$S,U\P-6)D96(Q9#1D-F,- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31E.#(P93E?,C@V,U\T M,C8X7SEA,S-?,#5B9&5B,60T9#9C+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/"$M+41/0U19 M4$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L M;V-K(%1A9V=E9"!.;W1E(#,@+2!U#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/CQB/DY/5$4@,R!! M5D%)3$%"3$4@1D]2(%-!3$4@24Y615-4345.5%,@/"]B/CPO9F]N=#X\+W`^ M#0H@("`\<"!S='EL93TS1&UA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@F5D(&=A:6YS(&%N9"!L;W-S97,@86YD(&5S=&EM871E9"!F86ER('9A;'5E M(&]F(&%V86EL86)L92UF;W(MF4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P M>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D97(],T0P('-T>6QE/3-$)V)O M6QE/3-$;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O M='1O;3HP<'@^/&9O;G0@6QE/3-$)VUA6QE/3-$)V)O M6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F5D)B,Q-C`[0V]S=',\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UE MF4],T0Q/D=R;W-S/&)R("\^56YR96%L:7IE9"8C M,38P.T=A:6YS/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/D5S=&EM871E9#QBF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/CDY,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O M;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/C$L,#@V/"]F;VYT/CPO=&0^(`T* M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@;F]W3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O3IT:6UEF4],T0R/D1U'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@ M:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K M(%1A9V=E9"!.;W1E(#0@+2!U6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/D1U2`D,2XW(&UI;&QI;VX@870@1&5C M96UB97(F(S$V,#LS,2P@,C`Q,2X@26X@=&AE(&9I2!R96UA:6YI;F<@;V)L:6=A=&EO;G,@ M'1087)T7S4T93@R,&4Y7S(X-C-?-#(V.%\Y83,S7S`U8F1E8C%D-&0V8PT* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U-&4X,C!E.5\R.#8S7S0R M-CA?.6$S,U\P-6)D96(Q9#1D-F,O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO&5S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!5 M0DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB M(")H='1P.B\O=W=W+G'1";&]C M:RTM/@T*("`@/'`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`\+V9O;G0^/"]P/@T*("`@/'`@"!C65A2!T87@@875T:&]R:71I97,@9F]R M('EE87)S(&)E9F]R92`R,#`U(&EN('-T871E2!T86ME('1H92!P;W-I=&EO;B!T:&%T('=E(&%R92!S=6)J96-T('1O M(&EN8V]M92!T87@@:6X@"!R971U2!E>'1E;F0@=&\@>65A2!T87@@875T:&]R:71I M97,@9F]R(&%L;"!Y96%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$;6%R9VEN M+71O<#HQ.'!X.VUA6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!W:&EC:"!P2!A;F0@=&AE(&9A:7(@=F%L=65S(&%R92!B87-E9"!O;B!P97)I;V0M M96YD#0H@("!S=&%T96UE;G1S('-U<'!L:65D(&)Y('1H92!V87)I;W5S(&)A M;FMS(&%N9"!B6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA M6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@2!V86QU871I;VX-"B`@('-E6QE/3-$9F]N="US M:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q M-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M M8V]L;&%P'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$ M8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R M/B`-"B`@(#QT9"!W:61T:#TS1#0V)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^)B,Q-C`[/"]T9#X@#0H@("`\ M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^ M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3`E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3XF(S$V,#L\+W1D/B`-"B`@(#QT M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M,"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^ M)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T* M("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/E-I9VYI9FEC86YT)B,Q-C`[3W1H97(\8G(@+SY/ M8G-EF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M6QE/3-$)V)O3IT:6UEF4],T0Q/E1O=&%L/"]F;VYT/CPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/DQE=F5L(#(\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UE MF4],T0Q/DQE=F5L(#,\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/CDY,SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@;F]W3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$L,#@V/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C,V-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@ M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*("`@/'`@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4] M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V M,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T* M("`@/"]TF4Z,7!X/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)V)O6QE/3-$)V)O'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA2!3=&]C M:R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\'1";&]C:RTM/@T*("`@/'`@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@28C,38P.S,P+"`R,#$R('=E(&-O;7!L971E9"!A("8C.#(R M,#MM;V1I9FEE9"!$=71C:"!A=6-T:6]N)B,X,C(Q.R!T96YD97(@;V9F97(@ M9F]R(&]U2`D,C0N-"!M:6QL:6]N(&%T M(&%N(&%V97)A9V4@8V]S="!P97(@2`D M,2XV."X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C%P M>#MM87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P M/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U M-&4X,C!E.5\R.#8S7S0R-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA,S-? M,#5B9&5B,60T9#9C+U=O'0O:'1M;#L@8VAA'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^ M#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#@@+2!U'1";&]C:RTM/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/CQB/DY/5$4@."!3 M2$%212!"05-%1"!#3TU014Y3051)3TX@/"]B/CPO9F]N=#X\+W`^#0H@("`\ M<"!S='EL93TS1&UA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!U;F1E6QE/3-$)V)O6QE/3-$ M)V)O6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C0L,#4S+#8U,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D=R86YT960\+V9O;G0^/"]P/@T*("`@/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D5X97)C:7-E9#PO9F]N=#X\+W`^#0H@("`\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O M;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$ M)VUAF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4] M,T0R/D5X<&ER960\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O3IT:6UEF4],T0R/D]U='-T86YD M:6YG(&%T($IU;F4F(S$V,#LS,"P@,C`Q,CPO9F]N=#X\+W`^#0H@("`\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/C,L-C8U+#(P,3PO9F]N=#X\+W1D M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)VUA&5R8VES86)L92!A="!*=6YE M)B,Q-C`[,S`L(#(P,3(\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$;6%R9VEN+71O M<#HQ,G!X.VUA6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@&5R8VES86)L92!B971W965N(&]N92!A;F0@=&AR964@>65A'!E;G-E(&]V97(@=&AE(&]P=&EO;B8C.#(Q M-SMS('9E6QE/3-$9F]N="US:7IE.C$R M<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P M/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@ M=VED=&@],T0V."4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P M'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R M/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@ M(#QT9"!W:61T:#TS1#@P)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q,B4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q M-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[ M/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W3IT:6UEF4],T0Q M/D%W87)D"!S;VQI9"`C,#`P,#`P M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/DYU;6)E'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/D=R86YT960\+V9O;G0^/"]P/@T*("`@ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^ M(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL M93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T* M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O M3IT:6UEF4],T0R/DYO;G9E6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA M6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@"!M M;VYT:',@96YD960@2G5N928C,38P.S,P+"`R,#$R(&%N9"!*=6YE)B,Q-C`[ M,C4L(#(P,3$@=V%S("0Q+C8@;6EL;&EO;B!A;F0@)#$N,B!M:6QL:6]N+"!R M97-P96-T:79E;'DN(#PO9F]N=#X\+W`^#0H\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6%L='D@07)R86YG96UE;G1S(%M!8G-T6%L='D@07)R86YG96UE;G1S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-# M+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W M+G3IT:6UEF4],T0R/CQB/DY/5$4@.2!,24-%3E-%4R!!3D0@4D]904Q462!! M4E)!3D=%345.5%,@/"]B/CPO9F]N=#X\+W`^#0H@("`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`H;W1H M97(@=&AA;B!.:6-605@@86YD($YI8U9!6"!!;'1EF4Z,7!X.VUA#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S M='EL93TS1&UA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!E;F0@<&]I;G1S+B!(;W=E=F5R+"!'4TL@:&%S(&YO M="!I;F1I8V%T960@=&AA="!I="!T97)M:6YA=&5D('1H92!D979E;&]P;65N M="!O9B!T:&4@9G5T=7)E(&=E;F5R871I;VX@;FEC;W1I;F4@=F%C8VEN92X@ M/"]F;VYT/CPO<#X-"B`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`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!0 M54),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A M;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E M9"!.;W1E(#$P("T@;F%B:3I.;VQ2:6=H='-!9W)E96UE;G1497AT0FQO8VLM M+3X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$;6%R9VEN+71O<#HV M<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'1";&]C:RTM/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P M>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E=E(&AA=F4@86=R965M96YT6UE;G0@;W(@82!C:&%N9V4@ M:6X@8V]N=')O;"!O9B!T:&4@0V]M<&%N>2X@/"]F;VYT/CPO<#X-"B`@(#QP M('-T>6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&4X,C!E.5\R.#8S7S0R M-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA,S-?,#5B9&5B,60T9#9C+U=O M'0O:'1M M;#L@8VAA2!O9B!3 M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T3IT:6UEF4],T0R/CQI/E!R:6YC:7!L97,@;V8@8V]N2UO=VYE9"!S=6)S:61I87)I97,@*')E M9F5R&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@ M/"$M+2!"96=I;B!";&]C:R!486=G960@06-C;W5N=&EN9R!0;VQI8WDZ(&YA M8FDM,C`Q,C`V,S!?;F]T93)?86-C;W5N=&EN9U]P;VQI8WE?=&%B;&4R("T@ M=7,M9V%A<#I5&AT;6PQ+71R86YS:71I;VYA;"YD M=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@06-C;W5N=&EN M9R!0;VQI8WDZ(&YA8FDM,C`Q,C`V,S!?;F]T93)?86-C;W5N=&EN9U]P;VQI M8WE?=&%B;&4S("T@=7,M9V%A<#I&:7-C86Q097)I;V0M+3X-"B`@(#QP('-T M>6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2P@ M;W5R(&9I65A2TM M/@T*("`@/'`@6%B;&4@87!P'0^/"$M+41/0U194$4@:'1M;"!054),24,@ M(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO M;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O M=6YT:6YG(%!O;&EC>3H@;F%B:2TR,#$R,#8S,%]N;W1E,E]A8V-O=6YT:6YG M7W!O;&EC>5]T86)L934@+2!N86)I.D-A51E>'1";&]C:RTM/@T*("`@/'`@ M7,@ M;W(@;&5S2!A;F0@1F5D97)A;`T*("`@1&5P;W-I="!);G-U7!I8V%L;'D@;&5S M6QE/3-$;6%R9VEN+71O<#HP<'@[;6%R M9VEN+6)O='1O;3HP<'@^/&9O;G0@2!O9B!C87-H+"!M87)K971A8FQE M('-E8W5R:71I97,@86YD(')E8V5I=F%B;&5S+B!4:&4@0V]M<&%N>2!M86EN M=&%I;G,@8V%S:"!D97!O2X@5&AE($-O;7!A;GDF M(S@R,3<[2!S96-U2!L:6UI=',@:6YV97-T;65N=',@=&\@;VYL>2!I;G9E'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO M+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L M+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O=6YT M:6YG(%!O;&EC>3H@;F%B:2TR,#$R,#8S,%]N;W1E,E]A8V-O=6YT:6YG7W!O M;&EC>5]T86)L93<@+2!U51E>'1";&]C:RTM/@T*("`@/'`@6UE;G1S+"!A;F0@<&%Y;65N=',@ M9F]R(&-O;G1R86-T=6%L('-E3IT:6UEF4] M,T0R/DQI8V5N#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/D9O6QE/3-$;6%R M9VEN+71O<#HQ,G!X.VUA6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F5D(&%S M(')E=F5N=64@=VAE;B!E87)N960L('1Y<&EC86QL>2!W:&5N('1H90T*("`@ M'0^/"$M+41/0U19 M4$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L M;V-K(%1A9V=E9"!!8V-O=6YT:6YG(%!O;&EC>3H@;F%B:2TR,#$R,#8S,%]N M;W1E,E]A8V-O=6YT:6YG7W!O;&EC>5]T86)L93@@+2!U6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F%T:6]N(')E;&%T:6YG('1O('1H92!D979E;&]P;65N="!O9B!.:6-605@@ M86YD(&9U='5R92!G96YE'0^/"$M+41/0U194$4@:'1M;"!054),24,@ M(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO M;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O M=6YT:6YG(%!O;&EC>3H@;F%B:2TR,#$R,#8S,%]N;W1E,E]A8V-O=6YT:6YG M7W!O;&EC>5]T86)L93D@+2!U'!E;G-E4&]L:6-Y+2T^#0H@("`\<"!S='EL93TS1&UA#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/CQI/E)E2!E>'!E;G-E9"!O=F5R('1H92!P97)I;V0@;V8@<&5R9F]R;6%N8V4N(%)E M'!E;G-E6%B;&4@=&\@=&AI M6UE;G1S(&)E8V]M92!C;VYT"!M;VYT:',@;V8-"B`@(#(P M,3$@=V4@2`D,"XS(&UI;&QI;VX@;V8@ M8V]S="!R96EM8G5R'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\ M(2TM($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O=6YT:6YG(%!O;&EC>3H@;F%B M:2TR,#$R,#8S,%]N;W1E,E]A8V-O=6YT:6YG7W!O;&EC>5]T86)L93$P("T@ M=7,M9V%A<#I%87)N:6YG3IT:6UEF4],T0R/CQI/DEN8V]M92`H;&]S2!T:&4@=V5I9VAT960M M879E2!A<'!L>6EN9R!T:&4@=')E87-U&-L=61E#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/D$@=&]T86P@;V8@ M87!P2`S+C&-L=61E9"!I;B!T:&4@8V%L8W5L871I;VX@;V8@9&EL=71E M9"!N970@;&]S"!M M;VYT:"!P97)I;V1S(&5N9&5D($IU;F4F(S$V,#LS,"P@,C`Q,B!A;F0@82!T M;W1A;"!O9B!A<'!R;WAI;6%T96QY(#0N-B8C,38P.VUI;&QI;VX@<&]T96YT M:6%L;'D@9&EL=71I=F4@51E>'1";&]C:RTM/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/CQI/E-H87)E+6)A&-H86YG92!F;W(@96UP;&]Y964@65E('-EF5D M(&%S(&5X<&5N65E)W,@&5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$ M5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G%!O;&EC>51E>'1";&]C:RTM/@T* M("`@/'`@"!N970@;W!EF%T M:6]N(&]F('1H97-E(&)E;F5F:71S(&ES(&UOF4@86X@:6YC;VUE M('1A>"!P"!R871E(&5X<&5C=&5D(&9O2!E=F%L=6%T92!T:&4-"B`@ M(')E86QI>F%B:6QI='D@;V8@;W5R(&YE="!D969E2!B96QI979E"!AF4@82!T87@@8F5N969I="!F'0^/"$M+41/0U194$4@:'1M;"!054),24,@ M(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO M;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O M=6YT:6YG(%!O;&EC>3H@;F%B:2TR,#$R,#8S,%]N;W1E,E]A8V-O=6YT:6YG M7W!O;&EC>5]T86)L93$S("T@=7,M9V%A<#I396=M96YT4F5P;W)T:6YG4&]L M:6-Y4&]L:6-Y5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1&UA#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/CQI/E-E9VUE;G0@ M:6YF;W)M871I;VXZ/"]I/B!792!C=7)R96YT;'D@;W!E&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T* M("`@/"$M+2!"96=I;B!";&]C:R!486=G960@06-C;W5N=&EN9R!0;VQI8WDZ M(&YA8FDM,C`Q,C`V,S!?;F]T93)?86-C;W5N=&EN9U]P;VQI8WE?=&%B;&4Q M-"`M(&YA8FDZ4F5C96YT06-C;W5N=&EN9U-T86YD87)D51E>'1" M;&]C:RTM/@T*("`@/'`@2!A9&]P=&5D M('1H92!P5!O;&EC M>51E>'1";&]C:RTM/@T*("`@/'`@7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2!396-U2!#;&%S'0^/"$M+41/ M0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T14 M1"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN M($)L;V-K(%1A9V=E9"!.;W1E(%1A8FQE.B!N86)I+3(P,3(P-C,P7VYO=&4S M7W1A8FQE,2`M('5S+6=A87`Z4V-H961U;&5/9D%V86EL86)L949O'1";&]C:RTM/@T*("`@ M/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@] M,T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@ M/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W M:61T:#TS1#4P)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Y)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3XF(S$V,#L\+W1D M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`- M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Y)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`- M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3XF(S$V,#L\+W1D/B`- M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@#MM87)G:6XM8F]T=&]M.C%P>#MB;W)D97(M M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W=I9'1H.C8R<'0G/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0Q/D%M;W)T:7IE9"8C,38P.T-OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@8V]L6QE M/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F5D)B,Q-C`[3&]SF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@8V]L'0M:6YD96YT.BTQ+C`P M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/CDY,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D-OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`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`@/"]TF4Z,7!X/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\ M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M("`@/'`@6QE/3-$)V)O6QE/3-$)V)O3IT:6UEF4],T0R/E1O=&%L('-E8W5R:71I97,\+V9O;G0^/"]P/@T*("`@/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0R M/C(L,#6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@/'`@"!D;W5B;&4@(S`P,#`P M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@/'`@2`M+3X-"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&4X,C!E.5\R.#8S7S0R M-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA,S-?,#5B9&5B,60T9#9C+U=O M'0O:'1M M;#L@8VAA'0^/"$M+41/0U19 M4$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L M;V-K(%1A9V=E9"!.;W1E(%1A8FQE.B!N86)I+3(P,3(P-C,P7VYO=&4V7W1A M8FQE,2`M('5S+6=A87`Z1F%I'1";&]C:RTM/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D M9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D M97(M8V]L;&%P'0M86QI9VXZ(&QE9G0G(&%L:6=N M/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@ M/'1R/B`-"B`@(#QT9"!W:61T:#TS1#0V)3XF(S$V,#L\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^)B,Q-C`[/"]T9#X@#0H@ M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\ M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3`E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@ M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3XF(S$V,#L\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q,"4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\ M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^ M(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/E-I9VYI9FEC86YT)B,Q-C`[3W1H97(\8G(@ M+SY/8G-EF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]L6QE/3-$)V)O M3IT:6UE MF4],T0Q/E1O=&%L/"]F;VYT/CPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/DQE=F5L(#(\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT M:6UEF4],T0Q/DQE=F5L(#,\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/CDY M,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@;F]W3IT:6UEF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$L,#@V/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/C,V-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^ M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@/'`@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C.#(Q,CLF M(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/@T*("`@/"]TF4Z,7!X/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$ M)V)O6QE/3-$)V)O6QE/3-$)V)O M'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2!O9B!/<'1I;VX@06-T:79I='D@56YD97(@4W1O8VL@0V]M<&5N6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C0L,#4S+#8U,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D=R86YT960\+V9O;G0^ M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT M:6UEF4],T0R/D5X97)C:7-E9#PO9F]N=#X\+W`^ M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V M,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T* M("`@/"]T6QE/3-$)VUAF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/D5X<&ER960\+V9O;G0^/"]P/@T*("`@/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$ M)V)O6QE M/3-$)V)O3IT:6UEF4] M,T0R/D]U='-T86YD:6YG(&%T($IU;F4F(S$V,#LS,"P@,C`Q,CPO9F]N=#X\ M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/C,L-C8U+#(P M,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)VUAF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T2!O M9B!.;VYV97-T960@4F5S=')I8W1E9"!3=&]C:R!!=V%R9',\+W1D/@T*("`@ M("`@("`\=&0@8VQA6QE/3-$)V)OF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M2`M+3X-"B`@(#QT3IT:6UEF4],T0R/DYO;G9E M3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/C0P-2PY-S<\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@;F]W3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/E9E3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B@Q.3,L-3`S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/D9O3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/B@Q-BPR,C`\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^ M(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T* M("`@/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$Y-BPR-30\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M;F]W3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'1U M86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@@8V]L&EM=6T@6TUE;6)E'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6UE;G0@&5R8VES92!O9B!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$6UE;G1S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE M;G1S(')E;&%T960@=&\@=')I86PM'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\U-&4X,C!E.5\R.#8S7S0R-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA M,S-?,#5B9&5B,60T9#9C+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^3&5S7,\&EM=6T@36%T=7)I='D@4&5R:6]D(&]F($9E9&5R86P@1&5P M;W-I="!);G-U'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S65A'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M,S7,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\U-&4X,C!E.5\R.#8S7S0R-CA?.6$S,U\P M-6)D96(Q9#1D-F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31E M.#(P93E?,C@V,U\T,C8X7SEA,S-?,#5B9&5B,60T9#9C+U=O'0O:'1M;#L@8VAAF5D($-OF5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB MF5D($QOF5D($-OF5D($=A:6YS/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)FYBF5D($QO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$F5D($=A:6YS M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYBF5D($QO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&4X,C!E.5\R.#8S M7S0R-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA,S-?,#5B9&5B,60T9#9C M+U=O'0O M:'1M;#L@8VAA'1U M86PI(%M!8G-T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U M-&4X,C!E.5\R.#8S7S0R-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA,S-? M,#5B9&5B,60T9#9C+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^)FYB'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'1U86PI("A54T0@)"D\8G(^ M26X@36EL;&EO;G,L(&5X8V5P="!3:&%R92!D871A+"!U;FQE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'1U86PI(%M!8G-T'1U86PI(%M!8G-T3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\U-&4X,C!E.5\R.#8S7S0R-CA?.6$S,U\P-6)D96(Q9#1D M-F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31E.#(P93E?,C@V M,U\T,C8X7SEA,S-?,#5B9&5B,60T9#9C+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)FYB7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)FYB3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U M-&4X,C!E.5\R.#8S7S0R-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA,S-? M,#5B9&5B,60T9#9C+U=O'0O:'1M;#L@8VAA'1U86PI("A54T0@)"D\8G(^26X@36EL M;&EO;G,L(&5X8V5P="!3:&%R92!D871A+"!U;FQE'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5R8VES92!P'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1U86PI(%M!8G-T&EM M=6T@6TUE;6)E'1U86PI(%M! M8G-T'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&4X M,C!E.5\R.#8S7S0R-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA,S-?,#5B M9&5B,60T9#9C+U=O'0O:'1M;#L@8VAA6%L M='D@07)R86YG96UE;G1S("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\8G(^ M26X@36EL;&EO;G,L('5N;&5S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6UE;G0@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G1S(')E;&%T960@=&\@=')I86PM'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S6UE;G1S(')E;&%T M960@=&\@86YN=6%L('-A;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XR,#D\2!P87EM M96YT'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,3DP(&UO M;G1H'0^=&AR;W5G:"!$ M96-E;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^=&AR;W5G:"!$96-E;6)E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&4X,C!E.5\R.#8S7S0R M-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X7SEA,S-?,#5B9&5B,60T9#9C+U=O M'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^56YD97(@=&AE(%)I9VAT'0^075G(#(U+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^075G(#(U M+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\U-&4X,C!E.5\R.#8S7S0R-CA?.6$S,U\P-6)D96(Q9#1D-F,-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31E.#(P93E?,C@V,U\T,C8X M7SEA,S-?,#5B9&5B,60T9#9C+U=O&UL#0I# M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I# M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U&UL/@T*+2TM+2TM M/5].97AT4&%R=%\U-&4X,C!E.5\R.#8S7S0R-CA?.6$S,U\P-6)D96(Q9#1D &-F,M+0T* ` end ZIP 14 0001193125-12-347793-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-12-347793-xbrl.zip M4$L#!!0````(`$V&"4$+.9J89VX``%*7`P`1`!P`;F%B:2TR,#$R,#8S,"YX M;6Q55`D``Y(B)%"2(B10=7@+``$$)0X```0Y`0``[#UI<]LXEM^W:O\#1IM, M.56Z[=BQX_248[N[W1T?&SGIGMK:`AR8ESV)'' MFJI)BR0(O/O"`[W_C^DX8M="&ZGB5[5.LUUC(@Y4*./AJUIF&MP$4M;^\=-_ M_]?^WQH-]N?KMV_8+R(6FJ*=WNS[4=)H[:ZG9U/06Q'^!>`J$/.D_R%`3=]&NP>T`J-=J>Q MVN,K:/1-TS---;,6!$Y+UTEHA7-2/'2833TKV1%H-7-21UPY.Y M.35AC;7L1"@\ARI.Q31E/1&D(+-6=.!9X.[+\%7M/!:G<#DZCD,17FUVCD0` M\SEP8*R(4YG.W!5;]1&BIPF(=(*).CT!S?D)P&D2F_59Q-Q\HXK`R;+.#4X>E0?NMTN3[+8?] M(BEZ_0@M_YE)?O>=1)JY.XB1+S=4;<2VB3:>. M5^^N>E>_*/#/,4KG52]1L5&HM,N4?U#Z$IP3,`H)>Q"'QW]E0,"" MP%6XWO4*!N7\*;$')RG>O1M[5!+3W,S<@YAVUV)Z*S'MKL7T7L3T&\3P)A'O M/!`Q70EYN&^]ZCQ,,?V$SE?YUCGUP_>\*Y:LY#78>Q#3=4[]<'SU(Q;3=;*R8B;S M1[GP'V(;UT*W&@;P,0C=.EE9)RO?7>B^1\EZU>7MH8=3=U(1>>A&Y,%HZYV4 M%M;:NK+:>BPR;'1W/G^ZQAU:^"ZG:W):7*V8;'1N=T3E&ZE1 MM7&_91%%A*#T75:CD$[B.JV_EN'B:G/I\^<.I;!!X4]?-L MZ$P&UWRZXL3'\Y9[!UHC[?%E\WIVH568!>D9'SMNT!B+S:IG-S?9Y-6RR/8T MV?9]6N1<*GM9W\A0*RZ5"[GQ`77N(_P@'E@ M,7A0U%^9X^#?+T>9/_!^RC7:F+7_^;H3W6U,'CX?+M.PKS^:O]0DK))0?E]' MO(Z*OE$J[^<[`[?CVM41UFY4_?J`B#EL'(R^D^1 MIP*CNV=>>[?1N07S[+`[-Q0/H_SSPPS#CZH[K:YG>1@5JY44F+LLE:V2P#P, MF[)6[77Y>>4X-5\IVC3\+F'B+/[5O),`S[IF\:E@LG[_MG#R&X^1 MCF1`P9""MC=6`L-[,E=_:S3>Q3+_PJ?_P&>&]Y`\[WI'QQ>]G!JAQ*2Y6!S' MG65CS)55);0:"VXR+7YRWV/=@WGV6_YF(?[+WZ=ICT2LQC*^:6+Z3.N>&7$M MS$TS+TZQWRIA8`?-(7P!T^3H5A=+X&=UJ:4S'$80<`0\NDJUY-'"7&0DJF-N M,6F/$+T!L&546#H+<&%ABALY5)X!/P9[')'A6_@8+'UE6`QES%Y'*OC(+OEP M*$)VIE*1C_$>_HRG,#T685QYQ3`GCF_Q:[0W*N/?H_0EK'-T?GCYSXMC-DK' M$;MX]_K-R2&K-5JM/S8/6ZVCRR/VYZ^7IV]8I]EFEV"IC<0E>-1J'9_5V)(O M[UZ^;4UQK@Z^['XVTM*;S3`-:X#%WX?I2Z*;`^1&A#NLP6Y&=LE$R,$ZD.'& M1]/Y1P,@&#/I+`+3@[\;`SZ6T6PO!6=E6"PF3*LQCVO,R'_!D&X-W\87^_Y' MJ_B%$]SC[(F?>LPU$+"1JF2O\R*9OG37?96F:KS73J;YO-\&T-GYY3$PY?#\ M].+@[)_L_/WQV_CXF`#]P9]?0?). MSBN3E22`CY.76@RM9+@G%9%A_W?FJ72HX@_9$+!B[RV]_[\.V`.0L;H&S(%H M2`O`(M%2@"='^*^%2>606W/C^03>B8N"+M,3/+0^J-P:N_TY\?2U1QM&^&=9K'C2)"!N_]'Y_YF2Z3>!^`EXUXU$Z M8P,P%8PRNYGFI<7!0-'"/P-B($V98>]Z!V#$XFS``_#^0,DZ.XF#)MO(A[BU MV]MU(N"&O+YQ^9Q*R+@8K+6SH<"\2`'W#-LX.W]CGC79UWBQ3O=N'*_$'Z=" M#R%'RG??[)^O`(:DG/T*5`,<#'LC@5'YHAOS8#PK;,)R6(`I[%1$?:!X#'IYD!F(!R/) M\]JS-(!TR&9A(@(8F`5\<*6*/0:H`ZX;1U=@;Q/C':KD=JF\6AT"G_ M2+X],^B93<5PT8!B<;1JSLTR<+!@KT'^R/4+L+],:4`!#2\E`B@O=JV`)S(% M,3+X<7YO,`AW,0U&6,D(R=,`+]&7&I/!#9M,D&HBY``5(&6GJ,_CT1?P&)&8 MC,!PS!IJ$N,,OE5LEL^R@7)M>0'">H+XQ+'+(T@PBN>.8C2_!9))L%(QAX6` MTMZ&=]LO+2`7E<#(6'7+1W5>`H%3.YNU?&`P#/#9VD-GYP]Z1P?_R^AO&&`$ M\A$T#90;EZ4(Q-+/TXPF(/L9HVUG(\'#OS+(RYU@6C\6HS`Q^A,*9G74LY?U M/P#9D9`47@@]-M:,@^^CG,=8P@Q*'"FT!P0@I0?@QY%[Z*U@N>KPO=MC2W`C M?.6(&G%OWXQZ;A>63)SR/K&+)N^#6@C="$`R,1+:\S]>,LPW&Z!7PWB/16*0 MUI@=^ZK6KK$`W)"+Y/-KD_#`7T]DF(X@7&RWGQ)`K%A=SUV'?O#SIW-L*T>< M580J9$O#FV;L/JVA=P`47M6`8#7F?A,ZWV;!O>IL?Q%`G3F`OA>^9;P6%BA) MU'?#_Q@MJC4MSIQF*186*2&28\R70*?!7H*7PBA=+5,('YQ1+<'^A10<298- M+$1N2M#ZMIO;V[O=3K>[V;$#G`7>P/@"##TA"9XE`V3&?(;3\O!#AD:LXH,* MA;Y1>XO,#ER*G83BB"CF.4JYID.H M(R.:&-PH5A)]"903KE@D;-C")B#-[88\Z`(??S[3^A8EO^/D[*(<4%:C)8)E M,9XSGT_G;@H&UUG:VK8]8-OF,BG,1PR*OQ9IIF.?8U6,7B5*A\R+:FU4ONXK M,%5/GF_EA>T-6]F5!N;[*Y,N:^OC=EH$)LI=DWI2L4Z$OBSXK&XS'<+5\%2: MP2/)``;T5??,!'2*AL"6,SV*,1AW:-%!7=;RU-8P?<) MFBT-%_.5\ZA\NMBF5+J:O%%^-9 M.:G%=YZP[E:SX*C/41,NK=>JI&PCY8@B*/F3.B>>8AGNC+@=D\#N-N8Y;I64 ML,QOFL(\ZU57ZD5CF)>$P:%$*>IF4_2ZEP3]7TLO9AXP\(!H9N=I^+ M_IRYP?UQ,']4$<%-$E#"A,\HPG,#N)84&M&F'%D6U%#IC!G!0(\X&V38@>-L M,K87^'I\::[%/Z MW:GJ]Z="ST\I^+(P]A.VXFMEX!""SFP\YKXAH11\2N,C5@(*A"+(0"2H9Z`4 ML0[(WRS=%Z/Y<.]_EHC%33(TN7D'2F7'K.0E*KMTM%U=VGZU7M%V&I0`=SZR M(K[Y+AL(*`]@M1"WX>UN%DP#\D4&M00>PF%WH!=VG#GD0WIL>T2NL8_,K5]: MC$.N\T%IF<[\0UWX#J41N( MA:7H\W%(,VJA1LBS=`2`_PM[Y.`U(D$O][/==KO> M=O_'FCHDB0F/P-OB!B]V(^35:<27:(QSAJ%KT;.@%/.!L2BSCNI%H>LC<#ON M_1+,KA!/$'.[E>5QN]U68[V\UV@W]&_+7J+$)UF,@RE:3?W.VWS(E'.WX&:9 M3JBDE:A0+:NENWC+E^1Y*?YUHJ^S2.2YY)+]TM79XJ3]FX3K=%:MM/2XRN)2_U%MA- M$#%-I%R[/JH/ MECB5DKMV7<00G5-+8;]B`4KU$H(X@(P%6]#<-!:[18')MW)\SR)0!!P++(KI M&BW(*0.L*$^IX852#^["C[\R8/1`HKDF)431PX8QT/4YL-"=1%$^P%?(S+W! M2VU]GX7W)C!`%G'/CNR/187P7XH.XEGHI4_^W`R6CS(MB?62=@2W:SP!*ZG@.4H[G54KL3:-(O&^/"Y'K ML3NX$<9P\%Y6H:PR^ MBUAYE*785)L1>;S%T1KO#_$ MEFMK'^C13M=V6><]$9VM^O.MG?KN[G:I66!A74IB*CT`3RJ%*80+_@7CP(>> M""8U)2#1EE4GZ#2W7U#-;8`VL=2OD$.7AW(5PF0D.OR:0YJ+<0-I*L`PHD;[ M51$C,&OH'!1FY1C[VXYU+2(YMMV-2(L9=N3A24IKX,!#G$+\C@$-NP#EBFTT MBT<:TMQ>`3UFKE:,$RLP&$Y17?MHT9KJF@\',J+$BKUH_(X4M65AY/&2,JD- M[M&.`?NHB7N0K[OH94MML#+G5A_"'8(0XQX?*!)G782^.ES*E=W51.8P^Z7W MNX-5.IZ>X@>J7:_UQ)I42ULQA2C:H,&=*!V%$\C2@#?YL8;(?\"GU,[KET#M M(LP7N\=]LCAW`,8VMC?*K>3%*0I_.J;)WH'X>5M+X.:5);+5S[87(E!JT M764*7LR#E(K;XH6_@LF&&(RY3G5`HEIYB#WR**)]"KQO()(K7?D:BL.T3O9' M:-QC!7X1#<=Y([HHD4J63]"(J338M5\B85YVR_O0>018Q39_Q=C,E#KW4S6D M8Q*N\F'[RJZQ9\SW0>,]0KA\\B4?!7"VE'L;S#V>0X&[Y5BVSD)E..X$:!=2 M@4'`VJ*U`1M>$@L@S3/?6S]'XD^0\PM(Z0EDRXNL=$XAP!I,B+%3?N+*"V3Y MF([^[,$>?VRG5'YT\02X@@@L#QZB0'H*#"$W2J3V?`:8EQ&F29S`Z$W&+LS. MC+57(!>A0LU7:]XB2M!=8!^YTM46_@4?A4$CRA1<.*;EE-K>JRY#^D2FV)^J& MF+`H/2O*/HB9,P94NH-_Z?1`@!N?FK9UEY0$EU"KO;NX-.07="8OCE'9<0.# M[&YI4V.9Y3%6PX'MJL(B?Y0I)SKY69H:L[>YZ9=/70?Q`)FWI\=2]ORI#8V] MGZ`#F50"IJ0IME>NX&,70+PAY9:X,6W8SM-ZGN_YHZ>V@AR*1%@]P!,B(^MA MOA1&%9J"/QK:@W!4/`CP(%O(-1W8HSWH?+/IR6:[D&J4 MF.WBVJ6%6O7MGCXE]DCW/+EVH"Y3!7?J0CLN2>J#9EGLAR(,+V9I%9(M5F'^W]^5/ MC2-9PO^*HK8WONH(0_O`!JIF-L)%4=7,5@$+U/3.3Q7"2H.Z;S,82):Q4?T@/3U M%QG5Q&BB3JB-,\*#U(J!D(+<961_C](J6?D5:`_)V55:N\/3S7&Z#^,OH6T3 M.5,YH.K4F*M.!T*=#]0&\#S1`'8.O4R0T&FEM@Z"="VG>U#X)CH!1CRHY4"; MSYN)/>UWK;.#1\+R>W!,IE*ZX4<\GA)>.NF:I.'-9T[;Z^Z;TV@8D:;J*M6V M(4='216I%I]Q3NFF&1H..A7078QIBX)-P.<*[@)RBR'04=R8E M(96FU^0>#14TW9PS_;??R@N.6-5;,'.SM#[+,C5<+J([%P"G"=#9'XZ0JL&' M?N!=6FK;Q5#'_%(:)!VGCWZ,R`4P;\2/A"=[715@VE8%F$VC*@?&\U13:3L? M^M=GU\[%)^?RZO3Z]/RF?W-V<>[TSS\ZU]^^?NU?_0M_NS[[?'[VZ>RD?W[C M]$].+KZ=WYR=?W8N+V#+SDZOMU&!96W[(TDS$Q#WF96:X'+MH^-H3V6)Y\(# M`[VSF$^M`^=CO9.ZQ`*R29-V%S=4-@O[&&C!`3K/T$V&,A5Q;OMY4UTB$"CC MH0:(,0\RZ0ST1?0:(\,P<'"1">F15;4K[&(LJHK#$!4P%F-+%J>\._$]"M:@ M`7P$*+(TM-,BTS[\&U5T*A(#7(E,:!R4!?)(DAN7,_V*$*=<,3"5I,48!X*& M4G];TH`T4ZET:&K,J28C5QAI0=$LF>V MFKC:3#D,PR3`>^_IZRKWD+4AW'=R<16M3YFX)VY4[`=CM0:'@E_$A`3&`2F7 M7`^'HF5&QNR?23O'M?;'@*J!Z[REPBJ?^_W+7ZWR/6:;T74R]I-\3BG6U(O8 M[0*GCX-`+"6"$(Z';Q#YM\;Q3G.9AM;TQJE,>:4EGX3CL1]C8<5]V$.8+)KK[)Z3=8YB>^PC@O>VSS+&E9B$$;F+ M/\%:0'S9^V]].$DOI3B-N?>/G1@:L)+]L/=B!^5F<\(I(]=BH>\L76P.R1IF M\HX*:+(B[*D4=LD!]"%?<"O69:R*2UT@6M]&PJ1Z`^6R/)D41Y]Q7,*LUN\G MS%71.J M6DPN99!&$3@84SIF8P@&4<#5Y75;^CV_9D+<[-`[JH&CAK.T95P*P8^QL48N MV,=8MY0#D(CS#RC>ASU.MKJE<;R#A_"3D4@D1C)G\'<0)4-D]R-*IB0IT+S` M'$,:]T884GJ-^J+GDJ52<9)]XF!P#LD]V%`1&CP;#TT14Z[3[>P]"O%75DPB MLX:LU22#"=EO/MW[XCZ2G4ORG0+PV"JN[:^@/_OQ>R9CP/Q5HJ@:0%6@DR9& M'6'F`T7C2*NL'*Q#9U125H'P2)8U((<2N4H^8Q%B)P^$6AU+:G3K9CBC&T6< MC&8NW[#H17.[V/0V4]J-O1N<**3%B89AGVSQH]^)0*GOE3G1BF?Q2%F1F1_N MG,IU,JJ_7,ZY%0,WC2W)?N1R/C%&K47)'KH)\72D5F!U+.QU[^#&G@#N&S,[ M(#W1!9M@[_E)[BUE1U5U$[CHI&9'&&(?^?%?#;+2`]I&/KSK68,SFP+*`DMU M1PJ7TJ)WW`0V,(V1HV-(U;X,",_!9\^O)H1#^(.D">(#!JK,D60R'UO!PW;( M:,/^'KAE,)@2CCX)-(FSS/=1D`8,I`GX&ZE6)U8N`Q:X9.U`K=-:7C*=2))G MHL4$)B&A\C0.L9A]V7HI!06H;*RC:'7\U1Y0F3TVT1(A0I4/'TFL*_'>20/0 M,T9D(+P#Q5/R8*[Z1T2<;(/9"4$`'0E9P9(]2CIT.Q+W&$[S(!2^W^)8OY)M M'IE\S(G\M"]X1H"(8E039ET9WFI-1P5QI,YB;1WRZR$(AB%9=:6>*$FY"K$C M=-L2+%!;N`GP>KF0:P4X8)PW[%XTM9^VX+7DAZ$?Q9A!]X,%*MHP%7W)%68S MH&-@F12(@$X-A$=Z)R/VP1>/J!S;?!#474M(4PH"63@H@@3U:59-L04)1I(, M0#OP$\+R$D3GI::"&6H6!IA":T1C"P\VY2ID9RS;VDYF%3>;LCS!8P'Z.=Z8 MJ!>2>CK+BNYPO`0:@V0Z<@DW4W=2\C%I#Y/ZF8,%!!.ZC42:/28M)`^S_S_+ M5_TD9;F""`LY026T%%^?3#.C9Z.X=:5/S44SS@5)X11UHZ474SC4VY0?ITMY M5OLS+,)"CUU@Q^*?82"F*KH!PT\SQDB)!V5NP`1UQFLQ.D`63\KJU$HCRBQ" MK-VR&9@$UXJ)D7N<-87-L@E[RZW8-YTUZ(G;)'\N3%@8B#03%0I>!&V>KDS5 M-MBPHV\O&$VM[_;N(M<3,ZR7[-)TYJG"G#3X8OT5G3"G%7=U1*FH,Q(T`,'< M"21&PA22)?^?'GD7!:$KZ1"3_K*\Y>>"\O/Y$14#@G?&:M1"YEUE[1F#T(_V M)$>,C(K*:B>7>*!+;^N9,CP0ON.HMYCLZ(*B6DEUMN,K$(U2**8$`=R:1/HX M_Z0PK1A80J3*O1&#T!5;V,\]SA8/MDO**IB!::/U\A$/*0?!29,IBB>R2P-: MWRF6;,\=A13?->)H/8I4I[1;C+23ZATF6E+*ATL)X3F.X4]),/1`-`VO6Q.QFGP,J"9L`R)TVM'A$?E+C&@VC[.QL M-">>SVGFH"`BL(!GH#D#0)46,%JHS']Z MJVT%&9=VK+<+;B2E4Y&?G@)A.5M1F@NK7Q,FMF4_H]T&YO'C>VV@S!08Y@X$ MN>AR>?AGX\LMF=<4G+>#IDU>&%-2/I8M#'ID*5-:E+(V,JLP-1UBKM"BE%M@ M@.WNKRR7BB&,E\16\MLZ"R>#/\ZDQ$-Q7!]+5];WR)V M?JR#R*0KUL(.1@[+X"Y2J%1_`+M>`^)U+))YJ,%)@A`T6A0=D<7F\9*+,]JB7P>>JFUA9O9*RD0T55!Q'-B;N;26&*Z3IVU[T].C)CAK3:+H-L)[(:7 M0'(Q!0BZ(W2U3DU&\'NY4MT09M$DJ@ZSYF`9D2+#I[B2H7)/T[H4U>-2\"7W M=7=HWN4B.46:,HI63^YP.*H!)O\;LY?RDC-9R`[#=;-V9_EHR`)U9HIF%HQ! MCH0_O@5!DVX=I5YE)6VN4:0%:!5DCO&8]_)`DP^>+)!J,!.7(C&G`K>I<0GF M6R*GI9SJ$AU!^;J09J%`L4,8M.PUHY%[&T:R:9&E3-FZEVI/%;#>(XPLIZ0* M6"L[%25-M?W/2*>4M>71C3Q=RPIFZC2>489E4< M=4X1%L[=Q97?16$<2TLJ>G.U0_J]Y4:'X5)5@$J0"[<7B!_OE4-G7G2P07''` MH?NE8#;V)Q8]6475E$H5MF9Q0`Z`7V!<&WW0L[RU2_S;JKW%)O7X0W<@'?KL M!Y"C:#^A;-IW9KB%3BL"^?A^`H@RR/B2K9@'I$N-)*JOP4*T4J2V8 MD"P@3.I:6H.8\@14M81+*5@I\"JX\)$=<-Z>K)U@%1JSW\KV5K!\0GR!F=Q+ M-S\7RDH40$KHD25!)(WP1RE+OO07+`.E)>HMQ+5YJP1J5 M(J`@U8$0K,'IKTU:=P9?^\['!4\4^U*XW(6TC;*-9A8"5B@6C<\Q&3K;+C,R MXM:R(-YR(:RIVE7,IP9)8RI?`G7T7FTR+CZWT7CBS$;BI]PFFN(TLC@DUZ.[ MI<.?>U[%'Y`>6HARYO\EBR:_:.+O:>Q86=4*5H$=#)25$Z-RRD'G])\QZ3.% MX.K6DO=`F_>8Y2G*J?'$>NB<@(SL3^UN0]I_ROPA*;DXI'U!U?X2GG6RR&>! M48``X%#X[.F1%3\IK(MK(L>Z\D_$;16YUJ.R7Z@:4L:JB*%BVIW""J3:7DGW M&4T6(9''HP,3/.@41>N(65&/V+Y,B:S+VFO MV";*IBL_4[P!50.5^<]4MS"(Z7`8.>:=+>\2KY=AGYFX-,5HY5`NZZEC=-'* M`)M,)R\L0!A.A3"6$JTV4&0ONLAG'M("21G0+)?B^/,8HI2O23YEGX.L^J3K MRJ![#;\9AYX8O<\LK'@ZFX;1S-HP.&?63(*ZRJ-DSUY1F2Q5HMUD]VC,DZ$3 M,M_MEK5CMC=J1_Q=;VY3; MG=W,4I?R>N+^$#.6&5;X:2-]ZS'+H,!>(3NT6Y8$<+&7*4=WJ(ATZ8BV@LI4 M?U/+,6_58X"Y@`(%8N@71(^/25;CXR,"E_8QXK#V/$]5L5ZZ-!#>JEN1/"(; M*`@YEVJQ6B\=QT7![S@//#K;7YK6%CVVVU M=CAH8Q131OY?>&XI@BT($Q9-52:;)/4Y:Y`;V"NA]">B[V_EX+^:RX:.?TW` M9)JRU9(07B%(*;?12DUY"]666!M0<";& M-`BL#K]/+E=T&W%-T#CCL-2ZEK*YRQ0P4Y*H!('J][AH= M$R+5Y$4I`$U*6=+`@T$V_)?QC6>%CB(Q-[M1\D%C,F)>09BVMMF^+`R#*?Q! M`\H$SEA&"PTE6C*5$FS!U48!&RV M5&0HGLF7?5?4,G3Y.@J9@&LM<_Z#TM5P!5'`8AA(:ZYUW"7YEK4C6+POR^V@ MXSQ)(ZSK1Y==<2A-Z8Q[SJ9+\OJBTJDZ!M"UY\8"/)$*AK`6?^"+JD\+4VH]YH!U9N&MFUG8-$!A&C4(1QK%4`0$+@8A,X4FJV^&+6.=Y%P9T,[7QH\), M+):M$,EWJ<\)QI$8AP]R1KO M-'W/E9^G<`&@]Z-L\;9EAP:HJTBUC32C+QL%2,';MNV>?\2X=WU2$`!,.QRAG'6NJW5F9;IE!Z'JIL%+'KA1-5M4YS"T[7 MMDZ$;QNW,KJTV$2W`6? M@HS0J*66DI0V&;U9G+H6%M5\J%0V9M-52K91=*:O3.8@-F-!+I/-_EKKR'2L M.C(55K\3I6$Z3O^?_;,O_0]?3IU/%U?.=1_^.#O_Y^GUS=?3\YL=+/IRP])A ME)#9`$T?#>EHGY=_14;;$H-109I7<:+)K1;?^*$:W)\<7&/AG#G\ MLY`T@/<)OYUT2(J'+HL2*NWELOF+?9ADG&.&TREJVA*)7BOG/*"B1!!@YO^$7W[3,9!;V&86G M'4+:S[P77TA\W2&LO=+-.%6Z@;TAGT!-,,OZ)^H+3[T5>1Z?D8E162^7B/-2 M\X?0F\Y*S<[M':`^!+']/P8#(8;#?)MGLYJ"/L19-HR"_#M0P)MB+"5\'RN\ M)>_V^,OU%+_/.J9SCWH.A>A!,MK9[K+;M5;]RTJW27ZD8*SUYC\^[E2"("=/ M;A0'.TFQ7O2N:NMSV\;"\7K'=W?'7P;E7LF(\UA6U\DNS MXI*TJ5&L0;%!;9Z+>'>FK?%8XW&7IJWQN&4\SB7%+\:D?4,YB:]>?WQN2TB[ MT3P\?@'R1;VOMZCJ7QF%7GKHF8GDO8.G(]GUR<7V)[] MV^E'Y^+R](H:NN]@MMY'53ZSV>,.D]2X3+:85/6-)E%X%[EC5:7TJ\!Z)I'X MC?_P/:N4JBGLB3FS^?=5D119OX.J0L#4;7E_30YP43.$9H_*D^:[,>#C^*/L M*$:K4(0)U-N00&D$L?Z2$NZ];GKBIK8H$)I$YVI+6;>Y%5]U8E):4A.%?5'N:SH!=V=[4A\]7 M^@',R1HNJB!*7/:XK`%^:S<^IL6[0X0E6V&$6N],K9'L?@Y9'%D8$K)3O4KS MKL0$UB4YV^`07-GBQOWQ^JE_UZ+^\Y:]$Y2]ZYR=GUQ\/75N^O][NH/D_`]! M3>KMLC^1`.DKT(TNL#5V@RGG@PM46%4`X>N,]3]!1W#^!+80`UF3[;FLYD1_ MJAXJ6!H*^S+2R"#4T5(S[Q$%Y7HKCQ(N"R`@@V8(+L^+2=\BFCJ!2Q7/J)TY MT(9`MHWXP13'#519%&`3#]2R;THM0;CT+_67H&H>I0UP&]D2UH55M5R2PA-; M7"THB_43E("\MCH,_)EZLBQ2K/9`-T:5%3^(5@.REPZ7=4TP\(C$>@14GQP?^PI^J_+8''VO])13$]WV#C9A$+7N-6%YD(^F@U; M0N!Z?KK%2B"=8&Q'Q0:\/^6V%0;XK-B*QXFK*+3LG6"<'M1=N.>O]B05TDBR\V(V8 MYE6UTJ@6-/7JH,OD1X-TC'6?!EB14+4&IDXY:<+5?X:RGAI=U=VI3?--]_%" MX)"&I=P6C-I"2DD!*UK#T;7J"9]ASAKNM>I@=Q)ZHJ'Z3(`:/@IA9R*;U"') M=(:R.VBFH)I+8@S-Q!2,L#`SQ;6L?(GGETG5+5=:!KFUN^_\'CXB'3-]MR4P MNLNXK)=HSZW*.MJ[-EMN495CA!>X2VIL9&XNN2&;!^`3!%E#'2`]/A%IZ88^RK)%:79Z[$NPXT1TIL"\-D0IK,VGMN8N7@P%10827A/:"._#'#$*4 M*%)U'Y%1\\!V%:=*&L`\L7,;TCWFK5*VJIGOU19=ZEGB_=QU[X1\WW,^]<^N MG'_VOWP[)2/.EXOK;U>[*NE3$2+DSE3F/$%";E5.TFU?)0V;@+2/]^7_5%G\ M8))2.R2FUUQ"6/=YSU1@TATO37-?2[-70A("8+KR9%H7?L$&+DX+Z="0RUS# M-;W%BM"R@Q^!HAC9OU-J:4\UKEF]X*J[;)_FZ\XF'JRHJJKC9ML?\HSM!3.J MPLO`XB2(:M9B6*AF./>O8-,%S=V8A5B!JMMD(L7F932PL!Q/+*'0#UD`8BLC M@`K%Q3"*0FH*Q%TZK(=D]W#/35P&3?43I&K#S(&!+%*_<57_F[<1'K9VL+#Y M)2.DD\%@&IC9"0%R!9I1PG@)0P\76#62[OMLH_`M()Y^8 ML?LGDFE=#1S[NTK3)@AQ*$4R;O"@^"!^L>8Z#@,Q51=NG)+?3;ZIELBV5!3$ M[\7(XZZI=RE0,E-H^A;D)]7X"!O'S/P@(0BCJ2H'RA/0FDVK05[;[IRO)8]6 MB6^RQ#TZS^[.)0695926%9QW8%>_V\R3LI3C2S@H(RHG\D8J\_2.EHROX:#(Z&X[ICE>%4\YT"YAE[B[Y??)#&79OQBWF90NX+R`F ME!Z.4AILOQ5"GWF+*4Z;+79FIIND1/ER0F!(\<6=.8A7#-P"3[DZBFREB[ M7'6L&)#?1LEU/#EIDB3#3-);4-VQ@;2Z,5(PT(735S.2UE4R1W:5S(/>FE4R M6U7+;#[Q0S6\-;SS@G,KQ=PM+Q@L7^+RZ>+#[5IK+[IJW):&?>YB=/]#XHE9 MPR7)*>:S'YB_^R1UD)5)5JW[:EDQSI188S_0)[%FA_#]2K?1\FR:A5R@4&/O MQH4V>)B'SDCXW2%4_@0[-+(+<8:[LBGK<*YJ-9ZK54@^Z*Y;(;DNCEP-3Y03 MO$-W])6BF-Z&K%_[;'J4JR;>I*Q765AY^YWF6] MJW7&?[WC]3W^V7;UY=_CE53QNE)Q7=)REP]UO<$K`G+8KF8RJ+?W16YOI]>M MM_?U;N_KED9>?+VIUUFSM,9CC<<:CZ\/CW-)\8LQ6I?X'5^%6OCJ?$K7;S_3CTN%KJQS3! MLA;?9`LV_ MM/:[1S+!/''N8*<358$#RYFVN5#;)(T&]Y1:WSIH=`\.&\?'/1XR5@G:F:(J`^X(9?NE,H:O%8Z=)0M1KT.9BH0 MK"W4:\S2JR/G^O?^U:GSH7]]^M$YN?AZ>7I^3<6H=X]R]9TX'<.87/IBPH7A M,'T.JV%PT66\^'SC!]9^.).1&ZAZ\64E/U4%#ZJ""$!X5O4'*HILBOG3PJGF M-%!-'[/K18SQX5B\>!0^OEN),CQ#/GOO:'?SV8^JIA^7YB^W7D?^\B:SP-IK M9X%=<*6E10?\YTW>.$^S^>+AT/Q=BKPZL>-I?&07:8+USZ@8+/\(OAWJ?_L#J M<7%]K+=]K%^WHVU7C_>G,!H*OZ;:6S_>;WL'C=;Q\T<(_/KS$.X)=@*IS_66 MSW6GW6VTN\^??;GNP7[ID1`_7YCLKE*>G,)?;/NMZ=*6<[$:O1X0IN9+B+5\ MU73I9XGA>*E2$JFW9&BM:=6ST:I6&W._#UX@K5HU=&E>P,P6BNW_(9P[-D]* M)RYU9E01'0[9U%0L!\=E"&GXD>$CX1`C,(Z.Y[EHE7M6MK*T@CNP5CJM^4&U M\*"2ZBXWAR/(:(;F_G&/.R[P=[<"FT#%"AA"[:U('H4(G#`0TG\<"2&[3''7 MVIFQ5>]"BB4IJ#`O7.J*A2YLZ>*6#;FR$'*%?OS^P\@=_+5W/;@/J0<\O;.G MRO1CC?5TY'*OKG$887'!CR-]'T>!LCON,67 M"@QPZGB`)XH':'8;QX>'+U#H?@E6L#H:H':;KGVX7PXI_R?1\?JT;]G;U#KN M-+K-%^]MVM537(<#/-E![C7:[>36368B!^ZM_^Z+/T"TQ?W`NQ(/(DA%/XK0$_.JTXV/G3UG MF>7O1!&$8P<0>7I^?7KM],\_.E<7_^I_N?F7T[^ZZI]_/OUZ>GYSS2?P5A^_ M)3V%6\@N_D,X]^Z#<,@?0#W@D]`92:S3A8K"J3M*IHY[!S2%T*XK'4RBT$L' M"347][!]4SC!!U9S@VYA).[M\1-/2E[V3RF M+N(@%'NT./..6JA`D&(J+>[?`LB+=A@!W=W=$(?^+>YH_R5$1B((!V>N2^-U4R M$#V/8?07KOE>C"9J\VV<,1Z0+$4NH([B$1`_QG],BX\%/(*M[=THH4H:1-IW MQY&NC]"Y/_AG_W]SQ^>K"[N+$#?I["#GP`.!W`ZV+0;4(9Y&WB/LK\[=A^7R M!:-=U<="8PC/!\\&1XL6_"A@<]Q8\T[KKB'&AN%H%#[NP=B!/P@3BD[P/)^J ME8#H-1C`-_&^\PU/`H((\Q*X:G?Q:!TTK2,'9-L=J9,%+])6DEPAHC&Y^?&# M!IT&4\$M\AJ\]2W%'A`B%P^_AK=T]DJ0)$D//$@KERMM4%T3C$`!0?+_^/K! M5J5#.%K`J@VZ'!]N:1I%`-5H"A/XP*X;^+U"H3KZ$V`S`2T3B)N(`A=E!`H< MH?7)`9/P3F#G6Q-.X_V9/E"L#'U-!5I<6C#0B$GDBP1C+O13`.=OH7S;\[%* M#&Z9C(V@^]X`.3?&`)V0PW-<;PSXQU`3PM=;"4C?`!G_RE4;WOHY%,]'9U54 M*@0-4_IX)P)%F0SU4V=*'TA8T0.B$^D7?(/E:]3A+#B2+!WBLZDZZ;1VX#VP M2R"NI7CZ`)\`RM1Y:Z%:[3/`7(28C12GF4-$YJD?3U3'!(_:/9[S`,^JP/@D M1$V"!]\+\;TPT<@,Z#KJ.#+<*8DV>1V]E(Z&C,<:I5SV!S]>$M,Z.SN#W823 M0NQ-I@!-1N`->=UKRG1"I;,,G2 M.3E%YV!V"F8LB(A(W*4P4!A-F:9B>-X#3((K4Z*/^R=0JC$UG8?EIB"F^"0& M,66=G5)*;"2?M9O'L],G/@G0;A`@^8K=$1?EFD-'X<+@=L!>AYD]41*W1CA) M#31L`-!6&KI!*[]%_2J0:2#=_^0B8HKS`8,$Z1(+:N$#+&M&Q-`U_+CNV+GW M[^[QOX?_*>-*\53*5_'V@I+LR2$>[YE?+@NN,Q;P*.P(,#&!,8J@M7/MM0P^ M@;O>"=8WW&`*[X]@:C>BV%,']4**_H0[2JO_I=,TIQI/3<]\)HGV5HSH:J+L M*Z$S)T]*L!;1-+(:#'8+JD)ZBY>>)`<7R;``UA]1<&WDQW_!`(D_4O??XZA: M.(FWH-B.L'@3X`1WFZ0P`IQ!*+I\,>*&SP4<4[S4::".,DL]\)4ZBK1XDM"R M8O^#&_EAJNF!M-+8U)?5&G5Y],6);9A(H:#8V0%+6AR;K`:7BR!Y`.[3[(-C M+#.G-0U2,UP^8IY`!!-:U.(82SP`S+\[1%]:(^8=$M+KXH3.OI+#A@*)S"Q- ME?7]U(5'N4JI3G3Z1?0`(\3[ABI]L4:T)/E(2.[ORRL./Z%=%=540#!(H$BD M(H:>9\4CBT=9_#MEL1E?N0M@L?22?!:N%UH^IR9V6@9(RP#C"2AP_L"?N"IZ M^T]B<'$B!"E\*'7Z"7R*^2*4_:S5:BF7S*`5#KHMX:-YCYZF=:/,B!(J(K"% M/(TMC$@2,N'D&?T%1$Q<412F<`AU$%R[V>[.DRC_]MLR%JJ-&P;/P]$5^EEB M;5AXK<;`5E-9`^>L>2H-N\X?0C>AJ?_2!&@`S`*G/`Z6!C`640'`?CI#R\7Y8UBT2$/J@8()8 M%SA4IY,/SM".`>:_FIVC]_`CP$$(0'L[L/6&\^7+"2GM$0_NWI&101H-AG"W MB0-+I1._?!,^@E`1W_L3F:?P1A+F:V'5;"6_PE&;J8'F*2K#(1(@-0._2^`5 MH@\Z.041@I(,$Q=\913&,9E4-/7/XX$Y7P$:/3$8N20H@G($&^S^0#,=&SM` M#/!0G<(Y`]*J);WFBJPZ68CP0C2.\F9"*]U7UV[-%()E><5#NP+FK#!UM;:1 M>!1S"B3=96=C'[8HD,372(*Q?T0U"V45/VA)@<,09@%R=*IAJ`2&?\3J^6 MC+>L&K++86(WB'L+"\5^/;MA3PZZ>$XNSF_.SC^?GI^ZP;\?RW-!=1'HF MQI-1.$79D8TRY&8PUK^!&]];"C_<`)`.06>1.@,ECSE<'WO@B6372"J@($(^!I(F&BV(=A!`_3O&"^`?*3[J'9+H?<6LPY!14-L M2&LQXHM,?I'B0X#T?>>,!&*`UF6),Y/*&$Y`#T`;LS%2H-SK/AIBL%6C;D^H;OA*1,=T#[0`X%'!I9*/2QCN$ M]0=H<%;^+L]/E'L>9N3BY7I1N%(Z?T,T,57RVB]'3M8D[?T!V8N0Y5V&H-A- MWY%T2O2XV>LTOP-B1/N[JQ_[/J''OE/D2"LCQ5]&N/D34`_+DB$H^D>"M0>F05\ MSW?1-NJ\U>(HFP45J6DWW^.@#?T9&R/`K-;O2K*W'[%^3N/,+W#_K1\?179@ M4M.!D,*?/EHG)J`.@)[>!XI$DBAR)+*L)Y2P2Q-K#+"8B?(GGE=WP`0'"3N0 M;.638&YDMH('EXI`.7YP%`\HM"N9&\KAJ%<\HN\%97U)XA[F^2ZD8+KB>9Y# MV39$M;9RC=MY0?E;+"Z&I[)<0%Q3.XDF2X#.8NBYZ9BU+E7D(]\[ON"R2D.9(1$-0<0A%%V44#T=GL(7>ET-Y6H205%J9PLO>269L MC86KU7IP`3AP_<,Q>^=EY"2OVRJ_P*^94A4-*UB(!#8UG&51Q:40_"G5(3%R M9)\-S4H@@^T<>3)D05E/P]C"<26Q+'M(MT:3&B7/M)FGD MN>244HX",HIIYPG&0M%R>38>&M0DM/=U.WN/0OQES[&/462R8H_0]B^RP$[W MOKB/I&A*);D`/'9,:SBS&L#SO4*ES0<9J4!9,XJ:]`L6 MZ6H4S`@"ED0N+UW5?JE$).SCLC42T=DJB3B8(1&J&=[%\)-"YUD0)U%*E)^G MJ&F'Q)Y-.ZH@[OF)BKHAO@%M1E]SHVA*[@7#U(=%+QJNS=81M'R@I/.`MQH] MPQRD0L&\L1@`_T\X4D4I=>S\Y0)Z*/BH[U4$L-7%S;/+;LUK#$4CE3<*:6!= M,#>-M7Q#(@9E63CQ/4@E>VCW0PJ#X$[E4[&PUUV-.%0Y#UNC&@=;I1K=C"7H M!/8=_W]JMAYTO:]Z[Z_UUM>VH&)T*EO0RIA\;KJ"0#=F"(",T"V@`3;).*46I0Y`W^%L%GSZ\F!!KX@TPLI-X8J#(4D;67V+G#6).`O06W(VE\!M)G M?8_.0V"EB*-/`I,HV!#V$70C.((@78':YF+DT4D8@;KDR@#DP5^"9"&U3FMY MR70BI39<&L<="W028LE#CB7#]$3ZV!X+2'@:Q25E* M!>4D%D5^[Z1!)"@LVW/N7#^0JB4YFUD.11TL-V$DAB..@?$Y\HOCI='R%8E[ M3#-X$`K?;W&L7RGV#7576I[@?<$S`G*@'Q%:+971FNY>C#P5LFIM':JA0[A* M(04JR@`R*8VJGJ:$;MNL!P(CW`3+8S%K^;,"OT%EQMV+IO;3%KQ%50G93A#: ME0GWG8L\Z$`!E)Y/KAPOC31B'WSQ"(!G1/G;J6U[4%93%QAX8@4QH4W"#_PQ M1M@/(H$_(I87&_Y6)EY;8X+=K3+!WJR//,#B='Q3KP!G)X0^_*OF=!)G&4=Z M*;J>K]$J_HGVNY158AX+KI]TIB+W0DDS MDN>$^`Z'V_LC$D`'Q%T+&:FBR5*,EA&*TFD!K_A!0M286+/'K(7,?!Q%GA7K M_21EU9@8"P6V2FC_G;H8]YL9/>>O50%&6HCG>&@9$R,YG.)NM/1B#H?.#-8Y M?FEWFUA;>']&1+#08S%J6WP/`S%5,?+#-/"`]7+4+KDZ&`CA\4(C,4D9K\7H MV'?Z9=6]&[;'/X,0:[=L`4:"*XT-UAY_"PB@ZX3,P+-B@KWE5DZ81!RNZ3;) MGPN3+@4:U03M/67;E^9]#"WE89 MSV&>\V)4+GU#E7VGJ!=!BE^;I`Q.^D2J!@!OD?]`(T.'N"X[.$=)$%ZAE*WJ.@ MTCUW%`8J&!:)%V!LD,:P2YCG)XW=P*'#`>7%DS(@&3YE#%/2E(:.2]E3E!/, MIR;3X4F^\E8AR8N!/)-W"]]I&%@]#(2-4Y==?V[V.6"XL`F`W&E#:UJ4RZ"W MF7-6K=GQF$>#HY>9^'DY];AYQ46;=6!>!2173I"1HGN>MF'3Y@<:I+OF#J2T"O&,NY' M9OYI&F@H37*?2>)3)_D1B&XN81:?M*:AVW6+=B:5-/@^E_X:A""(1T3-X=P, M*=H(8SF-=4Q)X^3\4_&DUAQ4$^%]49XK]C20.T^!56X,<@5>/0RE@.MK)9_U M+6+GQ[J"B6!6:.=%^D-5681L,Y0VS.=/^A;9UC(6R3S4X"1!&$0"M1!DL7F\ MY#(=LR\_RD3TV26I4`U@UV)BLRU+`'B?QY.]/)F-XI.,'XX>3"::G?:M05%X M?\@ME'U$LY"[DPEU5=&04Z@T?NLU5E! M*'Q[28$&](2@\6CE;AYZ]YVS(7J3K;V2`A%=%43\3+IL1N-S'BG8)'M_,F3.*@V5$B@R? MX@1@.X])4[V8I(J2^[H[-.]RD9PBK:)%JT?:YL!1!>FL85G0Z6M3ZB6CS9QT*.F:+'%%.5(^.-;$#3IUE%UFZRD'7-1%25`J\QW+"%U+P\TGB]V M9JC!E-*@,<<6^XA\!7@0A\AI8>!2'4%%@R'-0H&B6I#%0CUM:UK\X5:U^*-9 M\_%HY-Z&'&=K9>*::>K@BPP",[;D:KA[;IT^`V=&5[=5>YFP@P6:V(2F504E MM,)5XJA.R;+M\'%D@\HNS)VR9$ZEJIS$')A9,:N.!:5LK'I%BZNXF`(.NOR4 M&-P'X2B\F^X[GX@HQXFY^!(ZNMBQ&AA#/%AU\"-/9RL]8GHK19@9&9:9LB+. MVJ9HHTE5"\Q,P]%3\L=",*=?DW$H=$Y`T\MG6D5/R M;.6*)$&]1=Q]TQ;&86>\5%#8<$D+1EHZUT<6EAG.!`'"$+\T]SNZ,A*AVQ)X M59%79".6"TV)P$L+JF\#7*6,T,!;/+^JRA*W=VOT_7B[*:#-/($_!6L0'75&H1*R$`@.JJI]P'A(/1XYKLW;4UV"`VK5:)# M,XTO6JI=V&3Q4@O6J(QB"E*=(L'63/VUJ2*;P=>^\W'!$\4A*G8#9.FOF(5` MEHI9,#YG:ZAR>-F1$;>6-^V6"KV-IFI7L7PKJ$53^=)8)/=JDW'QN8W&$V\BBHGFVPAREE9*5DTA1LF_I[&CE7? M5,$JXO?&XX?Y.N6@DZ/"'9-MKQ#<3+N%/9:A%"O6>%JQNT%YF$DJF])(KX/I MZZQ/%H6"8,;QD+MIT?V0Y7(H"9#K#$G_)-4^@B=9.S2V?*DA6AXV3"S442IL M3%7;*P4)1A,G33):)2$P2*,RQ1Y14$TF5#-M(W,)OH*C[2QZ1@57\I# M\LSHV2-$6VE>EKIZ$%+*=QCMCA6R;\J,9D6VSOZA.22ZR+L5()>Y(9H*F##> M#`4PGB:),.V9RVVHVD9U?39^^MVR!1_L]ZHM6&\LPR,/1@:F>="8PF>LA/@1 M*RPQN4#)DGLKLG2EDORZ0#[97JI^<[O":ZN@JE5AFY1:B"U!8+8.5A7DD(V`RA?[H09??90E"8YX4:0L*'8B;;9JO436%I5=P7G@T=G*JYQ; M#1@D_L'RGHR$^9%011@D<)Q)9YM_8V'6CD7S4.49^7\A_:,D,SAXK.92[2A_ MK,3&G!O,#>R58(5TGV3%MW+P7PW1QH!:S0AE)7NVA%!,/[Q.L7^:^BJ1&F5< M`(XK1/PALAEH`DFZ+((J=4!:J:DJKPK6:NL^SL28!N77X?,<]!=RT1&DSN8NF5@>6457@R;+8TBY`?T8[;*JV7064:. M3J'(<*VY@P"V$"M9#5KX280)`^G&MHZ[%`-D0S`V%915%:+C/$DC&)HONY)T M-*4S86\V79+7%PU8C'>7KSW]+2=2Y1+L&D85Y(DRCK$]`6*[Q8E:,]6)KL4= M$MPK51R*!ZVEB1+T6=)$)*MU&'F*K3<)Y$=S9U69=F8 M!ZIT:RIA9GM7:+O%>UH'F3H<5V*0B22Y1I\`RAGU%2I!GZJ[415SSWV%&$XK MYH@36A#2=XZY2V?C; MA-3[M_WK;[_2%'O-;L.Q"L.:&I_('T\RU1R8BQE0]QT81HU"=0MB:0$'+`0" M!5JI-Z!@2?Q?594N+!/!`I(?%98M9+,"(ODN]3T2'B,Q#A_DC'9S0\FA=7WP M0DR<6%7$'1":9%@;ZS<&8!)J**!6BR8J)J]P`<(G=>AMR\X24-(#=4'2NDG9 M*""]O&W;D?J/6`V#BE@B(>4./V(@C=`6@JS=D-XZCH.7MBUR3<##4M(9@[S' M`K$L`XD5-DIK>&1STU53#L:\%'`)+_:)\.U@D6S.31N@C4OE9FWU?W2S[K`L M9.P#M-4%N6);0">S42G*<8C%U3&JDICM\:+MEH1J=?/BW+EXM*(:HS`(46RW MBE_5;*D$DY9DMRP2GYM#`;PV>YID(+9YE.[>+4T"'OG*YS"<6'G'*'-0YQ>6 MEJBE[#W)QY`NZ\X&U$<@G&2M*Z5M`:0C5J8/EU;]-R`H;;22>+KL]FZ/.BRJ ME4/M!6[PT:)Q.[E:VUK\'MP++QV)BV%?1;M\"J-KUZX&A)D=`<8T$C9IBE=( M$ZKAS];IUD1=#BPV@`[$:!3#@8;M__N;YAOZ/,'VQO+SH^\E]W]_<]S^SS?. M+89?1O2U)`?\S1Z%D$YB\4[]\=[!/=IS1_Y=\,X9B6'RQJ$/?W^#3$]$;THP M1!`[OPO7RV,QB4@I-)\]!5NW^9]%+8T3;^:%!PD#$SFSN(KO/_%#-;@_.;C& ML3AS^&TZZ^Z[4GR7IK(=#>4J0Z*%P@/L2_+EI$A4.7!,K-4.,M` MAX&H!RB,Y>ANCG*7X6T]9/7':%O[/^&999"G>Y6U;`E%KQ3SGS%S#=^^C9S? M\(MON@JG6=AG+`"W0TC[F??B"X7Q[A#67NEFJ,X=GKTA6)';+(MJ`^A#$]O\8#(08#M^4K@:X['PY`07Y=Z`M M-<582O@^-O)*WNWQE^N9##[K_*R]>(*)(=0M5JLVN\MNUUKU+RO=)OF1XN#7 MF__XN%,)@IP\N5$<["3%>M&[JBW?;1L+R^&CWO%ZQ^L=W]T=?QF4>R4CQC-+ M(B=E191?J0RRIFB_N2/=:C2/>B_@4-<;7'.I>NOKK:^W_E61]7FR2F8Z'!8M M5.6V%!O@95U1*[\T*RY)FQI%>10;U++SK"3./,&T-1YK/.[2M#4>MXS'N:3X MQ9BT;Z@]KK3+4.U[O>+WC+X]VOVK=L`/"G!>F M&$7PI$+DAN:M,5ECLL;D3X?)/$G6G[.Q4T5Q4;]1]H.%],>9JOLE#.17"%2\1ZN/#`.3:HDA^QM&_\ M:EW/06S,OIU4UL>>)'ZKAK>&=IPYL25];/JGFZ312.[K[ M1<>I;VG8YPY__Y\T3.RT@TNLNAF;SWY@_NY313><2L7)?Z76]5P#ZPRMXUBX MRWZ`>>$.X?N5;N.UK[MZF85<8'T->S"(OY`[=T5>*YB_8VWA>YO9U>M][>U[N]KUL:>?$1KJ\S2ZK&8XW'&H^O M#X]S2?&+,5J7^!U?A5KXW,:/EY(V4^]KK036N]IJ=+I'];Z^NGVME;Z=5OI> M:^)3CC<0';#B. M71Q%$%.RYG4"4UQP#T_* M1^+:)L/_VVN'_\NS."O9[HJ!Z;FC=L_3;*)@.#1_ER*OCNA]&N/H19I0JVYL MS^DFSNJ]TEZHZKXSCMN#1K/;:?2ZU=((=E=;W]6#_AD$&-EWJ3[&6PT/:S9? M^!%^.=3[](>(!GY<'^MM'^O7;6'=U>/]*8R&PJ^I]M:/]]O>0:-U_/RNH5]_ M'L(]\:/Z7&_]7'?:W4:[^_QI-^L>[)?N`OOYXJ-VE?+D%/Y_I(%5":33)&6_ M0`>MZ=)&@_`;O1X0IN9+"+)YU73I9W'>O50IB=1;,K36M.K9:%6KC4E_!R^0 M5JWOLU[?';FRCSKO7E['P]HN]U&?A\&#B$')OH)_1_X`_J)%?0O\I'9/$_(* MW=,KX*WV3)=YIMNU9WK&,WVPKF>Z_^A&7NV87LDQ78:[VB_]-**?IJZV5]JI MG=%/Y(QN=AO'AXX]D4_V4'N-=KMYX\AJEUV/YO+[N6PU(QVA&9QI[:&/PUU:AT#=>J^ M1%OXJR)./XO?;I,.C!4,UNOZ+K3;P1/^N_Y8!![6#O\TP+?1^[H#+CKC_\6TVI#T\T];!\<'/`$ MA4/-S!2.Q]+A1[[`V`ZEL:?]X([<8"#Z\<7P>[/33^]H4B>%>T:_\]MO'$\, M_#&<\+^_.3O_!`@]ZL#_CHXS(,V9,P_?)W\DHA-`^ET85<1#'^0<>,E%28)> MM^?.C)>?[$K<^3%ZW9)S=UQQ0\_['\Z<#V<7E[_WK[[V3TZ_W9R=]+]=.^=P%2P>MBKKP!@G(2!N'2G>#SB;[!SU":U?Q<)@5]E`+MY M%*,'\16^N8_A?`KO>Z?U40S:S6;O^^5]&(_"[U_)SFSMU;?KC_9&[75AG[IT M?/[VVSJ`V4L;ARE<&]?W;D+:Y/MP!(_'-P+?@A%YYS-+N0AX'6H9_TA'N4-6 M!/C!00;R:O/:D`9!ZHYP'?$-B+G8B\T&ZMK_D4%N$W:?3L%7]X<_3L>+L=M[ M\U^]IOQ'03DSYR8`\H/*`'6>`J!S?_#@_I#P[!Z^5>R.F^G\-[WS^+0`)9#0W'S2IX MJ`+Z8@1\FPPC6,\Y'I-A&GC48-R,N<+:%YS?2FM;`%7E9Y6`KU\YDT#7W%7=F(MVZ2,[65.5@X>:QVG<0*# M@A2,=.0F_`"'+DFC0(!DA,%^;C#=O*"C;KP$?3$(VX!W"4XNQ=Z5X/TDD&*/ M/HI)&/O)61"G$6I(JHD''*TO_MC/22.V&J5!+H>QJ4"4`%:=TP+S#(8&9I([ M)Q?!R0B&".XNAJ<_!J,TAB__"*.1]PA\B&DNE3(:B`"?*M8]\@+[5S>"Y337 MH**;!=;"PC]"/TBN$T$Z`"J@?@(?3G],!)J,F!.GB,HUZ-)EZ[CY52YDR?D6 M0BHEN.!N&:*_&*#.XTE M+//'S@!!I(?%V"OQ[Q3S"S^%H'4F?CR<8 M=@\RQW1#<,VNU(B$/#;3(+X%%*9]$5S<)BY0N.#N2MRE(S<)HVE_,HG"!S3R MG(@(?_WJ_AE&C.43'";:"!(ZA4C8(LC/AY]-"(@O`UV7]_#?F\<0#BS_>0_$ M\V0$\P_&*J%D!VF?!RD84C%U'THTO@.Q9QH^+ MX:<4J+@P:N()TCP/YMK`H6DWCU=$R%*`/C$JGD(-?R[$29X^5=Z@J/_@^B-2 M@4.R')^1\X[4F7(IF6UAK=:;_QII>:+5=L:$M>R2EIEP$;BPU(7"]@=W\)?P MT&M842*Z;!U]G0?RDI/.KN$JG+HC&$W:Z"^"S.:=BT=`Q!B9RC:,D-TW_]7K M%AVU9:"RU\2:G+)BG@.O`[U,'@Y4R0`[8]37OHKH3D2;%_.6F]^"G+,P+H8E M]'=9:JA>_I[@V[-.-@GOHEE7!7!I;K8]>/\0XJ_X+#"^WXKWKG/8^IB;=68H M:SJXC9BTX]Z)BR&?5=C\#1'V4GO*)0QKXPI]NOO-0PGV:B`]U9K*;"[%:^J^ MA#55=%^]X%VKZ`%[PCVT0@,N'@.00Z:V$W>Q)>W[I8OA+A77T.X5K&$^"-N" M^SJ]C7W/=U&/JPC]X<&:T+.(1"+?9(-Q!B#D-/]E0%LTBP73E?#'MVD4LX'[ M4Q2./XPO##R>M$C4KJE)%OIM60TGDD?DW)J+F-BSK$=$&34U=HF;+N%@BQ? M`O+R'"@X_3&XQV&O<(X*![=,-,Z3\F,DY;W><;O5;F/09LF,-CA(W"5!/X7C MG4Q1%SP;3]Q!& M:M&#'_PP<1O..>R(`Q#2DQ&CR46;BN-B;*_P"O&'0"8B&OL!1J9:KZ:E*-]7 M1V/]W2\Y2_2.GJ_OA71)EHJ=;>TUC_:T+[[:X'EHKH0Z#9=1>!>YX\O()S<9 M78J,A#/'9B1C!^B7B>8OGF4]2!:[UA&2P^[R@.C06`PR/0.5 M9N(G&"=;93LKH:=SV&EU#[.`+9QTD*-1.$`W1#$;ES)F M)8'^^P*1M]660N%RL\#[DKJ1.N9@)W!;963"_`>;@+<(`%E M?90F_H,5PD"Q*0`)JE(X1)K0"!?#4S="@2)6%)<-RLNJJK,J#R[G8`;]FX!M MV\NM=#%>TX(77ZWBU79FCNM+6&VEN_F,"Z96?>ORZ>/#XUY.?J!QEYNK&KL] M;A]WFQ7GVI"4=GQX=-0JF+)8*JHV\WJ+G3.S[L+XT8\'HQ";+JZ[_G;S\+@` MB(*9-@;0=WSK.[WV_2R`,QU__X)&M]9BURL*L^VB[7H.>-N5X&UUND>;!?A' M[+\+_-'?WR11*MZL#G^G!/[?UL9=L)4,N.UMJ@ MY@)=#*<$!A@E:/$^">.UF<(L4:PV[Y:`_:["8L3WC^(V^6X&JD:!FD>]75K- MM^_7WXT/YOOU)`SB,`+QZ13KATXB/X:%K;+0X^/.#JQS>>+WK&"N>;AV9QU; M.U;;6^*3R'/+S+Y5P)^.C#WYRG:`I#WYFA<(5&ON]HR8O_,+;V]FX9V\MOU4 M"]^T6K$T'O)ZQQ-OV^N[PQO?T0VB:#N;O4'9ZZG(RE/*84^^IN>5R9Y\N=ME MB2]JS1OBAB]JS2MSOI>PYC6N\N9L;[N#CF>3)EX4.K8A.3PM.CY'81Q?"7>$ MNOUGUP_B+_"%B/&IRR@<".&M&XW=K+B**J!L;5E+!TT\P:J&813/CO4MB*S1 MEA:"JPJJ6YE\8SK3=J![`OF_$N!;D/^KS+M5D+<@-#S_FIZ4[*^QW&*J9%YE MDM3:&C'9UOS;L\%L"L#G,"F4P/X45H7BJ;<-^%,H),^TLN<5+*LL&I/I^P'5 M6L-,A@<8($CB?G+B1A'64"+!M'2E[2[?E.9\:+N=;N\@8V6L-.UF(5T<]`N0 M'O5ZK:/GA;1J:-A!I]5\9DBKAI+U#HYW!-+*M7^Z!'=S2QCF]+:S8`!W,Q:P MW_3?=?-FT3_3:7:KW+1B`#8$^O(A[`#Y7@NNWJ8@-^D.&[EKO4XW=X!S$ZPZ M?;4+!-,?+C5]`!PG\6]1194Y?O3L>0B\P!-BC-SB(KK2?Y_%<2HB3LADB#R)4QFB200C4:`__#T2LO"KC#":K6FUZF5JYJ!;/.V:@*[$M3H'ZX(IL[)5 MOB-FXUX,KRA9^J,[)=3!`#-5EDHS]35]_4X$5F?LVYG!*TR>A1J-%:A.7`2H M<5P,+Z-P`O1]>@D',4%F/9DI+;':.=AK9T]IM8ESP%+IFQ%N@S?V`VH#@XDL MRR0W+J`VA[VLTK!@RM7A6Y4YM`YR]'!K$*YXC;J=9T)@58;2.EP#@2"NAF.! M!Y=SI:CR--;25CU!X@]H(!3\W(W[0\1?_2#$FH1G:"D0<0(394?AP@-?17*/ MXG!Q#<=5+UVOE;UV3PC_;B!NU7NV=]`]_LE1MYKV=W#4:?W<>%N5,NVU#SN= MEX(Z>&*48B642Q2(0#9*N&8,-8<,4>B$EZ)P-()'%"S/1-%6`?7)T?&4=.I% M(&1%ZL,%%%X=-IZ2ICP%0BY%],&-_0%EE:]`%V;+].PU]YN]99:9`6%S\%>] MR(4K:+5V8`65;EXQ^$N=LZ?:@)*KL@-'Z"-68I"U4I[M$MA`;'(-3WL1MK6* M)[P,3[816[T055>!,9(\@O#,`.W>S,BZ'HP7B3W(LK5%T3[W6`0P;$IZU6V(HI;K5F- MU:KW9Z]9*2FN M-&O%57=[K>[2LP(UFJVQO?E:@8MFW!1\JY;<6QF^#07T]-K==AE`A1$TRX!0 M#2D'S4YO51`NAJ`63,+8'7V.PG2B#92%RL*FZFKW>J4H6P6>W.)`W6$%^DX$ M@RE^5)T3,H#GFT(O!AV+".>K?LZ9+0M642_A3<64Y2L&S9DK"Y3L%'<9A1CD MXGV8?HN%AZW&`H`!NP,/$O]A4^)^MYVE+-4GKP0T,XM-`WW0ZN;<'M6GWPC8 M*W'VF1.Q8:!U.^Z-XGKON)ES<%>??B-@KR;^=BBF=3-0&XO-5CRZF1FJ3KXY M_^E*TZ^X*:W>-I:^LF]PSO3Z7&RJ-QBRV&X>@)E9E@%BU2-P=)"[T&M!L9J2 MTVEN$(25%9MNL[<2%!LF"$>M$C`6'LZ-$X?>T>%F05G55MM@TYW/=`PV`*8=-[?L`67QKSIB@$+ ML_N^N2#L_/F:.]_*L*U*$_(7<3O0K;2IK5QNRE-AKNIU:!ZO#)YJ=GX3]@?4 MA+)(>]R$2-+L=;)(K#3S`F`SR0W]P-MD8D5K/K2E4^=`9E]"H0]A0X3ZX#C+ M2BM,N4$8*TI`.3%L!1BYE!"ZLC'S$0$H;T^W&1/%PCG+0:3>P8'WU4WP($\O MAENZ5MUVLU,.="4H-KF(S9@K-KR$7`[4ILE$KCW($K//@%W\&"B/ZY*(HX,\ MC*5398&R7'=HU]A0SYZG6!?I&.TQ$VX?LHAO[`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`I6D;4)_.[AT0Z`7\E07;*"7N]@NRN8>8N2_I_P M`A0#L"G8MWWXMPO]5@_^$R-^PX>^%/J__?;C-AK!'_\?4$L#!!0````(`$V& M"4$C$AK[:0P``)*;```5`!P`;F%B:2TR,#$R,#8S,%]C86PN>&UL550)``.2 M(B10DB(D4'5X"P`!!"4.```$.0$``.U=6W/B.A)^WZK]#U[.R\P#`4-"8':R MIW*9F4I59DB1S-9Y.Z78@JB.L5C93L+Y]=N2;3"^2AAC0Z;F(0RH6WWYU&JU M9/GS[V]S2WO!S"'4OFCI)]V6AFV#FL2>7;0\IXT<@Y#6[__YYS\^_ZO=_N-J M9U/#FV'8U@V'D8E-[6FJ3B79#;1M;%EYJCV@VPRSDJNG=$_Y/'XW^K5W3 MQ9*1V;.K?;C^N$'5;@=]7"$'>`*=Z*QWHON_6,3^ZPE^TD!@V[EH/;ONXE.G M\_KZ>O+VQ*P3RF:=7K?;[X0-6W[+3V\.V6C]V@_;ZIT_OM\]&,]XCMK$=EQD M&VLJSB:-#M08=<2OT-0AGQQ!?T<-Y`H3%LJE9;;@_VN'S=K\J[;>:_?UDS?' M;($--.TSHQ:>X*DF!/CD+A?XHN60^<+B@HOOGAF>7K1L]$2`@][K#OI=3O_; M%;*X?@_/&+M.2^.,?DYN5_)R@A.#SD$2O=ONCMJ]LPYOTXG1=`"9CA\ MG/%TO,!,F$U%H"P&.Y7L&CG/7RWZNJU@$?K2,&!9C]YK.%]AV!.,;[")B.8_XS?60I6),*7:EI;Y\`7[HR<)? M*7M`%KZU7[#C"B<&?2G(+,.LM,3<',A>CB&ZOA#\JB!>@K*T+.`?`F"_9]@! M)86'`%T/WGR.V'(\?2`SFTR)@0!TAD$]0)T]NZ<6,0A6"T%ENJD2([L!QVY0 M,2<^-S#--14V@(E`MYQ1P_HC4>PL'2UW(-D/:DUXNN9YIQ@9=E9EI'SD7^\H7H:\*HD&RH+F,:DH,BC+F,]F MUSF)>N:4Q:#6,:BNQDYZVT-.JYZ.*_"L9%2J^R*72VD9'QE&P'+YX%+CKZVM MFLNEVA79KI9B52>"7CWY%%$2W MJ+'1I\5KL91MFC?0011B?]LZZI\-!?ZCWAUU]=!X:N0Y9KSW&Q,(K1^2@ M#9?\;-0?G`\'@[,S^#3L1R2/`.22;2J!F!'RAX\;F$D6N8,6'8=G19Q;&[PY M#^FGC,ZE+!KT3U5THLI(.W5U7&\0M&*"/NLC84?$?L M+XC-D&,_8,,#46!1D#]Z0C=RLY)[!;IV-2%0T3N_`DG MV;#1OI2<722U:JKW@CT`YQXM>1I4L%)/;=QH+ZJE"@H*'L1RSL]T#(-YV)0> MI_E$1^3M+1156]S5E!/>X"D&%*Z:O6AKKT3+K+$E5#\*__*PLM85&N?LSL6;-\ZVD4U+V M8V14:^SBRS2)+\H](N:M?8T6Q$561*>LA5@AX1&Y>$ME#V(`;QS7R!O"R89' MY&%)Y0K3\W9MNVDN(C8VOR!F0WKHP)K2FW/K8Q.2"F*0[*VU(L(C\O*6R@9> M/VM:\+ZF]@MF+GFR\#T+4D=A&T@MATJA?,L^P]23/L*T[T>A46W=3]VFV']CU MGZZZHTY\^P>ZC?]>QTA?]_\5()VZ^.?'!\;31_26,:156#1G[*;8/SD^2ZNF M5DFOJ::ZJ:7_5*('L]A:QU5UZ)XRX1W79>3)$R>''BFO)@`1F!Q$F]W:+F;8 MR4H+JNGLH'%5J1$.HJJ_>@8U.,ARA6W(FO(AE&C='`S4X.8LC,E9J3!,M9N# MDCQS7N$I93CR1/-W8@N90]M=VN8F%S]=^X[=9VIN/#&^9?#:F02_T*P8,:NU M_$&$4;'I"V:FOE&XD;F^00#(VQ+/)#I$&%:+A(R]=C4+JN6%_;KB;6@)7Z'" MS"Z]^2\(R80W!=NI;>77!)[QYF!(60'GM/P%&8FH(VFV@SCJ'>Q+9T$D_+EY MN)#U0EK).$>G@Z@;K'0/9KK"`1ZV.R8WRBE7F#XV8H%U31UW/'W@=X08F=[< M;-1@5^8Z)*T67ZC708S*"78PV(L_R7D#(<:BXB&1_#5`+LWQN%A=S8-8]GW# M-MC#`JTNS3FQB>-RZ[P4K/L*J(['Z]LHJI9B[VL#+7+IJ=3^67^K_3/>BR:Z MJ7O_+/V!]'L,AN>I-#]9@6^P_S=KME)@L3YD-QKJ/4#$H*:;)?CSNB#P/:,O M!/QZM?P)+KNU5P/@T@#\YCU3)L^@><.\M,>2$:"D.9IZQ"Y#+7\I60(F*0S> M,TQDS2&3*S0()E^)C6RC!$Q2&+QGF,B:H[FW+5`#8U-4IO@I(WXK%*0=U M"^F:!XJ2'DQ"8CL;',1CEC=XP;!!@IO^%A86GH)<>L[W^/X6WV<^45-,>C#@ MD$T6DN#8V@P!/KHGH_YY[A'1VD&2=3UV*BS2&[\#("@HOG;]\+3ISH]/H[=V MY.JA[(,4V33O``KJ^J\1,>KIPQQ(-**2G-0ON*DH?!`Q]<8B:;#(,'N7*-K: M,!%X#;JY\TU#\15[PE4:2C&Z=XD:&1M$`#+LG@[R(E`S)Z7P1HSH)2@\"TO< MD2$-'6F.[Q)4Y:P3@=NHV^LW/@GZAHC-=XW'-K^]G[^B(');V^JJMJRM&"GB M=X"B$H:(`N9,U\\5UMLL*49.RI^=BO`2:,G_HO./2;3M)$+&P?5/)U7<>-@KRW";,,3*/^ M"YKHI0'1D&&5,"%'VT3?EX@#"RLY6^1R.#(P MJ*@>'IN5#OY-"0G*@%!@<&1X4-`\?**^\1'BV![F'9[KCO7FNC9]J"]M'/R+;U'QB+>W5V[L76NX=VIO" M#[K#'A=Z]=(\?D2/\]$$(RW*2?L0\-("9A\K5$;FY=IQ5?IQ359,-+"_QMEH M$3XK?>IYMU1,P74"F/(JPXR`I\0C.AP'^K"_&<<:H?DW!B'HI\TPLLC?V.0! M"?,W^2DJG\XF7_]:7KA0VGW)4+X3JZP6(,U.+E:ZPNAV\G3EA;PB%,GP>&<0 MVMHDX5&B;/PT"CX)VP5G8?A$FIEL2E*_,\AL80R96^?JS`5C+ZN.IQW0/)YV M!!3:FJ2R-*G,*ZB3FB120<&>/X41[4!DMD$7_+=()]JZ%VW=31U)8E(YQ>RP M0K'Y24SB]$/`XOEU@S;J3[1T]`54@M/Q.@KDSKR+'G2N&=Q*?W66M"\,J'2 M7ON=E&X0EXZ3:8).VR#<\]HL*>E0=C%6H:S)5U8G4=F-R_EC?*?Y5%J$K#(9 M\]]1G;3K*"YOR$`,H8"%MLFCD4%;_%W&%3RM)G1K'$/-2WU'S=.;8;:GJFO M]'U&56J1%HFRQ)>,1_L0.STP90DN'9[V(7HL,KU*!9/*897FY''(O5L_/)HO`KYY;5CH>_`TL M?CDTQ//HU=#)K/@T+OF:3(O2[5:VCE[-;EI<_=SB[)QBA M\)__`U!+`P04````"`!-A@E!QWM\4RL1```K)P$`%0`<`&YA8FDM,C`Q,C`V M,S!?9&5F+GAM;%54"0`#DB(D4)(B)%!U>`L``00E#@``!#D!``#M75]SX[81 M?^],OP/KO"0/LOPG=\FYN69TMN_BCFUY9%^3/F5@$I+0HP@5`&VKG[X`1$JB M!%(`10HDQ;.SL M^'3^BX^";Q?BGV?^N\.Y#JC\^/%HS-CTHMM]?7T]?GLF_C$FH^[9RBY+<]8^=.6OBZ*R03[<`"'CNR0"S:;PH]'%$VFOF!)?CU'SV,43SM?I2>?D0^?L75>4Z:81 MZ!;"7N^%4P///OR,R2/PX4WP`BD3HDS-6=4A5@S;GP$B_P)^"*\0=7U,0P)S M\)M)I1A&G[@]X'1GCPR[WR+:3_"-A<`W8#232C&,/HX!@=+."(&#`97*E9MC M/7+%L'Z+7-X`I+W`&^`9\-FL1P@(1G!5\LPAF)$M!LH]]@=B*J"]$8&R(7.I MSJ"QRB0@KBZ?*>8SMOK";KZ3[(\Y">*&S[#C(=ZPF.J.G*BA5=X75%#`NKQH M-RK351(HF^M%4QT/3P`R9'FS]A[YA4,0^BPWPW'UTCF6/=.9P,DS)(;<)JN6 MS2GP?3/^9(6(*^ZI.;_%$NQW*(#.#8,3ZC"\+/.#].-B/-ZB M`B_^+8&)6QD8>-"+48FF\[L.$67$!)&3]R>G3L=93H'\0U31B6LZWT=UG M_3!WCF+.?>PFV/6%;X;)-FLGOOESC7F5Z31QJPW92,B*VSS2-=NNK5-U72>%C M=2'Z:?9`L!>Z[!Y,5!.(3H7J>R@Z*`RE_X!=%BMB50IG5XE92HNWJ\0RO0CN M[I'[`MZ44[CB]^+:?>#8`&5@.DYO>[-,@>V/,?5Q1MN)W^VY+?K"O=W4Q-)C MW4,PT8L%K*0DUA/#ID2O&_Z:X$AH1X3AO'7=FNVZS7<54#!:1.?I$R?2'_:G M8D@HEYL7Q(<@;E61P'WRG.X6F%(KC_0J^0!]/[_E@ M?H$!)'(_--UURBQNV9/*(S[&JEXM/RN?Y"U`9XZF8:2]G?FK/O.O"AN%[O$( MOW0]B.8Q8?['>BB8?_7G+1P!_SK@73936%UEB>K/[4JV(W'_L9V]*RE'I7$V M;U(Y-6_^;&T[Y@$0;MPS=V.21:QQ^A@^4^0A0!"DF?RJ"MKS(#*$-#8925&P M[@"D">_J/DQ2)FK!LDHL"MD_ZOE^ZW94)^"P1E\XBM)/U.!EI6R9@BQ3J+8Y M%QM\+YQK=0=&HOR.%Y@&^6+#VV"4@9,87L3+G/<5;T*Q;7+_+3/'K-WK)7 M:(_ROKN#9`3)(K"BXCH?G0)E5(SG`$Y#P@60P@>"1P1,'@AR(6]8\I`8>J4$ M&],H//@HNF5UE^KKE,^W`;O'P0`.P\"31W<@%PD7HI?EI*.(2QI3*AW+/!"W MTF8_N'[CBHGH,DIG`$B/7#D6J!<$?!ZYATR>0JRA`ACROQ M5FMD0JG`9`W9JFSR"7"=9.K<$46ITJ7DD@\;\B+T.>0\I?Z^-/4!S,3'_`JZ M06`?/MG3":A+SM8A207F>)0 MB$.&O0D.`R8,DNH".N'FF#-N[J*MX1.:H)3M3J+,5C.Q=E5+E/6<#&ZNO@DA@N] M&%Y=_)4B%GXQYKHX,KG7A#'0NK@WN9:,,RGQ[YM3HS.E>Y5N_ MMXT/06J?N&XUH#V-4]AIG/UKCXV#+]JGW`Y;M]I<>1M:D3>96_?P1Y7..NE< M;KLN^^?KLK\@(O-%!1EGAH M;_%ZL/]@(FPO[0^OX#/K!9[8JV2S)8L9JRKMVE;/9^4>S^2E6)I0JWQ9X&'H MK169KA8^Y729H[XUC%\?OV#N$P5"IAZGW"7$!'I\_H1D2A`55Y,_LR6[F4&5 M?*3L):QC,L4$,&@`<4L=^Y&MS/&XW!JZ"CB?O#8#^Q9!KLF9O,.8 M9@_!/=;A\3;EM%9.&GL]7;@3SL0)6OW!7"JQI=.($<\71J!;B]$`;=HGUC$F M[`F2R`0.`+ M/K^D+ZD,:=C'NC$::WS>\D^0GAH/:AJ9"B)6O'AE#%=)P[(#OO-BZ.,G0%%F;*E`^M8LP0+#I]GBS]\0)%S%QK-;<20@P]#I5J[$ MQFSATK!J)W1[HLK[MDVW`ON3F7>!4*Y33Q"6.:6ZJ]AFE=HU33R&O%KXV&;5-1FV34>N9 MD-DFH]8]&;6A\VKK8.^GCVZWY.,5W(:5[-=2^DFY>-]=F)9+?)JE]; MTO1YL4TK*".MP$JBH+7]WU9GJQ)&;L/D;5JO*L*Z6P#NULJN]Q.1QF@F[_*/ ME"^Z\6M3BW]:U^*XMB.K5^@6UDL?4#YN"7190;:,\G9O:6M?;YQ M9VOU\UT;JAZ-OZ1XGQ,JE[A).,GD=*V,QE<]YM*7M1&N6;]1+XWB=K0T.SV^-^E7U,H*$FH?$+M&:] M(E.EB)[48O',E2?N].?=(I^XVJ8:/Y^MZX:DXTA"SBJE"FG)\N(5->CD4RG+ M,M';9KU70#R]BR%WIM]&$8WO1B]H3&L8=3P@%6[\1-=&(MM(9(5#>FTD`[RTIE0K&[]U1KZ@Y/C7>* ML2JYT0@":U8LFU.-?HO>?/S""S)Z$\S?V+Y^X[X"HG#^21]@4>W9OMNV4).\ MA_ZJ>L#Z@"QCX]?V;1"[+"V9O\L+Q2F9`9X!G\U6O;1MVO)A75EB<@X(/"R)/O>PXFF_;[]L?5JQ\T;I+*E"N,I7"6_J#Z MUBK%E8.:6EE"FN_7ODOH"W]+:3O]L+Z.H+V7;+4)EK=DSDP-M3S^$#I^^25O*FQEKK2KJTKMV^^ZUYTG?;X MVWWS\C:@J\^VNC)E$)QO%^)FW#P])X/YA<80"+WIM(#0YG%+<>) M\HB/L46H5A0IG^0M0&>.9B&[4N4GZS7/`-;#P4AK[C8E6\:LZE[3VO*@6C,< M6SI_^02RI7PTP>J%)L167ZNK"25:E^T98H8$"G=29(+12HN7?(;CL]M\VAI` M%Z(7J,S\,JM?.M]?I]SN!"Q*F!J!??0XX]X&_S/1=P^86P*&@'\)Z#CB MRFP<]*D6A_%&V#7@K_5B/[CDQH6STQ]>O[E^2/F7OV-NGU\Y8W.W2EX)N^YX MJ?`6W4*!&\"AN.%11-'(I[[T)#@/VA#\M.)")@OU@WL>OF`M"2G<`+#>`H]$4#L]YTRM\`^0:Y M1>%D"-JU>_*W:J./GA`D?)T;!'P^%E=OT_[P<\BXP[12D5F*RT[+XG0$:0J7.G%*6*X^&?F*^3'AF$ MXA)S<;4(8OS#]=L4NDSD0`M)",7B(CW!WIC$GCVM!T`8[T>MR_$6"-G.UEW**./5"T^QWUQKMZ]L9V]SW"][Z> M^';R\2/H/]43>LEN?M0Y/S>]<_([^5$/?6AZ#QEZ^_$6TDD]^R7OPB"&78G- M07/8JG5&#*FFCI_QRB3&VRS?3V,)$P/_47/7:>_GB9W'^>( M6D5ID^[;`^UY\I5;U6B3)O>>-+G_^<=&?J)NSG*5C@S<8W^`1F-&%U#3GBL\ M/5E7Q?O^K3.O["QJ5^"QPNCV]]^!,`JL3R2+&J^`*"O8NPB/\?6MZ-&(.WD9 M>\8TFU&^$E<8;Q^5Q/5TZ6BJ?-U$`[6I-#G0]8ZGJJ`UKA\X+4@( M]"0[F=ZKNJC],XY;A4?QVD^B\ZUG_F\7H54(ZG&H27)_`XU7,UP!)5,;\4@= M)+>6[[+50Z(P"LH!J,:Z?P:E:S9ERLD5K.!1Q_` M3&C6%9^T^\,!=+F"78'9'5>@<2_P_@U!FO]A1*',D>AYGE0NX.<:DXSJ!3_, M-L8^-UYT_E[9/6;P9C+E[?2#A^@9LCEG_:`?,LK$?FO*?.<[BQ-!Z*EP!X+-$=SVYK6HQ^P8Z M%6T$_7W8I>L9%F>39'[]Z^^UW7R&W5VB3QX<=SBH4%SBJ\`8]'-'M+7J?9QE.4WQ$]]'C(RYJKNCM=]_2 M_[W]\OL^V_?\K^D2?;Y@?P) M$8&S\H]?/575_JXEN\14R`GZKC'O_QJS+9 M[5,J./O=4X&W:BG2HGA#Z=]D^)%^-]K#C[2'M_].>_A7\>NKZ`&G7R':\I?; M2RV@'SN\!-$;+B7YBN%+RM3*SY#>YU64CI)6IIQ_<*N^O)6KF%5O0%/ZBRLB M1$<\_%+A;(,WM8"4W&`MC#NS,L:4LLWC#L.4FEQ>=`%GT4-"0+W]_KM__^$[ M#HG\YN_OA-B)1T573E MC(JX9DU^'(`M6KR)<^*+]M5YR@>7DV^+?._J0GB+JP"EPF1^* M&#M]1QF%Z_ARB8A7)I1T4L+9^2]W7_U'38JB;(,X,9*HT6\U_?_]`^]_7DCU M),@Z6Q(:YM"2EOK;4T`VAB'0,"0ECK]]S)_?;'#RAMH*_8$9S?EW;\5T\Z_D M5PV$>\+V!&+_SWZ-0"<>U?73OWE3:77'^L]+V_CZEBO2XX;V^C&-'A5RG_S= M_]=4"EA_SLX?O7Y/1<^]#]JT0;21;^N\P462$Q^S>4\"!H-&GK2#LU>EP*>& MVVD$8L$*"?2FS!N3>6B#:'/?.O`Q*>,H_1N.BH_D-Z4!5:\EG!YHA#[5A)-F M(+J@E$&O#;PYHNT1(X#1!ZZ4=AK1:0NM$PK!U5HA-034BYX4@YHAW(57W>!1 MZ"U^3&CPF577T4XU7:B;^=<(D[BU,JC:>-4#O0`]%1!+E+8MHHW]?OP+HH)% ME%Z2=?C+G_%1"ZC7#NKS:P3N?O^31@`*H)1`IP&B,6*M$6GN2P2=@\!U#%R7B:&C7.J-&S%^U/$55D24094[K01 MC'*I1975J-O"N\*HNN]OBK)&2Q_#/./B(2_QU61I[^X^W-_!J>=%5#ZML@W] MSX?_.23/44KLL5Q5%U%1'(D'_TN4'DX#=4=:&&5V`B;KN!6A=]5WD*KO+`D1 M.])C/TCD9RBJ4,T!,1:+&,N^WM$VFH"P])6HI4$MRA@01E%E,PE$V)'"&<(MC3,R1B%->X\IL`IJV M,,IO%%Q6>V5#[PIOD**G(E+;,T1:@VOY2.'AM/JFP/LHV7QXV=/%))FWUM43 M+GC@;M9Q*TH8C7<`)>N_!9EW:["6J:=>@A()4A96,&+$J<%M93HTS$E+ABUG MV&*QK1\Q-M";'F8+"L)6!JT"5O]MU,&'/E?2;?#1@K(KY<&HZ$V1DY52=;PA M,K*[LF2YL:>;D63FTIJLB03*V0_#Z'IY?7L`]SXDC,+Y<9(SQ(CX)>R:C$5! M<`Y]-!A^W[I%D?51^/;=1CN']=9Z-PWDGP<<,_-[D&[9Z(^A_?!5$CTD*5O= M$J-A)XE/>;K!14D-J#H.G)S8D\.HK"L\6:EM:;VKO9M@/<63R!O_39P@_(G- M5%R7JW>75Y?WEQ_NT.KZ/;J[7U_\^;_65^\_W-[]&_KPW[]-HG?F`65+__."08S^/"$:(]$:?&DZ3OH];PVGX'P! M''@8E!UQC&3LRBR_:A;NG=+DQB]!]OB,9(M`8W@W'2 M%[QU$$N,]?9]4N[S,DI_+O+#_C*+TP.]J$A^2]2M2HB26(1U+4D@D9T]AI""NV&;#L!E#_AJ2"<][)W!G;+1&P?AA9U/,,([LW`[ MI0CH7,)YQUXF^+?Z'&)5547R<.!W+ZL<4R MG:W_-RYSR:QZ+EAS1@WK^MEJASO*"]3R)\MVU@/B79PM^$;&YFV%E_'9-^-3 M4MZ0[J)YEFRV_=-F4(:L%K=KE=TV`":F$D"A#_*[;M92F`+X4W$I<,8L-;AK2/9KTK$LZ^F=U^60#[9-/WQV"VAJV1\!WB4K$A%L31A?*Z M\?!VN(8,_)##",?EBGMP5]LMK[3+A,)NP,].7/#T#E08JK#,YS*+\QUNDH@- M'+-H6\,8RX#PLHUHFGHW#:,)V MX^YN&X`H6R6`(J;FS0(X9G.3&/`\K19T``>T>IK4$DP=!]006O?,X@&^L>$. M.WL4>2N&7*6A/=#+FB$`G4D_I:G;UPE00G"LXT'43VA`+R^4 MU7I[AXOG)-:ZW--&4">1*E&[YY!RBT6TV>I(KR^%(HXL*QHJEJ+9(LIK/C)U MD/).(Z7/H*#$1%=H$L;W9+9(Y>6@`LLM@56X+[12B=MFP&I\ M*HA!-5+2"$Z#'03E3='7M''O9-_GF<IC% M[QY[J-L"G'N8!.GI3-M<*`U]^\TIH`(29P3\SRAAK8$S^ESG6=XU6'.'H%`J@]7'V'MWF!>;O[Z`67GY(L+Y+J6%LZ6:ITN?#+`9]P]91O6N^A"YJ\ M2@!Y7N]UD/MW`+QT#Q,\>@?8O\)#J!#]Z"AN>I=2E*`'UG]M_!65P'OD"C]* MG3B8#UV-:3OTPK?]U.]ID!WE31RZ)2:-&_J17PM*&:.3^R?.K@A M$'_E!FER42&%)4U>J9N\8#4_I8O%]WG7A@<7NLMT%FJP,67HW.**,3V%&D*, MQ^(:+008&B5Y[KP9'B@(")VT@;&3I6"RH;8:0`3?RA$ MT/I\[_&!K7!=@_?XU,_"1J<,L#^;JI_=WN#B[HF,U[NH3.*!:](#-#`V9P5$ MMD$C`=0E4PNA^JMIVJ;9YD^9*1`?CDK*H'<'>7';'0.A>9I.B!"C.D,<5@@/ MK8;C;"(V$Y>)/CI:/^$20HQI#=9MF=YA`1QI6LHW85E)E9IK,^,71M`X%O;% MZUWYN5NI$[\0['7$`(Q=((9DP\Z2SK9T#-*VIP_'^]`J'YQ&%>^3]%#AC6.D MVJ,*(U;5@#%%JRN73XAS(4. M@)VC5YE)F/%K7\*)$6RMV0'-<^.AO^XHUMEF'3F&8+VC!F%"+!N018^0==9X M-D!+GV-(@HMI?\7)XQ,-,\AP1(_X^K![P,5ZRS"4ZT-55E%&3Z58M*X9)D<> M,)8]"JALRTX,H&+A$4)J]G*_"$[G$6?%P^(2Y2T3[R'R'.AJ'D@P09P+2T7` M$4J,Q`YP<.8I>QH9N-NXZ;D$9:)#8"V,5,?7N`5+U#PHS+O$B9(<8MB(T5 M$G=2B6[HE9@-WKP[_D+DO\R:][>KN$J>>193LP*.801VI64DY)-[+XY5X(:R:(8R&[X`3PEHLY@.\(&/J=+S&7@`.L7W>$_@ M)DP.\G.*V9.!;+/:T5O1_V2_UWP@.U*H0MWVL+HUNX?I`,IWVPJEJ(+=DI+U M6DW,4Y))Y'!5O6>!QE.2&?!X7)**^X]X(+SO;YF"UDL<*'QN$]YBB,DHR.@>OL[LHQ>LMF87)?%8= M;XC<%7U3SW)I:K#;$@,EK'2"ULE;:47I/WVE@UC]K(^$N`XD:0')B)8@WJ*: M!V),4,,%ZC7Z)(SLK2PMRBK`[6MP=%[!.FA>[PK0;_E8)<41ISN+:, M-0.PFP".$$\._BVI(<[YG413'>LS0O1US>(;NL9HEVUU=53X-=MDK%+BE*@L M<<6K.DE5G@"72GUP9%6*DV?Z],R0=\I$$XJI*8"8K4LB","@>M+8VI!$")A% MQ1F-06Q(<[@I\#Y*:`E/7!1X(]+"D-4<2TJW8O9L/0IVS$(Q(!?H9LNRX12` MR=F+:6N+@B/=I>`\FTQ'=`K@>0TYWW!,=<(H"-(F72CFK0%D M-N(3H@!,52F1K4$V4Z^FC!^!2RA6.BBBJ[4V#,.Z'C,; M_)-+>TD#-XA+>P1?C/&&/0BC!SLDS/X450>:+WR]_105GS%+_76'8_H[_70Z M@@^,_8X&+)NO,Q.HAQDC!57LIG`^7(?I,1Z[0[[CO)+Z7S4_5#8,O;_46`8R M.Y:EB\::%P7<-O` M#2XNOBS+`Y$-K[<7^6Z79W=5'G^VB#XT=/!QKQ&0+LY5$GFW/DN)!J*YFI*] M@V2TB!%#&=4\J!)!R8+QF,,J*37:Y@7"NWV:'S%&#Z)2S)ZP>A5SY&1/%/Z< M.&TN#"I:UJ>:,.#;R*6U<#P3[`;<=C#'1+'I(F.%]]^\_?,?,CO[F[_1-2I0=UR0X>$[P M%\TRT-S4KQG9B$W-Q=3.FUD,"Z%(FL%:H[KYTFNM31X?Z*L'U?NU">+GHOFW M@)$=W2(E\6N;5$XWS2H:`D5J6I$[$5FOE?_=!XT(??_&&M*5@%22];=[_%*A M=^3;?X;;0+!%<&J0@%7HB\<<&-G29F%\:IRO1&%H3LTT+XF14&MEQKJ$[BB[>85J9!BNV31*T8=W MS[\,@)[7E;LY0YV.6$PL=T5GEZ8S.;U8VUT04XZGH:.Y-4O^=E<:(SIH=X?= MCA8UIWG^DLL19W1J:2>R`8?NR`-H M-W<,T,YVK@L#__NY[M*I%M`U#[ZO*W,)PO=;H1R:!ER9!*ROQLG!C4.8&COD M5LTJ&]BR8GG$T-5S[J,7ZUG#2`%9_<8(HE_=1MDU#4*,AA]3J46C^=A(82&?Z,4J*OT3I`;>"#VVJF$E@+,$& MAFP)IO;>+6%8F)[R4!+$:"1+",.WJM`,.=C01!:-603]*I50`> M=CXX,UZ5N:*C$&$WH>NV_*KTN#7 M8T:)SJY#`UZ-Z0@]Y+!UC6$\M5ETV46K6WKWS28Q!I4[`&<\0?[0TK,/U0P; M(`HI7;NQ;IB1(I#T[0.NDA&A=[TT[D&$O6V`P5['-,+=XI0F%[S(RZIL4=]$ M1U[>9,#/3N8*5(-CGL'HE.>8QM)_Y8XYY%46-1;;'OQ]6&L$@C%BG)%L*S7S M(*:.9<9%YQIFC/6O\_26EL@L5X\%9O=O3`&_J35`U#\L?!/ZZYOZC?^'Y.A? M*UY?(4Z!&A+PI<`H%`5'$=4DHU8%UFJLFX.&FP>AR,I98Z@MM"H/^3.U+@.Z M[QEQA&*(-K(O:8E725$<3LX%R0(YD>?&::#UXAX$42_5*&PI.[RI(:IR]K4F!3L8"EM!4# M'9RQ#`HU8"V<_L1:H.>^.0$JW`&\#Y@(:FDG<%,D69SL4US2=:/^H01[K7`T M.H71K`"O$YDDI"(#3SY!#$O2'82QQA M/!`<7L"CME]*O-Y^**MD%U7:'$*GC6!VIO$9R\ESHI]I8BHS89WUTF")]-^*E-_!!+;+#,1I&BPV M$/Z2O0\G2@)CD7N0IZ3JGB72>Y6V%-@@SQ@?VY%"/YMS@=9_+V=%"!0IN M\BG>C4GDG0TA[P'#K$@D^K->@HS`0G.QG7>+X_PQ2X8WQASH8.S-&I!L:(-$ M4!9F*9BB_#/?&R]:0N\V-55VB3#,9>TM+C'13)K&\SV1.^I'G^P"YIQH9+FAZBPBDP]+=NP[2UYFVRG7'I MFP,_JM/YTBW0[(X21/V%>YIFT%CF\P6R`YG&HZ.B4[DZ?_IZRP" M]RU"L*6'VPWCP6@.TH\!^P3\2;G M][C8=7(1/QSK\3NBBS0J2Y8E>^S[PKE6=8U\M4BT&AC-T4?O[1^BM"X'_9Y@ MMW(KTUA"%#-H[H.LRA*SH]6K)'H@VD%5Y1-+.X`W:[+&)Q^OH,71LLUUGA7U M/UE6=*NA6:(CX*M-LP^9\A[4;+W`Y4^:&8+A8M(9XGVQO5RI-U1WA]B.D^B! MM9*[1#S+?S@.W=L07F;[`QFV`R]BB':,-1V1+1W;Y]KC1^WHIJT@(82'ZGP8 M+&'*>L\J$8EJC$?'`'$\8^@0<>J0J(/$L5P!P\1I(AL#17E'7F9^)G(-"?YG M=2W08T#.9;D!:BNB"^$\:Q.'-+?G_(HG) M3TS<7[*D&NM#1O&$=A\3!D+M.48P!'0:HZ4U^HN&*VK9"G-@C,/V$S..2>LB M#$.R^A(5FP4KLS)1E;=.E>W@:[)V!-859&6-0*NQ2A)8E&)EK<.HPVHC>`!% M6&_I+BNU*F`G1M1]1^]>_>3GOM7@>C?T6^T!>3M.2K%)[Q[ MP(4)1]T"\`MWA>Q]8_YGF*\L]ZW[SN_S791DRWB>"A<#E^\F2NE/'S]%+\GN ML#-JY$D;&)U4"BIK9:>!=[U4]-[[YJ(-^HVW`HOYYI#5HX8FV;"&=ML`::A* MT(Z&R@W\:VB_]_Y7YVW@-70&62>L).0T+^^.-T6^.<35=;13A64V!`!K"RL( MS2+#V-KO:L-"E'[F`CD7TL,1"2I$R301GY\5R!Q@]@),1LCF3!FDE8W')$YP M:I*0%+T+8UC5>?M`E%T6QE'=EPQ\QRN\$Z"E5/XZB9^C%V4DH?@[1/Y6A8!M MPE;ICYXSM/9Z[J<#3>*_K/X*%CB$).9PLE5;.6?-$$PYV>"-;AG@1@^65-4-X$EF53MBB/2J+I)ILG722S$MCS-$N;0GW26J M&8$N*F9%V^3N+E$EP.8"[%[P@;`P_1K$E4/`5J99H;B1AVEIQG#?U=9`5S0S M(_9L;^+)^S5^J7[&&2X83'T`:&P.8$D6XC=F8VCKUT8&!>G7+>(4B)*@E@8V M&YHY[?+D:L)5DN'+"N^44:6^+?R=E9[@NGLK34/0 MNRLG4EC<7Z$4B)&$<8G%%L&DBRSFR81E")-V['[9$_W(JFN:+6)[R#;L91*F M&9!P\HPW!IMTY@0W!8T$?3H[.;(!F;A&R:ASHNP=:F=_5["C5P-1RQ`1CJAF M"3G?S8/^DF;PBE*TYQ7Z:$:RY9#93H'S?U@Y>^$9.H@OF^79>=%^V2WX/ M[HC'Y1*.=?;A!1=Q4K9!N\,@V;$+QS&YP!_R3C:\@G!1]H):^ZFS^GF#[)CH M"[.:L;16]7O);*&!$'"SG"9ZXR0;>ACW\]V?S]!.7`?:YV694*/>)2DNJSQ; M*!7/2&<]`?YJLV%)%XG3I@XKVM'\I?1[8^E[YPM^[[%>?";=[[IR#K3CNC5C MX2_`%-5NQ\>5/0;A>&TS1,LH\H0Z",]L$LW!%]=!H^`3)F01[7K9"=!"27YL^+BL> M3'';9FO"PYYZM?@I(5VRX2(!Q<(AY5A'-Z]:=+U?W*I%W%6+?:,6K)R%<(_> M@ZV;J*B2.-ESR+A(\O%QEY)7.![0&KA;-*9@%(2WLY1R?(Q&7)O,%'&N(3FV ML4/P@>9%CRK^YIM?*,SWS'+E`]Z@G-@<7]L8N!&/U?G:>\:UYZ_@=D;F^-@_ MW_U9%;#J:DU,<,ZW.-D]'`A,)OM'XKQ^IB&-/B*_\_`TZ\CGTU@194$F3.B`X]:WH@S1]N\0$/U%&!V`_V.S&,[,H_M MR!0@53,&YX-7,32`V196),C>).F!EK!J\VA^>(G3PP9OZ'C1$_4#'^#U]C3% M-5_9G`S\S+QA7K/..C#R*]A9&'M_/3NCU/WEL<1;3D5;<^>V)?%GQ8\5:=-7 MRVT36CS:77*(VEV29J!8CON2^!`Q2(G8.(W2^)`VP\2:D[]FF*;S9GGRM0GR M/7H=;0;?GXN\+&]QE";_Q)N?HR0KK\@O<$E;W11YC/%&EQAF*E,@/S/+4'0< MS"2._CW+#.+V78HIQ_498IQ1S1HQWNAKSOV;,\2R/=<]@+F3)<:E@?S((:<< M,CUUH8-4LCRH_;'3%\H-*UN^*N?9"'KH[(26`%T3W?O-G392L@FIZS7)UGPF M$_I'7M#7$>5Z^QX_5&0]04L[5\=62$-B,VMJJ`1$3N"ZJ8FL2`&2%CG(I4@1 M1*C9LQWF-BD#ML+C+#J*"9QTS0*G\L'9"/I@=;/_V,R9.$3]-#Z[4FGH2JVA MX(G8?KEK-V;N]GE6Y@7>?,@J7.R+A,0H5/A68&,VK'&L8#1W"FQ9BRXPLM:#IS6:T;\+:/SLL%>#D/U6<2WV.=%5&$'RQV@ M@2K8:P&D6Z;70.#=Z"RD4;RB$C3!F=`T-!N*)B@KL5D=76E>1X[D$>[JM@?4 M=85[Y?V5Y03IIJQTK_3/,D/8Q5WM:-W%?_+"V<[[6R?4H>W+*L'9;!?LD+:`QX:"CL>P+;F M`E1I<38,X.S.7KIQ!QHM)WZD`6Y_$P#;(0IALCO!Q,]BWHX[U5&P"6WZ,\-U M.(CL\0AH0C0).-DV.;=YC?-'CC;#C[26[81S15O0EJA",-"FT.3[I(S3G-:5 M=!X;)8_03-,`U,XN%0P",DJM=*X6*55Z;EDMI1T7TH4PB;_^C6IGI)LG>&_X:AH!L!YZ.R80M38MI5Y MM:UP042^?RKRP^/3Q^2925_.-286_"&&ATZ*S0.Z^$C_>:E^1V9%`3/A6("0 MIQ=#<^^3R:`L_525-*R12,Y88$-O5\(\X!J/I)T6^//Y$FW(A'=@16KW11+3 MUUK[(G\LHAV@)_VPW6):7!-?LMNI]]'++9&9(ST0$==[\294M_OMP@#"!:SK MIW'L"T9%<223&JO]J0%D(H``,%N==@W>&?G#^,?9!TCVIK,Q]^Y[9Y:\Y]_: M8/<,\2[8]2NI$U3W@EBN/<&8M9)[XIO5\-<'FP%[=VQ^_*^$.(,B?CI>T7=# MAMN#ML3`)F(%3:G_1DHXY;80RZBY#1'X+<$&A[`:_F*N!\YX4]"1![`RN@!5 MZJ0-`SC5M)?.H*%(YB+OG$B*"WYYL$%WF>T/5\7SO9CS?!V0\WX\QGN^#-!XSE+OD,4NVQ#*R M"JVK)UR@]4.)"YXEBW.I;44/[W6MA:\&KO/-W,?K71/W!FKN=?$5V'7!!:1? M?GU\%<*E0YINCHP&_0]]QO(Y#R%?2B'$VM]>Z#3Z2$`G9-H M76/_I\YF2?I'E"*,\W>4;'/VZ@CBGIY.`]Y]K_+X\RW>DY%XBDKZ=)V>1:P. MU5->T"LEQN0RML001GQ?,+]Z9#*RY![E*B;.INAE[;:B@#%D"Q"R*1N:>S?F M05GZEB`H$",YXPEEZ*UF009ET>Y(K@\T1*9/"$2"F**QD1X*((O@@8^`0>]8 M?\+$:JU,0TL:@(T,P-(:BX8.UFJ,0@V:3QUU"OHS_B:`LPC"E!SAT7D2/;-9 M/F3#J@&MR'!$CYCBJK-+V0R*D3P``[.`IS4R`RVLH0T*-F!LDI$)%MS8FK1H M0=B;.\H:#+VI0OX_2C9MXC*15;$VOQ!>;S(H[Z@OH$G><%:R*R=R`MYWQ[:- MR,*[HK8/_>ISI@%2OPB=R!SPM>@LDAM?DC+J\P=*CN0^NE4)'XZ= MAG6=&=83_,V(P5'2#=+07NL"VK[Q@%&UYQG6B"E6.`E@9S(K\5YP\ M/E7-\HG]\7U4X:'7,]ZE^#VX;>O!7LZO#XKPRAV_)3[/,T,M5;.1PIH@*IAT MSO?[\*5COT`]-,S9\L)`6SHTS>9HWO7&,]8$FG<`ZAK!^J)NR_8'4$7(QP`V MY866[,QOW:'ED7CVU5@>U:@[JJ74KBYS%O%1S>M1?6Q& M=2]&M:D-OF3IMZ%*4`"C^J&+&WU-QN1(GUY_,]-T$$9`OCY4915EFR1[Y$?L M"TW3BGY>9U"M';`YP^9>)XM,#5RS[ZJHJ):,T#1@^@O>MAV*2'R*8W8M&OWP M]@P1[7^[B.=9//^0"\<\_F&7W=B?Q0PZZE&NPD]@A&0,]G;GXWS<8*>*B MME_W%4!:C]G&I_G[ZPVQI"WYA4^;E#V]SC#+,&AS!EJ*;E[='J06PZ+.1NIU M*7=CG_S1WQ"*EJ_9'WUXV2)13V\?N:5;M^_HVE%!0QP5N'BO.(=@'D& MG#?Z/?K(9@,6S$TJ)/B]>4KM(/MQEKWN?T?^4H,-T&4V$OV>O:;ML$\ZW]'= M\*;GW4]YNL%%R06]SBM\N=M'<;7.;L2CGEMZ<[U<9])EEK8JC/)2Y!QL(>YK MSS<<[;7LZ3P]W[Z>2^"^XY`XURZ`\CY#G#M-BECS1[P#^BOY#E7;!\QMW\7& MYAX7NY+>WR7>`14<>_188.9;@"Z,^U$$S!4A8XJ0-(I0ORBL!X/\*I<485I- M,HT[O$IBXMDQS0YZFQ^CM#K**1M4>4/LR0#4_ M^M7;?L^][TB;7.5@.<1#$G/06JSEG%/WS29ZI4EUXT8:W+S0@V4Y-UQY3TCC M+M28.>)*GU(FA(G"">%LD\5<>W%Y4='(]Y*=IS!Q5@]DI4QB0.TZW$0"M=LU M#(,:$6'A)/\B1C,LA&+#AS0_KTA[)!&@WVH2[S/7"`RJDLUTN=6M?'S'"EG<.F.%E]T'-%%&I4EJZ)!C3;\JL@#1N7.QBW)MV9ZI3MI479:F_N=.FUDZ1F2($(U%?I:T'T#Z!!>(YS!>7\2 MGEQ0S1D.OZ-52=;;&X*VEIO$)'>'W2XJCNNM5%EH%<>T&`!]796G24QP!,L,#R-VYB1MU\?,[O@/8UG/="I7.Z#1;NB%Y:35:IZU7:$ZI["<6+_ M?[P]#2G&SZ-UJ0@U<++NE`#.%%W<(V/M"?U MZP)=Y5*D`!,,6!IVMD:1%R;!^*[?#=!!IS,STI(B35H>M@DZVSR\9!@DBG4&2#>9O^&]QC)/G7GJO$?0`@>$8@$V@ MZ$+L-W!TEZRG:A*+KC5WF*":"TA0.0-,7B4P[F`J!`E?5^$TI9$*-;2(%^06 M9O<805\O<)AT,1F?^U/*I_IEF7`!/^WFQY(M#45"\`R>2ZK:0 M%;8U@MF*46:\L!XL*)[R\U>V47"T=@21A, MK94A%V!%%4+U$SN58K3H77]/)YP-^.GP^$Z47$\DI-(?'C[4_"6=7&(!9Q;! M.`/[R,"1/@0'X3K[Z#4PQ'AA3LQA^P^H[SC!J5SG*7\%O*H?+%NX$0LB`,=A M#:5Q%8,4?IV#I3C]E&;KJ_K)?4,9S@V$UXEJT*M-@76:(\#?NT<+XW9D$-P; MR"&C=Z(.Z3VDG7X-OXH,QX9FQVOU1M*+UPOG4TX)#E@BS?7VAB;SN"=-\04A M2F(2WQ1)E"H?3P_30(0&ED#:R&"`P'-@8"5-?ZIA9.R&&,O&PBA138HX+4Q, M,!70G@&ZO+Q$<0VG6@[.<#`P#YZ*?:`31',&![6=O.%)F M!S$T!C1AK>@]V^VUA#%:C1@&96`4]#X6IT&4"-1,W2%\J2%L.83C4A"L37,> M#',:XZ>H^(PK^I"@?;/=OM=681FB`#!+.Q"-;9J;^S50&UEZZM$22?GL4$L& M8J>O!\F@N4Z%TN:60[N&;$ZK_5.>9-5=A3&M/WF1[W9)1?ZQWK/+6G5%2A4R M2T(`&W:"U)BR%95?BW80J:=#C!;5Q*BA1@TY4/'3RAB4,I.TG@PN6?203.8T MP(Q:.J6IZ1%E`)[LV1D;_1/++U;#H#DB6H:]4RGX%,_3/A\[CFI/HU!4X]X0 M!H"3Y`WAA8L";YBTQME1W11F6C2)7<^'-O(N-A%J!.SE9*V;B8?@D+/>S"+/ M>F'"Z0:6$WD0ERCL;UXYT$)?K'"]J:.^C`!PV\K]ML6KA3KB"L88K+-F%FC4U$N1GJ(X^.0N(R78:I.L\.[^/7M@JLYV/:Y[D!V*1R<.! MFNF9`*E<)_@S.Y81>+W]E=T:J=8%7-42X68+H*(![SUM29>@0@%G.N7I+3LSN+]D`Y888`-!E<;"5?3&=, MHFI51BP":#-`-9$E?I_OHN0TF#$U!'4G"I%/W(A!UJ7=1U>X(1W@#>&UH.OT MKC1E2&R)`IIL>E",$XX6@]])1Q;:8>*YTI<5`3A"XID82$`FO4?_Q-+>X(\Z7M9([0CR_(6R6DX4'BY_"H4/)R^3N&$.*?4M'\;DN=!*U MXRAEQ@@X8:,N%UN[/_,SSG`1I60U&*.<([C< M0F#A(5N@8K:T=RJZ1E+?X+68/(]GFYM6G#*2=LDSKA;C"ZA^'M!Q0RR*(+.5=$)=9G!YH-7,UZ'8N MI`>1[XA8G_4J.Y$MF`[/,AR24L\Z#LL?DDW&;ZG]7A,@^H-U)@7!Z#?*`#$. MD%MJ[*&7\@F'N@G0EI9"S&9+RB#? MRPZ/E>ST[9]X-0`8)%U0W<@JD5PZ*3]?%)@LPNA/N@,$$P70Z<$PB.;HP%[Z MY\_932K%+EB,NV7"&@8A M&,V,$"6C*6L&,'>8E\,#62TD9OY_2]V@*FQ1M8+*%:\4MIL.OM,$(..[ MHG]-,O"Z)6)-`1.VVXN,:Y'9QA!@/G9KDKZ2X8WXA*->'&O0N!"#6!I[N`:"[0G]6N9KG+U7YLW#*A[YBR$)$^R%069@FOB:9/RELQTQ7OPT.9;)*H M8/?<#5JH:@ATF5HKE#6Q?12*5S_JE[;"%1'K:1]E^15M$2*E4_12[([ M[%8[NJ=YB\DZJ,#TLN,=F1G*[9$_L[C%-)<9^9G\87VHV+8G^9?T/$,UAEZ'N@_U1ZD5^\@24 M%7C)(2(K*%R6*([*)ZA,P3XT(.(:4,@:4'8UH.AH0"YI@/18:\X4Q!_**MG1 M?>X+,OCW^3M\BZM#0>+7^US4)56-EPT5@%>S!],XK&$2O[[(5IZ^#=6$B%+2 MG+L/&-7$])^"',1]C$8EG"9=8;6H"D$,XRMF^$(*+/2?,2>?M2Y`DK6.;;V] MQA65^EU$!(LQ%3@KZ9.."G_"Q6,O+A_'`B*<&0>S#5O8:&,6Q!0?O1/.$G=3G`^<`5"(,>M7C)JOF%&4$CKN M2)JO6#W57W+R!E2)XV\?\^O*TR$19X6(HU_IT MQ!?R<H=P3E.P\!BZ'_%Q?LFB_Y%Y\R1.,IT=2@%GEX4#/6U^-;>%' MC_26+0O`^/(OQLDSWK`[@NN,EVW\DJ^RC::"XRTOB_,I23&1,S-N+B_5(=R6 M\[)#>+H1O4QO(-O32T+1;EFVG=8+QWICB7>,6,\T^98H"_LE9_N8^B*Q2(B` M6AE`]WQ!AC5NAS62A[6HA_6A.ZR7E]*H]BO5GM>5MG:-`#!7IR#&5.01*N5R M8[I1`9D1U@\5B>])HUO\>$AI!\?5GLQASU%ZF5W@@O[U4_2/O."E!R\HF\)\ MYKAHKT'/#5,'<\0$,;;+4&>):7AFF"H:`5`K`:I%H+D+A1"(28&X&*B1(_3I M8J'QM9\S\F9\BW9\(VE\8S&^.S:^.SZ^<2U'Z%/'S..KFC\4XP8R==PGN,"; M598=HO0N(K/8>OOQ0)-T\31Y5%FQU*6[ZGG-O2+Y*SJ%?XVJ4MQ[+"?@-ASMHY7L.>S9P;SM< M91QX-B#<'SVI#M<%+H&?1*$Q?8*(:3A:Y,)N8I6"TH\ M:(N31)[5>IK$Y&WTT^Q(UM':+S37.!6VJ1VIQ#26%80=3H/=&NLX/IXM>HJ0 M?8UL$_1+JZ&&'VI"?,:1N8>%JW\/^H>E\$L1?+,%#SS)PV`5U0BHEYI8&]:\ MHW3+`ZD:QSKKK,2N\9>/>;&C&UOFA9X;&[B=H#%P3W=Y7'B`[."X"ZA=40M6 MK0NBE4=.-F!H&D")(^2>RPS(;X-869E4EUEY*.A3G8N\V.?6D%U17YAUTA0D;>YTT!-* M\W=Q?H<5\[9K@9LR_-F.7M MF*7-F.FC$R_>%73,9JU!P3.P7!]HNJGU=G6HGO(B^:?(]EVN2A(E\E?31J\Z MC@](;8KQ@*4Z%>Y,?->L&"NAHAB"2-+#>;'+&@TW)#*_1B5[/,DY`B_K9L3> M0HY.(4,5MIC_NV8JD&7S7>FKPAW_KHLL"=5%$&F)CD.4:BK3NA`".!DG2(U7 ML:+RZT8<1+*N.ONU(/]FZ=K/@\8T&[IF(Q1HK0?UF298_9_R)*ON*HP+$@C1 ME\])1?Y!BXG0\MG\2/I`UYO*NJ'C6`!X@I$P&Y_@2._7.XP2KJ>`C`NJV:"& M#ZH9(8F3*'<*8F7SP&U0Q1*J?;.?_`\V&F4]&G'=#8R'G/,+]S&Q0D":L0!, M$JZN<[0J"EK:@`Z7R(K.FH@5X.I+5&QX;9'+C'C+`S_8KIYPRO>Z"$TIZ'E_I2WWU[\\,PP(REOCIURR0):!D`N5V]>\;$.$-< M$"1)@I@HJ"*RB'VS\@QQ<>A=>9B9()`!9XUFW0GJ5%!JK_-9K,-L*0'"+S=0 M3=1E1^8WV'*1J:Z)F87E4^7 M&0GE\'WT8BX]:B:!"4)L8-09$UWD7\3^AX7HEQ=B4Z=HCS@!(A20A40=(9"6 MYTQZLG@HHG.Q1*H(AHA7)%5<[_-928C?-[W/5S';1^4I%FB=RCL<'PI5K0Q' M6JC:0P[`VJ)$(Q`M9BNV$+1OSJL<"4K4DJ*6=E[K^9&CR?`C?>BNLY[1H$2N M0'83>M>B*;5H/!I1D<<8;\J/1`/IC;7UEOR&&'IUO"$8JE7&HN6]XM!Q%`<@ M@W('V9C5>'3+&9<3G)XV"FI$QXC?`25J67,X0XS'&3OK;]B`E!.;$67S#F$O M6#!X6`X":A^DU:R0=+V^X29*G9$?)(:@3_%F1+ZKD>];Y%$'.7M7 MD+0,0?/K@2)?VBVMM\/WO]]%\6>\N<[-"?,F\@W%<8T<$+,G?O`N$.LC(/@6:ZLCJ5<4#'YTL5R5`@G.1KT!WIN2W86_X M;J)D#E97_X.EY3_'Q%Q"'_)O\B/]`K".0? M_P]02P,$%`````@`388)090AS_D")P``09T"`!4`'`!N86)I+3(P,3(P-C,P M7W!R92YX;6Q55`D``Y(B)%"2(B10=7@+``$$)0X```0Y`0``[5W=<]LXDG^_ MJOL?>+F7V0<[_DB<9&_FMN2OG/=L2R4[.[M/4S`)R=A0I`XD;6O_^@-`4J(D M`@1(4`0AUSR,8P--=/]__[=?_^/@X._GXUO'"]UD!H/8<3$$,?2)/:[T.#K)OG(.(T"3] MV,=.#H_3O_@H^/E$_N20`0?1;Q^>XWC^YX\?7U]?#]^>L'\8XNG'DZ.CTX]Y MPP]IRS^_16BM]>MIWO;XX]_O;A_<9S@#!RB(8A"XJUZ43%D_PL:WC^ROI&F$ M_ARQ_K>A"V(FPLIQ.=P6]%\'>;,#^JN#XY.#T^/#M\C[0&3@.+_BT(=C.''8 M`/X<+^;PMP\1FLU].G#VNV<,)[]]",`3(A2.3X[.3H]H__^\S+0V"+RK($;Q MXB:8A'C&1OW!H71_C&^6PZ?]#]UP1@9V?'1P].W@Y/-'VN:CF,S'IJ,\!S[5 MPL,SA'&D,*R-?HW'\1`39%,^H^%D.(>8\:ACUP$U4#7Y#.-N1R\`.2#)Q]>A_@!^/`F>(%1S%2KP(20 MB@Y4S%!*C8CF(F0R(`N,FJ"%5!J/\8:L=S/X"-Z4QK36J_$8K@'"?P-^`B]1 MY/IAE&"EP91W;VYKG@&&;#VFIJP2/0>&3WH3^F;D0TF&+(S)G"J,HZ M-Q[1+7()?Y`"=!PN@!\O!A@#`E/5"5E%J%/KR/Z_V)&-S#_6IJ5\I+_69"]S M6JU8`^6!BHBT9!F4QR@FH]LGN80QT9WBPE-*H-,YJ,Z&EJ^U.0NSCSS"MS@! MOI[9N$ES!^/7.O"6[(CZ4(54&H_Q$4-`2"X>XM#]61L'0BHM6;O:@Y4CU^ZH M=0VW[7$>ZQKH<2M>I[HT!31:]D%KXU6-;&,NJ)FABQ#TI"(O:5BJM(]>XU0U MAHW&KG M4OP1!)Z3DG2*--F8R:C]T%TC[],P;(BK)$M_\X=HT(.G*,;`C7-"9*6&?DI) MLM]'I2%F`F;AX`BZA]/PY:,'$17T"?V!#?_@Z#@+!O\G^=5R'(^$[,8X-__\ MQ]GII\_?3L^^?#T[^_SUR_'IU]/""(NJ'^#UT0+LYK3)CVMHV(Y?9RT^SHD9 M#N(#]QGY2T5/<#A3$F`VBE"2FQ![$/_VX>SH@Y-$9)#AG));`;Q-30S(R#PZ MNFL?3$M4L?;W_NNBFIU,&<='76@C9^F:&#_@_P,"?$U^$PFFR$;+_FM(A;%< M5R?=ZVH$,0H].6T5VMJFKRK6JS/59>HDRW:4^8Q4^9))TM9.N8QG"+* M4Q#?@UF9JU?6S!:%27"U5%%WTXVPAH%_0W8V;_\+^09QHYTM.I)A*U-2)VM6 MSEFZL%X%WB4QWP(/8ZU=_Y4DSU:FI$X6KHL$XS67E:\G7M/^JTJ)L]S/X.YY M?_VX&=71$.O9N&DE$]PY/J;AG>7%(_+S14C:!?2>'_DI"GWDL8N$&6TG)>[\ M\B,`B8?(7_ZD%O$IXF\"HB>FNR0ZF`(P3T$(_3C*?[.)QNS7?RP'/)QO9Z=GWX[.3LZ.OC:99_7Y'$01D78%1^N-C)EI MC06^FG\*G/(]#L+Z!)(Y[-VFXN.RQOAZ@?@IC"!KVXWN1SB<0QPO1CY(+=7_ M)6A.Y7@/>4@0=3$.%Q+*W$:`,H=\YZ9O>$CE);0!=NA8P`L_E*RFS3B,@=^A M+F\16<-]8@+9R1W;\SZ'/N$MHH".%Q467[:[<7C0N!8TDH$]5N$R&^X8OL`@ M@?=AX*:.*@,E(2E.F;E2![?3*(&#WY<)0/G0F#V$GR(X0S>B%RB,?+ MGV^B*(%XR#AF5Q`Y8-)`V3C4-<996T*Q9_=;.`T2HVN]F8U0D>#0'G=EX'DH M'?L((.\FN`!S1-;2@A1X.^#*CO9AHR;/NKR<[M$RIC9 M)3Z-6!-_'[F(Y^)4=[0/+35YML?)V9:@M`-L'QHD>13<%^Q7R"V-*F:G>)P- M$/D\KUUOHJ@"'BSR#D'T3)^;D_]1[+X`GSYW&,07`.,%L6U"EU&FKS'S7:#. M$E^Q-FOV0.,.X)]DH2-;I@?H)IB%!BZ$(5%!CW["0)4A>W8/8^A"`GOZ1OD> MQF*UE[;MI\+E6;'']1]A.">;GJLW^IH0$JLWC)\A7A,9]Y2\LF<_85"7,7L\ M?!GU6Z!H:97J==L[/\DH1/NK'7E18PN.+*I8M,>CRQ)?1".PH$MPN;6S4 M-*]&\=I4M<'-6+._48`C48L\>EW[BW(89`>>,>JUZ! M(7M<^X*(AI-+%,W#"/C?<9C,;P+73^B#,)8^@29#2@H)%,38:$BUQR!J@W-[ M]@S2ZXM5:XK:.F+O/J+4!:]Y[=88.+1_>TZ>?SL1M)902'3:L-W0.)0TQH4D MCQD2OM0&PK<4"`&G67_^SDZZ?3DV]?.GI(E_G/54_I-IL9-U=5Y%QV3B#!GCU1 MA)S="F4;IV0I-?&U:[E65^E8T\EP$\20Z(AOF3 M$,-"R8@[%+"]13Z#R%9GG4KJ(]_!^#GTUDIR"#RCG8S`,N1V+3E!^KU^77VL M%N0R#C@*,<-''&/TE+`[1(\A?2M).A%>?&8_*M;;-CZV=]#6)B1!2L(^H[@T M8$UO/PTGQ!)(85-,PFK$U6!=D-*H;TX!X7,E#@Y4UMI8AH5JW@1Y,OME-/*W M+B.(\Q($R*T(`@G[6`8%=5X%63?[9@>J5V$B%B81)IO:#L\:%>,`I`Z!.OY, MM0S:B5"M3HI.30"9>.%5AYL"O3T`7E-IM'-KJG,(;@KZ$OE)##W%97"CEW%P MTKL0RG";6RPK@NH2!CR32>/%L$C'.!C5`4+-!;%2#N]+XEL=V"E1W`L`-I>( MI4OC[Y`6?"/2)>,"4WB?S)X@'DZV"A`PQX$#/B4:QL&MV;+9G/?;UAL9IWDUW6WK7H(]>VX[C8EZB&AI6H]+^`+]D&4[%]]O$?:Q#@[J MW-IC#K[#@`C/)ZP/O!D*6#FF&+U4W'^JZ&4=0NKP:\]KNBWIR;H.UN%`CD-= MER/+WZMTM,]=LEYY\%W2TC@@:/(=Y0[![4H&OKPLE\V!N#;759X>G; MV>?3XT]'%`4=W6"B@QOA\`41O9TO?A"5W`1+RS9PB7^3/M04\,9O6G]+_9[#E9ENAJ'O9U!9!N=M>5ECR7-;S9! M[R*<4>]2A*_RQN^(JB4A>Z)\1*PTPP*\A.G_"X+,*CY4O\Z7)/".-6U2LR>" MN"V(0L)A:<@5^AB'LH:JEL%.%?MY8$%K6*'SN..V'+(DQ7EBN])DQ=*8DB&V MCV"K+9?<\;(=A7E*S6)J5>J8;B79E%]192GN(QZ;":[`;8MK(]BF-O8U^ M^X@P&1%8>H=5/KC4.`AL'+):"ZPUE(F=60\Y0DD3:6@X=A`0,@YY[1T[J$K! MGD`'D80+H<>>+#P`YB+<@9A6,%H,)V55C3CP4J9C'+HT06,;5%8O_R5"+:Q:=H?4#64B2W+7WDUVA$DNUAO,X## M>\FD0,(X?&E8\AKSW^YE]L\F`VMC@4>=YUMWB20W'Y;PGEP)N^SI M[2NQ4'*\?&[I**^C`Y816&3"'KC$L&*H$O26ZVN@@=$0U9;C/4--*V^WNCTI M&4[(;\B,DS$B$%.T&C(H$<.GH-CA$V1ADY"@3L!(Z" M`'+CE*%A6_WDWV8_JWP M:6?U;6?Y\2[BF'@*@NR-]BK72RJR(BO#27:N#?Q5%IBJ+*5Z:'<2WFTR]!4P M'@F"SGW^%1W=GS'&%K4"K[6X\2XDUSO3-W@!R*=.]G6(Z6ZRI&YIE64[W;1L M2YK.),0.I>H4R7:1MF:#RU7LMRH)C43'3O+P<,=594`D>AIG$^35MY8"IR:G MO9O#]%8B2B<7/7QGVYDI#!2\D^,R7S^GR7R2=:J=)+CF,KD:>,5L5J3131YO MB2%6S7$U(L9-]UJJ7D\$WIC_WAF!0K%KV87[\^:D3VDX*9$N+8Y`2DQAU%SBN0ZP'$96Q5S M4=REB\E8-J*JV2CL8]QTE%%3<3ZJ<]>["2E.K%38M;Y*:U40)O'"Z`'R\&&`.R+U8*]G[;G"(Y M618ER@@[:Y1U`%0\>-'VI91X5/Y;FFRI^3#BG)+N:-;_4U+*<:TUX[=V\ M:W*XS/Z_D)N;G]HY8G9^R7_JI%"'=:?-',LQPHA\8.Y#6HQ%,)84$4)+4I.4 M,9:EM9-@[=*QYW':CXCL&*ZB&,V(`'DWF=8;V8\7!;[M2;6VC!`5Q'03$.$D M3$[K*Q(O=B;JNS^XJ2\.$XJJ\.YK@NAY\WTW316W_:Q.8JFJ3A3W`4IN5:"YN'#1>:9ZADN]L/,RT2R8%E0>HT8=%H(:8D>NX/G.H* M(T>2!>7$>/%W\;*HV+LHQ+.CDR_V(JJ)0/)]F@4;M>6%"CD8\9KO#VZ4))`# MQ89]'(IK-+_-7CN973M/"D.DY1(AI$^QQBCZ>4$803'] MJ43CPM;6`4#(K;9<8X8!(CM,H=D(I@&J#A=+]]LGQ[6.*')`6;!N7`$ MS27*;HK((:BBU]IB>_SUU%[\U!'$\ABA_^AY@%,JHC&=!`#D-2??<' M2?7%D>/)@G#,/7PM1*!P&)`?75@(GXNA13T!=1)6P:F>")8)\8SQD#C'$;1Z M:C%*2801>`![,JO>.S^XS]!+:+(S_@CS)&R(`85)O]+E:$C6.&^DWDOI5L30NXMZI6]C ME$R$Y'NN3DV#70^[THK59"4LE`J^@X`.T1O2TNH)QC196.#=AP'._\GN14H9 M"/T?,LYDU'Y"UJY(>F<^RE_KJ!D0Z==GG9H0:YZAK=:]\M&Q0E]#!KPHRS>X M4/0KZA(VSDRH/T9K20CV7+I="8@82+IQH%7*B3R12WYBTOD1H+@N\FK0M`IT MNOAO\VKO+M)]7L*8^/222]!9==9/YY>,HD/EE@!?<0TR)@^HW$`80B1&P=H9 M,X%D,WNJ<2(RO1T761K3"XN#-\1[N[#\N]$JXHN^Y*12R)&,JKHZI:8#OX.S M)XA%RDI;&*,N.;%SU"3@19<[4\Q7WKF*[\`;FB4SH9+7VIBI9L'8MA5=S4\[ MGFOWRD9!M;*+;6Q0=B4_[;B-^@_0BB^OSQ> M-RAZ)$1HD0P6V_A6_P=!EFA'+ZU%S3O)Q;DUP%5UMM>Y'4A8,,PWJ(`WL1P M5FK^>6W-TGU=4Z_$G3`]0E['HA>Z+V4JS>(712M[);`*-1RK M:/&;,VG"52Q>H.TYC/Q0$&0K_-VL)5M'@*V*N;83(IQJTB*[_W7UYCY3B8RI M"LIT6=:J!_./.W;CUM:B(8Z@>S@-7SYZ$*4VF/RP:7K)K_ZXA5/@7P4Q^6)) MZ).^2MQJ88S.)+:WI0SPTS:V+^]T'*5A2#K6]3]W(>E2B:T+='V0_-6ED\NZ MR5.$/`0P>^50LJQ0!LH:=27K,D#D@BX;I]%6I[[>1DQ(7(VM_]E$7:V/T+@[ M1)R5.[L--9C1]\5C2/Q*,C+VJ#!&T621O@NB60*)Q0VFY`_#)([H&V3RK\)[ MHK+E7AMI4]8;^5V<-M;[`J,\ZS;;G3R&YW`,XP0'T'L,,R&6(42FERG*KU*Y M#"_MI(O6'V7+;LVE\!U.[F%,F3H'/@A<2/D)(EJ7(H9W$$_+]VW*)$S1L\(D M5V71N)6;>_D%TZ038)I6)YOE3\!>"9K/%VPG]!SZA)=2LZ_2VQ2E5ZE:A2?C MDACR]NR4@S&<)]BEL<81#J<8S$88N3!/BK7&;.F.7IF&3J=E63`Z3N=@:G73 MDP_V&&T8I&'4UY#F8"F/J&8Y:N^0#Z,X#(2N3%L?-&4:*#LX;0FD]?,HS>ZS MA!R&3S'9-)!&8SA-?/J!Q6`^Q^$+K35Q`3']ZQWX9XC3J@$7E`P6>]:M?M5F M3-:72DMYS[L$YB."9-"#(""RI:EDHN'D.B&N*US=];F@.Q.OI.)0NY^R&8** MHF@I]62[OF/*'?&+:\&J+B534*/B4ZKPUQL35`#W(R`[H+A4S66M^J+"LK'W M9J:NK-K*7"U]L+SD](^`<$,9W*K1O*;#NJ1ZH^BZ#.XN*:,>?R&K#INS-`S6 M5JA[^'H=XAEUF0@3`E]`C4Q?4%"+N=YD:*6.21[+&LZSA:=,QYR&?=$B9_BY MGHP/M:?%,@C&F$)0L-@I*++?^Z$7Y)KR>6X^/F"7B7C!_*_-CW=3/W0"11`^CP2)UB%*7 MR0P>W[X>'I]\-L6DM("0-)][)@E:5O<.DDV0%%0X72W%C`JW*_!\.OUB,WIR M>0S((,$44K'D^SX9!`FZ6XHB58Y72")_,@=*O`,@%@0=`>0]AL4K;(\TXS0M M`9$:WM(#']FNO<*`&FO+P'XORVVQ\A[#2;$PV2#P'NB%5;P83A[0-$`3Y()B M[3%6<@S!2#%3^<.,6O.R#PG.S[]&^%$3BK(3CY&)IF-]=C7K76 M?-NPO9IHZSH;JHT6B]=$N-]#\IF`_O,[X9O\CAXJ1I#H MA"9;*,CEZHT6-BGWAS20W1^LM26LME]7=;2%&Q#A>LA/8O12*/-X]>;Z"7&W MJ/BHKYOD"\MF8?/4G^7X&%IH[P5RVY=82R?56K,S_0[AS^@FN";>//#_029H MF3$4-+8-%57\]N;\_*\A"N*'&+(=+KT"@&+RC^QZ%!$%U[62[&BEXB5Y-R]A M%P<$UY">U/F75N=%"JP9MQBTC=[O.(RB,00^ MO:;]':`@NB6_@!%M-<*A"Z''*P3:C*A9,0GUR;,6+PIRX9<,E^QM'`B:J7,;'DWD8'`9 M<@FV2K,I*_5H?.#W-Z58=PD2IE:%VMII?EJ3HTK8KJ3 M6.V/`&?AQ#22>%PO.KM%QA@34JUXY0"L'+/YI=C:(;=O*9X".*79SFB`?&G"*H#KU`4Z8X]T*8YM,<4P3@MIG0? MDK4S^R>[M"4Z.-)&WQB#H*+^HE%H5Q(&'SDM&3]?+'_\'P0Q?7.TN*4OC@0G M3G*=S05'*\H6@$M=3`:?1RU9R226OF+;XD]X)J5$PUPM5`)+:HK#M:&K) M_$TP3^*("?18>#`@Z&$N>&KK6X`A2?XM/5,J$\.),G!.]APX(OXM/5':S_LW MNW:'--S/,?%\Z?U^CM7W>V,6.OW:+CGB5Y)"V[[8I_=;(19"3-$\I5_/92](S\%IJ.4]_QIMB50AXO:= MQ`5\$)$-\_K`2FZ7T.DG:-M9<@$A#')'1#!P_CK1A3;&-#FQX#1B^7>CS'(E MAHHV5LR"P5[4%[]#`0JC3,,,W;ZU^MU871+_.US"P:J\JGFH"2(UZIYKKY'2. ME'VI;JH),35KF^HN3[.KG*&,L7/B-7FT/@\,(D:F7C3_ZU9%2T;=8>2=(GTS MLHN7\U[Q*K2J4[>9CSBC*Y2N.U^LVF3UZP:O`'MR"44;TC?&8JA!H#PG4ANR M,/AE:/\.&':CLO=S"D/4_'Y.\7Y.\7Y.\7Y.8=LY1>6BQ5NS>,<8^@@;AZ1= M+_4MB5#7U1+>84+IJ"7BRI(=#?3HFVID\\A!3A"].5TJ%YK*D8,R"0-!PCU@ M4N7-TO?P`Y\1AUZY0+(JY"6'YK(=.PL>UIP`^7&Z+'_&E6)7LP?51G3(&(K2 MH-8A=%D%\MN.CJ"^]50:H/?E8FAE3KQQUN]6E'^D#?)5. M6W8@'N/`[UQ(EGJ9>@W$ MA@C9'R^)J[9\EK43*UXYBGJ'21S%(/!0,&T5]5O?>4=]^^+4Y31:A_JKMSG"K$_; M$;"2+[TC?Q<"S;V_Q'Y[8AGWZ MJN$FBA+H728TEU$JA/3I%/OCNE/(?5RF3FC/D:M'7ADPCP[/ZB/3SLVG26[X M\3X!>S?R7`+_]+@Q\E-G_"$&.+8%_?M\%MU+V,L?7!\=?CK[^J5Q.[ M/Z98ULFN/*/Q^5-'HM0\D7T&%7CL^FNKWS?+=%.>@EN5( MC\3>PZ3*1$ELT&O:$CN]#_-V92.H/^^N??<:]! M7BV=%M@%>_/=GW?@*PM,PV&!A8&I2M&V&[)2_/S[3-`@K^5$:!ZNVEG=BOO0 M']/;Q-%@BB&3D-J=VN.CS5#5_?#624DZ2YIU[]-R7N1M#UKT&%?4NL-2$;\# MBLIXB-G@*FI%E#;N[$9\M?PW*D:4#I\?/.KF9)AX7925;,BIZ=G.\,2B[?RV M'2>[%H!J>3>8/WBS-%(<7VEQZ`+?:XTZ.X2I@M#&K%@;M%FR'^6K%1LCMP1D M>;..YT`)8'+!EX_7GNQ'I5;@5I#`OZJ#^>:LBH.6L\>4+(4JB4*4NANEC"U4 M+=_G*_%DW+--4GQSB[1"_)@X$4CL*"N#(7M<#*&+N'W$BSNPB!^'@3>/R`H\[65 M>ALTT2N21"BQM3-@M!)KNT4NS7Q%Z^V.PP7PXT4Q%T:]-//?-L-O^4<%DNYGEAZFI8VFZ%6@E@W-2C%H7+Y!WD8&N2_@C:_-XM^MTV0E MNS1(R$RG&0'WT0ZU$/W>*NK2G^S4*!IL6TL`-'M8=W! M!]G!\I=B-0HF:KR!JFJJOHMU6Q=B+N$+],/Y/=DLID_$Z/CX1E_0O)]8D%\2 M5%DW+LQ5:\_,.UY4Z6HB,C2M"_5X%V6;JEWZK%Y(I#HVK4C`4+V*%:(6)S$^ MH"VV]>QLI<#/CSF18A!G]R5'`,?(17.F-WX:^[JT>F4+*HZNM,H@!U'C5V:: M"K7O:R5%36N$'(.B7:0)FGLOD-AB@<3.5?Q>3:\7?OM[:AE*Z=9C?ZFKKOU_#$.D\;-\R9>>PW=EQ,P9M;ORC\7 M,MZV>="UR>,)W#X,(/::Q].+EZ<_TD(K_\/<2^]TJF0QIO)X+$$Z(1?XCYC(H_04HKI/3T%0S5C^)OW(=+UFV^[5 M8CF8A4D0/X;G,`[0_#%)F7T,B,@[?8^C3%"IWR(=1'`;E3V]:_F!/$=6R M5'(X&K^.R3M#YR."9-"#@+B3_@,@$W$XN4YH&I75#84+ M^HC.(S.U(205/V4]#A7ED8//>`^LP-$CP%,8EU^Z+VG54Y67L9)OR(P/#I(= MI$M%/87#239K5F^#L^>,)T>? M-I\SKKHYA7Z=/-XE`V%QN2('!"/D#_,P`OYW'"9S4:)X90K=O%$NCN4F^L//L?,02$MP7+Y;`] M[;]L3ON\O9-VT+'SC^5!#0``5H(``!$`'`!N86)I+3(P,3(P-C,P+GAS9%54"0`#DB(D4)(B M)%!U>`L``00E#@``!#D!``#M7>MOVS@2_W[`_0]:?^H"Y]A.MKU-+ME%GD4. M26PX[NW>IP4MT3:O$JFEJ"2^O_YFJ(<;\_Z/W^^/"LZ3H!X=G;5-HL18Y/(H:3'N.>(MRD$;W-^-<"
0OMB M\6OT86M`V=.>+NT8BL@Y54_$H9Y+3!J3S?!!#\&B%2(SXDTU5U2BM>OV!]V301(42\4L21-_[`6%<;O`1@4& M@XYA&.>$^&>:;P M.?3LH4NEENO=4$68[4WHFP);=PQF770JT,4-B)I@T1GC3#>U_ZG_D]$U4(HM M/%_2\$L@TEC)-#Z$4HU0[(_GO:RP;#T^C*$A_T5_=B7UH%-I80_P(.0.28HX M36*;OKT%XZIEF_G"IQ$HVV$U`1<$MEL^*V%^#6!)/RI$X+C_]RP"$;>AV5M# M%PV*S<.@S.S5.GYK_<#7];O]T^[QQP"(*V+CA/6\H%2%"*0?%9I^,.B#M9_! M2GJB@<_7@EN4XY0+GSQA,TO/Z:%,(Q!J?/C"B6\Q*&F=3QXJL46]X2P[0#:4 M%>-T7!&GE7!#S%*31HM89<2NB;>XL\5K#F"KHF*\3K;""Z4;6GR+5PE>-V'6 M<2& M)H&!8>H8"U+[$?@CD]$X?MA!0@FFQUE,=67H^Y+5Z9$65HAEB2J-59U&5&G; M#W+ZP>4+Y(AD:N/BP#.QZ3U_H9[24TT`0YSDC67ILI:2U\.3`<\_A*9V0MPB.Y(.2 MX?$Q:_Z`U]#,K;5SK'U'F/P7L7VZ,EMH]MR2$OM_RMH?A1A:2N)YBT1N'K0@ MDNHU=XRV(&-)1-0;RDK0^#F+AA9C!.OZ24$M'CEX/`E[C!LDWN5<4ITI!ECD M/"^9%/I9')Z&#T8@PXB%M!CD8/#`3$S=<1H>BR6QU?)22@+39R*:*J$I&2.G M66PB<7JV#@4:28DM4'O.??3_R]TSH%!.(>`_'28/,CY$G]HUHYHIT00?ER=& M(5DAN!_KID?&AT!L"UK5T#")5D%Y"4P5P\06GOKQ8A*@0HH2B"K'CBU(-59C MP_,#N8NR45G)4872M=GVE,+!(Y84C/L05(+Y@6*6MI_L%KKDG46J3EZ"^C+4(%"*6.^^6YQB*"$H1* M3@>VOF^'C"$/JDJ4)9C]O!:U;$XA6OAVA:\";J6`U<:KQ:DV3H,*0`U*D5J+ M#U9G>-OHHN,QQ[7Q?I9^MI!T=M%!I+O1G:$_H-%';XX=D:#\@AM?ND=D M]`SKC200::X)6;L&UG.E<*E4C'J]J.V1`,44LE^O:C&P&N]O!K&AG;V]J0Y( MUU4]VSD.I'MJ0>DPRD,.7%=Y8*'V`;5^0/D'4A>&6%UUTZ/R0#K?Q)7D*G[> M2][=@V_INWWGH+>0RN!KMRF+[G8&=T0 M_$O0%;U&Q(!F^%BMOEP==E<>GVRG>^2`Z)NYJ.VU8B;]:;<&Z!TKN:S=AB1? M]&532\)[_CIYP&G[CZ*[2Y=33TEB0G?`EA??*.AA9@WH^$#/EHX3/4OAN1,B`!*IEMMY`B$0%93#/,V%-M%C+E^&Q MT4T*9G:=LSIM+&Z8&LE,C[Y0[M-D)H;YUY6M;Z(':E4F#]0*WL)PIJ+GWU2U MU#IY%I\-A0U#9WW9)*M'(46F!3LHD[7+?I19ZUZ%)`WH4L7K(EELJE(WK-.- MH$:303:&MX7CJ[[!<8QD6AN<$UW#<&OV!N"+UY?Q[^V?/GLA=GASZ9'(KU2A M[&=J^I*I^)#LFO(["&B`^F/*G*DOO:"#WDGA?!8P@7'\^AEZ+CP3<@P00NZ\ M`+UN8`JPA8O%MV^N[NN1(?8B*CD0'`%A,9'+@Q@D*)L&KXBXZ)B26DP5>#)F MOI"W1^I,J8Q=5^I9"DQ+.(3Q!CFJ!\8I-L>KYJD2Y`US5?G;/XFV7RU7)".R MU//C*Y'6T$5"+^B)]WRD:[U]H])D'@V^1;8Y;!U)`T;Z?EL38@"T$+9%I8=> M2RV?A*+W$+V::LA'/@Q/7#?3L_*0#WV%:TGX-K65*XLMM1=1^PM:MC%'LM]? M+4=26+ZI7W5V^<9B14N(]C!(+'5F,9#OA=UA/UAO;/>-]E"EZD5D[^W=$I-% MLJU?W)D47(5C<$Q-REYH/(YK,KW7W&/1:='4LT&+^#JTPI"+6>%;H)M820=9CZ>Q_K*J&FGW69?KO0$.'<$3I!R?*0_'>[I' M%I(TI/T;'/N3X&,Z\[FE#R%36F]:V,S]?V>DK9]62P)!T/[YZ`>72]*=T?[XZL^"> MTBR_['M192U;WUS>L/0\:_?@-%?)5LD:5<.4VN6>V@8+[%5DP\Q5=!<]WQIU M.!JF;&I7:8-ZQ30-4VASDKA*#2M&5!MX&AHP9/=O+4L?\2)V-2=60-\PA#=< M;L_7LB+Q=Z%B*:2UV1JF=OYF:HZB%0@;IEI)J)JO9DVFAJG\Y&.V#4$"KJ%/ M%@#4MO/E.D<(!>#@!ES?4K5'\L8, MZ9\^D]32V:9BWFR)2_=XOM'#6)[/H2"Q5_W`0(*=\?9[$M?07.@6JG7PV@+N M_4W$%1U3F,H`U(D(TY[($E4H&ZKD(P1),8C#V1-5J$/XJS'8?.[A>HRBCU3. M5SLCM=D:JKX>J6/JAH6#=8][T)J^?RM/&`59 MEQ#M$!L74KWA[,X'?TQ7>[C7.`MA0+N%:6N*;ZH]DU%+H`PX\JZ-M.25-16Z5TJQZ:^PGPSU9[PN'@!/U2;Q^/%1U6_:&3N'A MR`W7MB(%ACPU0I_H*_[6:G@M/S/HZ[$VM5N@>XKBL?CWXQ);;7F%3=4E6%;1 M1^7!][I%W;D2Z;LOS]Q1W`*R;Z@K/*;N(3J6:(EK(5TAPY%+7RV$9/^EELX;O$L/.GV06*V9:#O>U-*7ION6R8G^T5B< MBGR:^.W9#4M\%8D;MKB7OXR,5WY,7#8(%,+.467UN8#MW1U=^H)IV7IM5>J& MH1G&#>'6QC*>@@I_NBT5`L``00E#@``!#D!``!02P$"'@,4````"`!- MA@E!(Q(:^VD,``"2FP``%0`8```````!````I(&R;@``;F%B:2TR,#$R,#8S M,%]C86PN>&UL550%``.2(B10=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M388)0<=[?%,K$0``*R`Q0````( M`$V&"4$A(@G0BCX``$AK`P`5`!@```````$```"D@>2,``!N86)I+3(P,3(P M-C,P7VQA8BYX;6Q55`4``Y(B)%!U>`L``00E#@``!#D!``!02P$"'@,4```` M"`!-A@E!E"'/^0(G``!!G0(`%0`8```````!````I(&]RP``;F%B:2TR,#$R M,#8S,%]P&UL550%``.2(B10=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`388)04>SC^5!#0``5H(``!$`&````````0```*2!#O,``&YA8FDM,C`Q M,C`V,S`N>'-D550%``.2(B10=7@+``$$)0X```0Y`0``4$L%!@`````&``8` *&@(``)H``0`````` ` end XML 15 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share Based Compensation (Details Textual) (USD $)
In Millions, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2012

Jun. 25, 2011

Jun. 30, 2012

Jun. 25, 2011

Share Based Compensation (Additional Textual) [Abstract]

Options granted to purchase 1,000

Exercise price of the options granted $ 1.89

Average grant date fair value of options granted $ 0.96

Share-based compensation expense $ 0.7 $ 0.6 $ 1.6 $ 1.2

Minimum [Member]

Share Based Compensation (Textual) [Abstract]

Exercise period (in years) of options granted 1 year

Maximum [Member]

Share Based Compensation (Textual) [Abstract]

Exercise period (in years) of options granted 3 years

X

- Details

Name: nabi_ShareBasedCompensationAdditionalTextualAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Share-based compensation arrangement by share-based payment award, options, grants in period, exercise period.

+ References

No definition available.

+ Details

Name: nabi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePeriod

Namespace Prefix: nabi_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: nabi_ShareBasedCompensationTextualAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 16 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share Based Compensation (Details 1)
6 Months Ended

Jun. 30, 2012

Summary of Nonvested Restricted Stock Awards

Nonvested at December 31, 2011 405,977

Granted

Vested (193,503)

Forfeited (16,220)

Nonvested at June 30, 2012 196,254

X

- Details

Name: us-gaap_RestrictedStockAwardForfeituresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(e)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 17 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6

Licenses and Royalty Arrangements (Details Textual) (USD $)
In Millions, unless otherwise specified
6 Months Ended 1 Months Ended 6 Months Ended

Jun. 30, 2012

Clinical_trial

Jun. 30, 2012

Maximum [Member]

Jun. 30, 2012

Minimum [Member]

Nov. 30, 2009

PentaStaph [Member]

Mar. 31, 2010

NicVAX [Member]

Jun. 30, 2012

NicVAX [Member]

Clinical_trial

Jun. 30, 2012

NicVAX [Member]

Develop Next-Generation [Member]

Jun. 30, 2012

NicVAX [Member]

Maximum [Member]

Jun. 30, 2012

NicVAX [Member]

Minimum [Member]

Licenses and Royalty Arrangements (Textual) [Abstract]

Total consideration received for selling the assets of the vaccine products $ 46

Upfront payment received on the consideration amount 20

Amount receivable upon achievement of milestones 26

Initial payment received 40

Number of phase III clinical trials 2 2

Option not exercised by GSK, maximum possible milestones 290

Payments related to trial-related milestones 47 47

Payments related to regulatory approval 34 34

Payments related to annual sales 209 209

Percent increase in royalty payments 7.00% 5.00% 7.00% 5.00%

Annual sales targets $ 600 $ 300 $ 600 $ 300

Expected continuance period of joint steering committee 190 months

End date of GSK upfront payment recognition through December 2025 through December 2025

X

- Definition

Annual sales targets.

+ References

No definition available.

+ Details

Name: nabi_AnnualSalesTargets

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Development arrangements, consideration received.

+ References

No definition available.

+ Details

Name: nabi_DevelopmentArrangementsConsiderationReceived

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Development arrangements, contingent consideration, potential cash payment.

+ References

No definition available.

+ Details

Name: nabi_DevelopmentArrangementsContingentConsiderationPotentialCashPayment

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Development arrangements, option fee received on exercise of options.

+ References

No definition available.

+ Details

Name: nabi_DevelopmentArrangementsOptionFeeReceivedOnExerciseOfOptions

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Development arrangements, upfront payment, participation period.

+ References

No definition available.

+ Details

Name: nabi_DevelopmentArrangementsUpfrontPaymentParticipationPeriod

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Development arrangements, upfront payment received.

+ References

No definition available.

+ Details

Name: nabi_DevelopmentArrangementsUpfrontPaymentReceived

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Initial payment received on closing of exclusive worldwide option and licensing agreement.

+ References

No definition available.

+ Details

Name: nabi_InitialPaymentReceivedOnClosingOfExclusiveWorldwideOptionAndLicensingAgreement

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Joint steering committee expected continuance period.

+ References

No definition available.

+ Details

Name: nabi_JointSteeringCommitteeExpectedContinuancePeriod

Namespace Prefix: nabi_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: nabi_LicensesAndRoyaltyArrangementsTextualAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Maximum contingent amount to be received based on obtaining regulatory approval in certain major market countries.

+ References

No definition available.

+ Details

Name: nabi_MaximumContingentAmountToBeReceivedBasedOnObtainingRegulatoryApprovalInCertainMajorMarketCountries

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Maximum contingent amount to be received based on Phase II and Phase III clinical trial-related milestones.

+ References

No definition available.

+ Details

Name: nabi_MaximumContingentAmountToBeReceivedBasedOnPhaseTwoAndPhaseThreeClinicalTrialRelatedMilestones

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Maximum contingent amount to be received based on tiered annual sales of future generation candidates.

+ References

No definition available.

+ Details

Name: nabi_MaximumContingentAmountToBeReceivedBasedOnTieredAnnualSalesOfFutureGenerationCandidates

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of phase three clinical trials.

+ References

No definition available.

+ Details

Name: nabi_NumberOfPhaseThreeClinicalTrials

Namespace Prefix: nabi_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of annual net sales of future generation candidates.

+ References

No definition available.

+ Details

Name: nabi_PercentageOfAnnualNetSalesOfFutureGenerationCandidates

Namespace Prefix: nabi_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 18 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6

NOL Rights Agreement (Details)
6 Months Ended

Jun. 30, 2012

NOL Rights Agreement (Additional Textual) [Abstract]

Terms of the rights agreement Under the Rights Agreement, the Board of Directors declared a non-taxable dividend of one preferred share purchase right for each outstanding share of common stock to be distributed to stockholders of record on August 25, 2011. Concurrent with the signing of the Merger Agreement with Biota, Nabi and the rights agent amended the Rights Agreement to terminate the rights under the Rights Agreement.

Date of Adoption of stockholder Rights Agreement Aug. 25, 2011

Preferred Stock [Member]

NOL Rights Agreement (Textual) [Abstract]

Non-Taxable Preferred Dividend Distribution, Record Date Aug. 25, 2011

X

- Details

Name: nabi_NolRightsAgreementAdditionalTextualAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: nabi_NolRightsAgreementTextualAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Stockholders equity note, impact on purchase rights on outstanding securities

+ References

No definition available.

+ Details

Name: nabi_StockholdersEquityNoteImpactOnPurchaseRightsOnOutstandingSecurities

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Stockholders right agreement adoption date.

+ References

No definition available.

+ Details

Name: nabi_StockholdersRightAgreementAdoptionDate

Namespace Prefix: nabi_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Date the holder must own the stock to be entitled to the dividend, in CCYY-MM-DD format.

+ References

No definition available.

+ Details

Name: us-gaap_DividendsPayableDateOfRecordDayMonthAndYear

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

XML 19 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6

Discounted Operations
6 Months Ended

Jun. 30, 2012

Discontinued Operations [Abstract]

Discontinued Operations
NOTE 4 DISCONTINUED OPERATIONS

During 2006, we assessed our pricing programs under Medicare/Medicaid and other governmental pricing programs for the period from 2002 through the second quarter of 2006. In connection with the 2006 review, we identified additional liabilities related to discontinued operations for possible overbilling under Medicare/Medicaid and other governmental pricing programs. The estimated liability related to these programs was approximately $1.7 million at December 31, 2011. In the first quarter 2012, we undertook an assessment of the remaining liabilities and concluded that these remaining liabilities should be eliminated after determining that any remaining obligations related to the programs were not material.

X

- Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 43-48

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

+ Details

Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Balance Sheets (Unaudited) (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2012

Dec. 31, 2011

Current assets:

Cash and cash equivalents $ 92,649 $ 94,310

Marketable securities 2,079

Receivables 995

Prepaid expenses and other current assets 301 497

Total current assets 92,950 97,881

Property and equipment, net 84

Total assets 92,950 97,965

Current liabilities:

Accounts payable 75 146

Accrued expenses and other current liabilities 1,435 1,918

Deferred revenue 2,526 2,526

Liabilities of discontinued operations 1,662

Total current liabilities 4,036 6,252

Deferred revenue 31,579 32,842

Total liabilities 35,615 39,094

Stockholders' equity:

Convertible preferred stock

Common stock 6,357 6,359

Capital in excess of par value 374,792 373,157

Treasury stock (92,567) (92,567)

Accumulated deficit (231,247) (228,078)

Total stockholders' equity 57,335 58,871

Total liabilities and stockholders' equity $ 92,950 $ 97,965

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value of outstanding nonredeemable convertible preferred stock or outstanding convertible preferred stock that is redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7, 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7, 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 48

-Paragraph 6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of current obligations (due less than one year or one operating cycle, if longer) arising from the sale, disposal or planned sale in the near future (generally within one year) of a disposal group, including a component of the entity (discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 46

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 2

-Article 5

+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6911-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e7018-107765

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Technical Bulletin (FTB)

-Number 85-6

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 21 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

Basis of Presentation and Summary of Significant Accounting Policies
6 Months Ended

Jun. 30, 2012

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies
NOTE 2 BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2011, has been derived from audited consolidated financial statements as of that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission.

Principles of consolidation: The condensed consolidated financial statements include the accounts of Nabi Biopharmaceuticals and our wholly-owned subsidiaries (referred to as “Nabi,” the “Company,” “us,” or “we” throughout this report). All significant inter-company accounts and transactions are eliminated in consolidation. All of our wholly-owned subsidiaries are dormant or are otherwise non-operative.

Accounting estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period, including such amounts related to discontinued operations. Actual results could differ from those estimates.

Fiscal year periods: Historically, our fiscal year ended on the last Saturday of December. Consequently, we periodically had a 53-week fiscal year. In 2012, we amended our By-Laws to change our fiscal year end to a calendar basis; this prospective change did not have a material impact on our financial condition and results of operations for any periods presented.

Financial instruments: The carrying amounts of financial instruments including cash equivalents, marketable securities, accounts receivable and accounts payable approximated fair value as of June 30, 2012 and December 31, 2011, because of the relatively short-term maturity of these instruments.

Cash, cash equivalents and marketable securities: Cash equivalents consist of investments in low risk, highly liquid securities with original maturities of 90 days or less. Marketable securities consist of low risk fixed income investment instruments such as government obligations, government agency and Federal Deposit Insurance Corporation backed notes with maturities typically less than eighteen months. Marketable securities are classified as available-for-sale and recorded at fair value; unrealized gains and losses on those securities are reflected in other comprehensive income (loss). We assess the risk of impairment related to securities held in our investment portfolio on a regular basis and noted no “permanent” or “other than temporary” impairment during the first six months of 2012. Our investment policies and procedures are reviewed periodically by management and our audit committee to minimize credit risk.

Concentration of credit risk: Financial instruments that potentially subject us to credit and liquidity risk consist primarily of cash, marketable securities and receivables. The Company maintains cash deposits at major financial institutions with high credit quality. The Company’s operating accounts exceeded the Federal Deposit Insurance Corporation limits of $250,000. Cash equivalents primarily consist of short-term money market funds, which are deposited with reputable financial institutions. At June 30, 2012, the Company’s marketable investments consist primarily of United States government agency securities as well as corporate debt securities and commercial paper. The Company’s investment policy limits investments to only investment-grade securities with the objective to preserve principal and maintain sufficient liquidity to meet operational objectives.

Revenue recognition: Our revenue generating arrangements may include multiple elements and deliverables, including licenses, options, research and development activities, participation on joint steering committees and contract manufacturing, among other elements. When we determine that an element has stand-alone value to our customer, we allocate a portion of the total contract price to that element based on its relative selling price, determined pursuant to a selling price hierarchy, and recognize revenue for that element according to its characteristics. Revenue consists of license fees, milestone payments, and payments for contractual services.

License fees received that do not have stand-alone value are initially recorded as deferred revenue, and are subsequently recognized as revenue ratably over the period of our participation on joint steering committees. The joint steering committee established in connection with our option and license agreement with GSK related to NicVAX is currently expected to operate for 190 months from the date of the agreement (or through December 2025). Our efforts under the joint steering committee established in connection with our asset purchase agreement with GSK related to PentaStaph were completed in the second quarter of 2011.

For milestones that are deemed substantive, we recognize the contingent revenue when: (i) the milestones have been achieved; (ii) no further performance obligations with respect to the milestones exist; and (iii) collection is reasonably assured. A milestone is considered substantive if all of the following conditions are met: (i) the milestone is nonrefundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone appears reasonable in relation to the effort expended with the other milestones in the arrangement and the related risk associated with achievement of the milestone. If a milestone is deemed not to be substantive, the Company would recognize the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment will be deferred and recognized as revenue as the Company completes its performance obligations.

Payments for contractual services are recognized as revenue when earned, typically when the services are rendered.

We analyze cost reimbursable grants and contracts to determine whether we should report such reimbursements as revenue or as an offset to research and development expenses incurred.

Collaborative arrangements: We are an active participant with exposure to significant risks and rewards of commercialization relating to the development of NicVAX and future generation nicotine vaccines based on NicVAX technology. For costs incurred and revenues generated from third parties where we are deemed to be the principal participant, we recognize revenues and costs using the gross basis of accounting; otherwise we use the net basis of accounting.

Research and development expenses: Research and development costs are expensed as incurred; advanced payments are deferred and subsequently expensed over the period of performance. Research and development expenses include direct labor costs as well as the costs of contractors and other direct and indirect expenses (including an allocation of the costs of facilities). We expense amounts payable to third parties under collaborative product development agreements at the earlier of the milestone achievement or as payments become contractually due. In the first six months of 2011 we recorded approximately $0.3 million of cost reimbursements from government grants as an offset to research and development expenses (none during 2012).

Income (loss) per share: Basic income (loss) per share is computed by dividing consolidated net income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of stock options. The dilutive impact of dilutive potential common shares resulting from stock options is determined by applying the treasury stock method. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the three- and six month periods ended June 30, 2012 and June 25, 2011. The Company’s unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator.

A total of approximately 3.7 million potentially dilutive shares related to stock options have been excluded in the calculation of diluted net loss per share for the three- and six month periods ended June 30, 2012 and a total of approximately 4.6 million potentially dilutive shares for the three- and six periods ended June 25, 2011, as their inclusion would be anti-dilutive.

Share-based compensation: We expense the estimated fair value of share-based awards made in exchange for employee services over the requisite employee service period. Share-based compensation cost for stock options is determined at the grant date using an option pricing model; share-based compensation cost for restricted stock is determined at the grant date based on the closing price of our common stock on that date. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period.

Income taxes: We account for income taxes using the asset and liability approach, which requires, among other things, recognition of future tax benefits and liabilities measured at enacted rates attributable to temporary differences between financial statement and income tax bases of assets and liabilities and to tax net operating loss carryforwards to the extent that realization of these benefits is more likely than not. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year. We periodically evaluate the realizability of our net deferred tax assets; a valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. We recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits, and our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. We consider discontinued operations for purposes of determining the amount of tax benefits that result from a loss from continuing operations.

Segment information: We currently operate in a single business segment.

Recent accounting standards: In June 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2011-05, Presentation of Comprehensive Income. ASU 2011-05 revises the manner in which entities present comprehensive income in their financial statements. The new guidance removes the presentation options in Accounting Standards Codification 220 and requires entities to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements. ASU 2011-05 did not change the items that must be reported in other comprehensive income. The Company adopted the provisions of ASU 2011-05 in the first quarter of 2012. As the Company’s net loss was the same as comprehensive loss, the Company did not include a statement of comprehensive loss.

New accounting pronouncements: We have evaluated all Accounting Standards Updates through the date the financial statements were issued and believe the adoption of these will not have a material impact to our results of operations or financial position.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6

Available for Sale Investments (Details) (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2012

Dec. 31, 2011

Estimated Fair Value of Available-for-Sale Short-Term Investments by Security Classification

Amortized Costs $ 0 $ 2,079

Gross Unrealized Gains 0

Gross Unrealized Losses 0

Estimated Fair Values 0 2,079

Government-sponsored securities [Member]

Estimated Fair Value of Available-for-Sale Short-Term Investments by Security Classification

Amortized Costs 0 993

Gross Unrealized Gains 0

Gross Unrealized Losses 0

Estimated Fair Values 0 993

Corporate debt securities [Member]

Estimated Fair Value of Available-for-Sale Short-Term Investments by Security Classification

Amortized Costs 0 1,086

Gross Unrealized Gains 0

Gross Unrealized Losses 0

Estimated Fair Values $ 0 $ 1,086

X

- Definition

This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS115-1/124-1

-Paragraph 7

-Footnote 2

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 19

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7534914&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 12

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Available-for-Sale Securities

-URI http://asc.fasb.org/extlink&oid=6505594

+ Details

Name: us-gaap_AvailableForSaleSecuritiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

This item represents the gross unrealized gains for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 22

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 13, 19

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGain

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

This item represents the gross unrealized losses for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities.

+ References

No definition available.

+ Details

Name: us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLosses1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ShortTermInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6

Discounted Operations (Details Textual) (USD $)
In Millions, unless otherwise specified
1 Months Ended

Dec. 31, 2011

Discontinued Operations (Textual) [Abstract]

Estimated amounts due under pricing programs $ 1.7

X

- Details

Name: nabi_DiscontinuedOperationsTextualAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_LossContingencyLossInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 24 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 25 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

Available for Sale Investments
6 Months Ended

Jun. 30, 2012

Available for Sale Investments [Abstract]

Available for Sale Investments
NOTE 3 AVAILABLE FOR SALE INVESTMENTS

The amortized cost, gross unrealized gains and losses and estimated fair value of available-for-sale marketable securities by security classification as of December 31, 2011 (none at June 30, 2012), were as follows:

December 31, 2011

(In thousands)
Amortized Costs Gross
Unrealized Gains Gross
Unrealized Losses Estimated
Fair Values

Government-sponsored securities
$ 993 $ — $ — $ 993

Corporate debt securities
1,086 — — 1,086

Total securities
$ 2,079 $ — $ — $ 2,079

During the six months ended June 30, 2012 and June 25, 2011 we had no realized gains (losses) on sales of available-for-sale marketable securities. Gains and losses on available-for-sale marketable securities are based on the specific identification method. The contractual maturities of all of our available-for-sale investments as of December 31, 2011 were less than 12 months.

X

- Details

Name: us-gaap_AvailableForSaleSecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27198-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 03-1

-Paragraph 21

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS115-1/124-1

-Paragraph 17

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27337-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 19, 20, 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Statements of Operations (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2012

Jun. 25, 2011

Jun. 30, 2012

Jun. 25, 2011

Revenue:

Revenue $ 631 $ 3,744 $ 1,263 $ 12,917

Operating expenses:

Cost of services 549 1,174

Research and development expenses 1,330 6,456 2,848 11,791

General and administrative expenses 2,176 1,426 3,453 2,768

Total operating costs 3,506 8,431 6,301 15,733

Operating loss (2,875) (4,687) (5,038) (2,816)

Interest income 33 50 65 122

Other income (expense), net 109 38 142 75

Loss from continuing operations before income taxes (2,733) (4,599) (4,831) (2,619)

Benefit from income taxes 671

Loss from continuing operations (2,733) (4,599) (4,160) (2,619)

Income from discontinued operations, net of tax provision 991

Net loss $ (2,733) $ (4,599) $ (3,169) $ (2,619)

Basic income (loss) per share:

Continuing operations $ (0.06) $ (0.11) $ (0.10) $ (0.06)

Discontinued operations $ 0.02

Diluted income (loss) per share:

Continuing operations $ (0.06) $ (0.11) $ (0.10) $ (0.06)

Discontinued operations $ 0.02

Basic weighted-average shares outstanding 42,664 42,307 42,578 42,221

Diluted weighted-average shares outstanding 42,664 42,307 42,578 42,221

X

- Definition

Total costs related to services rendered by an entity during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Subparagraph 1(i)

-Article 4

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 36, 37, 38

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 11, 12, 36, 37, 38

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of income (loss) from a disposal group, net of income tax before extraordinary items allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 13

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.14)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.12)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income (loss) derived from discontinued operations during the period, net of related tax effect, per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8, 9, 10, 36, 37, 38

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss derived from discontinued operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section E

-Paragraph Question 3

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 27 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

Available for Sale Investments (Tables)
6 Months Ended

Jun. 30, 2012

Available for Sale Investments [Abstract]

Estimated Fair Value of Available-for-Sale Short-Term Investments by Security Classification

December 31, 2011

(In thousands)
Amortized Costs Gross
Unrealized Gains Gross
Unrealized Losses Estimated
Fair Values

Government-sponsored securities
$ 993 $ — $ — $ 993

Corporate debt securities
1,086 — — 1,086

Total securities
$ 2,079 $ — $ — $ 2,079

X

- Details

Name: us-gaap_AvailableForSaleSecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information
6 Months Ended

Jun. 30, 2012

Aug. 03, 2012

Document and Entity Information [Abstract]

Entity Registrant Name NABI BIOPHARMACEUTICALS

Entity Central Index Key 0000072444

Document Type 10-Q

Document Period End Date Jun. 30, 2012

Amendment Flag false

Document Fiscal Year Focus 2012

Document Fiscal Period Focus Q2

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 28,328,389

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: nabi_DocumentAndEntityInformationAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value Disclosures (Tables)
6 Months Ended

Jun. 30, 2012

Fair Value Disclosures [Abstract]

Inputs used in measuring fair value of assets and liabilities

December 31, 2011 Quoted Prices in Active
Markets for Identical
Assets Significant Other
Observable Inputs Significant
Unobservable Inputs

(In thousands)
Total Level 1 Level 2 Level 3

Government-sponsored securities
$ 993 $ — $ 993 $ —

Corporate debt securities
1,086 721 365 —

Total
$ 2,079 $ 721 $ 1,358 $ —

X

- Definition

Tabular disclosure related to assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a recurring and/or nonrecurring basis in periods after initial recognition. Disclosures include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3) as well as transfers between levels 1 and 2.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 6

-Footnote 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a,b,bb)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2C

-URI http://asc.fasb.org/extlink&oid=7578670&loc=SL7498348-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19279-110258

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19190-110258

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 33

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
6 Months Ended

Jun. 30, 2012

Jun. 25, 2011

Cash flow from operating activities:

Net loss $ (3,169) $ (2,619)

Income from discontinued operations, net of tax provision 991

Net loss from continuing operations (4,160) (2,619)

Adjustments to reconcile net loss from continuing operations to net cash used in operating activities from continuing operations:

Depreciation and amortization 34 110

Non-cash intra-period tax allocation (671)

Share-based compensation 1,634 1,215

Loss on sale of property and equipment 29

Changes in assets and liabilities:

Receivables 995 304

Prepaid expenses and other assets 196 (417)

Accounts payable, accrued expenses and other liabilities (505) (1,119)

Deferred revenue (1,263) (6,534)

Net cash used in operating activities (3,740) (9,031)

Cash flow from investing activities:

Proceeds from sales of maturities of marketable securities 2,079 52,035

Purchases of marketable securities (10,632)

Proceeds from sales of property and equipment 158

Capital expenditures (1)

Net cash provided by investing activities 2,079 41,560

Cash flow from financing activities:

Proceeds from issuances of common stock for employee benefit plans 525

Net cash provided by financing activities 525

Net increase (decrease) in cash and cash equivalents (1,661) 33,054

Cash and cash equivalents at beginning of period 94,310 53,564

Cash and cash equivalents at end of period $ 92,649 $ 86,618

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of income (loss) from a disposal group, net of income tax before extraordinary items allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 13

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.14)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.12)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_OtherNoncashIncomeTaxExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 31 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share Based Compensation
6 Months Ended

Jun. 30, 2012

Share Based Compensation [Abstract]

Share Based Compensation
NOTE 8 SHARE BASED COMPENSATION

A summary of option activity under our stock compensation plans as of June 30, 2012, and the changes during the first six months of 2012 is presented below:

Options
Number of Options

Outstanding at December 31, 2011
4,053,652

Granted
1,000

Exercised
—

Forfeited
(64,198 )

Expired
(325,253 )

Outstanding at June 30, 2012
3,665,201

Exercisable at June 30, 2012
3,121,084

We granted options to purchase 1,000 shares at an exercise price of $1.89 during the first six months of 2012, with an average fair value at the date of grant of $0.96. The grant becomes exercisable between one and three years after the date of grant. We estimate the fair value of each stock option on the date of grant using the Black-Scholes option-pricing formula and amortize expense over the option’s vesting period using the straight-line attribution approach.

A summary of our restricted stock awards as of June 30, 2012 and the changes during the first six months of 2012 is presented below:

Awards
Number of Awards

Nonvested at December 31, 2011
405,977

Granted
—

Vested
(193,503 )

Forfeited
(16,220 )

Nonvested at June 30, 2012
196,254

Share-based compensation expense for the three months ended June 30, 2012 and June 25, 2011 was $0.7 million and $0.6 million, respectively. Share-based compensation expense for the six months ended June 30, 2012 and June 25, 2011 was $1.6 million and $1.2 million, respectively.

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Treasury Stock
6 Months Ended

Jun. 30, 2012

Treasury Stock [Abstract]

Treasury Stock
NOTE 7 TREASURY STOCK

On July 30, 2012 we completed a “modified Dutch auction” tender offer for our common stock at a price per share not less than $1.58 and not greater than $1.72, and purchased 14,547,996 shares of our common stock for approximately $24.4 million at an average cost per share of approximately $1.68.

X

- Details

Name: nabi_TreasuryStockAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for an entity's treasury stock, including the average cost per share, carrying basis for each class of treasury stock, description of share repurchase program authorized by an entity's board of directors, the number of shares repurchased, the cost of the shares repurchased, the remaining maximum dollar value of shares available for repurchase under the program, the treatment of the purchase price in excess of the current market value, number of shares held for each class of treasury stock, and other information necessary to a fair presentation.

+ References

No definition available.

+ Details

Name: us-gaap_TreasuryStockTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6

Available for Sale Investments (Details Textual) (USD $)
6 Months Ended

Jun. 30, 2012

Jun. 25, 2011

Dec. 31, 2011

Available for Sale Investments (Textual) [Abstract]

Realized gains (losses) on sales of available-for-sale securities $ 0 $ 0

Maximum maturity period for available for sale investments less than 12 months

X

- Details

Name: nabi_AvailableForSaleInvestmentsTextualAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Maximum maturity period for available for sale investments.

+ References

No definition available.

+ Details

Name: nabi_MaximumMaturityPeriodForAvailableForSaleInvestments

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: instant

X

- Definition

The total amount of proceeds received for the sale of securities, categorized neither as held-to-maturity nor trading securities, during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 21

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 34 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share Based Compensation (Tables)
6 Months Ended

Jun. 30, 2012

Share Based Compensation [Abstract]

Summary of Option Activity Under Stock Compensation Plans

Options
Number of Options

Outstanding at December 31, 2011
4,053,652

Granted
1,000

Exercised
—

Forfeited
(64,198 )

Expired
(325,253 )

Outstanding at June 30, 2012
3,665,201

Exercisable at June 30, 2012
3,121,084

Summary of Nonvested Restricted Stock Awards

Awards
Number of Awards

Nonvested at December 31, 2011
405,977

Granted
—

Vested
(193,503 )

Forfeited
(16,220 )

Nonvested at June 30, 2012
196,254

X

- Definition

Tabular disclosure of the changes in outstanding nonvested restricted stock units.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments and Contingencies
6 Months Ended

Jun. 30, 2012

Commitments and Contingencies [Abstract]

Commitments and Contingencies
NOTE 11 COMMITMENTS AND CONTINGENCIES

We have agreements with our employees that include certain cash payments and equity-based award modifications in the event of a termination of employment or a change in control of the Company.

We are parties to legal proceedings that we believe to be ordinary, routine litigation incidental to the business of present or former operations. It is management’s opinion, based on the advice of counsel, that the ultimate resolution of such litigation will not have a material adverse effect on our financial condition, results of operations or cash flows.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Licenses and Royalty Arrangements
6 Months Ended

Jun. 30, 2012

Licenses and Royalty Arrangements [Abstract]

Licenses and Royalty Arrangements
NOTE 9 LICENSES AND ROYALTY ARRANGEMENTS

We have entered into licenses and royalty agreements for our products in development.

PentaStaph: In November 2009, we sold our PentaStaph product candidate and related assets to GSK under an Asset Purchase Agreement for a total consideration of $46 million including a $20 million up-front payment and $26 million payable upon achievement of certain milestones, all of which we have received. We completed our work to help develop PentaStaph under contract with GSK during the second quarter of 2011.

NicVAX: In March 2010, we closed an exclusive worldwide option and licensing agreement with GSK for NicVAX as well as for the development of follow-on nicotine addiction vaccines. Upon closing, we received a $40 million initial payment. Under the terms of the agreement, we granted to GSK (i) an option to obtain an exclusive worldwide license to develop, commercialize and manufacture NicVAX as it currently exists, as well as certain potential alternative forms of NicVAX together with an adjuvant other than a GSK proprietary adjuvant and/or with different presentation, dosage or administration (NicVAX Alternatives), and (ii) an exclusive worldwide license to develop, commercialize and manufacture certain future generation candidate vaccines for the prevention or treatment of nicotine addiction based on our NicVAX intellectual property (other than NicVAX and NicVAX Alternatives).

GSK has informed us that it does not intend to exercise the NicVAX option due to the failure of the Phase III trials to achieve their primary end points. However, GSK has not indicated that it terminated the development of the future generation nicotine vaccine.

Notwithstanding the failure to achieve the primary endpoint in our two Phase III trials, if the future generation nicotine vaccine being developed by GSK is successful, GSK will pay us up to $290 million in contingent milestone payments as follows: (i) up to $47 million based on Phase II and Phase III clinical trial-related milestones, (ii) up to $34 million based on obtaining regulatory approval in certain major market countries, and (iii) up to a total of $209 million based on tiered annual sales of future generation candidates. GSK also will pay us royalty payments on annual net sales of future generation candidates, beginning at 5% and potentially increasing on incremental sales to as high as 7%, with the increase depending on whether annual net sales of future generation candidates meet or exceed specified annual sales targets in any calendar year ranging from $300 million to $600 million. We believe all future milestones under the NicVAX agreement to be substantive as they are at risk until achieved. The probability of us receiving future contingent milestones or royalties is uncertain as it is based on the achievement of various success-based development and regulatory approvals contingent upon the occurrence of various future events, the occurrence of most of which have a high degree of uncertainty of occurring.

Revenue under the NicVAX agreement consists of license fees, milestone payments, and payments for contractual services. License fees received are initially recorded as deferred revenue, and are subsequently recognized as revenue ratably over the period of our participation on joint steering committees. The joint steering committee related to the NicVAX agreement is currently expected to operate for 190 months from the date of the agreement (or through December 2025).

X

- Definition

Licenses and royalty arrangements.

+ References

No definition available.

+ Details

Name: nabi_LicensesAndRevenueArrangementsTextBlock

Namespace Prefix: nabi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: nabi_LicensesAndRoyaltyArrangementsAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

NOL Rights Agreement
6 Months Ended

Jun. 30, 2012

NOL Rights Agreement [Abstract]

NOL Rights Agreement
NOTE 10 NOL RIGHTS AGREEMENT

On August 25, 2011, our Board of Directors adopted a stockholder Rights Agreement with American Stock Transfer & Trust Company, LLC, as rights agent, in an effort to prevent an "ownership change" under Section 382 from occurring and thereby protect the value of our net operating losses. Under the Rights Agreement, the Board of Directors declared a non-taxable dividend of one preferred share purchase right for each outstanding share of common stock to be distributed to stockholders of record on August 25, 2011. Concurrent with the signing of the Merger Agreement with Biota, Nabi and the rights agent amended the Rights Agreement to terminate the rights under the Rights Agreement.

X

- Details

Name: nabi_NolRightsAgreementAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

NOL rights agreement.

+ References

No definition available.

+ Details

Name: nabi_NolRightsAgreementTextBlock

Namespace Prefix: nabi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Basis of Presentation and Summary of Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2012

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Principles of consolidation and presentation
Principles of consolidation: The condensed consolidated financial statements include the accounts of Nabi Biopharmaceuticals and our wholly-owned subsidiaries (referred to as “Nabi,” the “Company,” “us,” or “we” throughout this report). All significant inter-company accounts and transactions are eliminated in consolidation. All of our wholly-owned subsidiaries are dormant or are otherwise non-operative.

Accounting estimates
Accounting estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period, including such amounts related to discontinued operations. Actual results could differ from those estimates.

Fiscal year periods
Fiscal year periods: Historically, our fiscal year ended on the last Saturday of December. Consequently, we periodically had a 53-week fiscal year. In 2012, we amended our By-Laws to change our fiscal year end to a calendar basis; this prospective change did not have a material impact on our financial condition and results of operations for any periods presented.

Financial instruments
Financial instruments: The carrying amounts of financial instruments including cash equivalents, marketable securities, accounts receivable and accounts payable approximated fair value as of June 30, 2012 and December 31, 2011, because of the relatively short-term maturity of these instruments.

Cash, cash equivalents and marketable securities
Cash, cash equivalents and marketable securities: Cash equivalents consist of investments in low risk, highly liquid securities with original maturities of 90 days or less. Marketable securities consist of low risk fixed income investment instruments such as government obligations, government agency and Federal Deposit Insurance Corporation backed notes with maturities typically less than eighteen months. Marketable securities are classified as available-for-sale and recorded at fair value; unrealized gains and losses on those securities are reflected in other comprehensive income (loss). We assess the risk of impairment related to securities held in our investment portfolio on a regular basis and noted no “permanent” or “other than temporary” impairment during the first six months of 2012. Our investment policies and procedures are reviewed periodically by management and our audit committee to minimize credit risk.

Concentration of credit risk
Concentration of credit risk: Financial instruments that potentially subject us to credit and liquidity risk consist primarily of cash, marketable securities and receivables. The Company maintains cash deposits at major financial institutions with high credit quality. The Company’s operating accounts exceeded the Federal Deposit Insurance Corporation limits of $250,000. Cash equivalents primarily consist of short-term money market funds, which are deposited with reputable financial institutions. At June 30, 2012, the Company’s marketable investments consist primarily of United States government agency securities as well as corporate debt securities and commercial paper. The Company’s investment policy limits investments to only investment-grade securities with the objective to preserve principal and maintain sufficient liquidity to meet operational objectives.

Revenue recognition
Revenue recognition: Our revenue generating arrangements may include multiple elements and deliverables, including licenses, options, research and development activities, participation on joint steering committees and contract manufacturing, among other elements. When we determine that an element has stand-alone value to our customer, we allocate a portion of the total contract price to that element based on its relative selling price, determined pursuant to a selling price hierarchy, and recognize revenue for that element according to its characteristics. Revenue consists of license fees, milestone payments, and payments for contractual services.

License fees received that do not have stand-alone value are initially recorded as deferred revenue, and are subsequently recognized as revenue ratably over the period of our participation on joint steering committees. The joint steering committee established in connection with our option and license agreement with GSK related to NicVAX is currently expected to operate for 190 months from the date of the agreement (or through December 2025). Our efforts under the joint steering committee established in connection with our asset purchase agreement with GSK related to PentaStaph were completed in the second quarter of 2011.

For milestones that are deemed substantive, we recognize the contingent revenue when: (i) the milestones have been achieved; (ii) no further performance obligations with respect to the milestones exist; and (iii) collection is reasonably assured. A milestone is considered substantive if all of the following conditions are met: (i) the milestone is nonrefundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone appears reasonable in relation to the effort expended with the other milestones in the arrangement and the related risk associated with achievement of the milestone. If a milestone is deemed not to be substantive, the Company would recognize the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment will be deferred and recognized as revenue as the Company completes its performance obligations.

Payments for contractual services are recognized as revenue when earned, typically when the services are rendered.

We analyze cost reimbursable grants and contracts to determine whether we should report such reimbursements as revenue or as an offset to research and development expenses incurred.

Collaborative arrangements
Collaborative arrangements: We are an active participant with exposure to significant risks and rewards of commercialization relating to the development of NicVAX and future generation nicotine vaccines based on NicVAX technology. For costs incurred and revenues generated from third parties where we are deemed to be the principal participant, we recognize revenues and costs using the gross basis of accounting; otherwise we use the net basis of accounting.

Research and development expenses
Research and development expenses: Research and development costs are expensed as incurred; advanced payments are deferred and subsequently expensed over the period of performance. Research and development expenses include direct labor costs as well as the costs of contractors and other direct and indirect expenses (including an allocation of the costs of facilities). We expense amounts payable to third parties under collaborative product development agreements at the earlier of the milestone achievement or as payments become contractually due. In the first six months of 2011 we recorded approximately $0.3 million of cost reimbursements from government grants as an offset to research and development expenses (none during 2012).

Income (loss) per share
Income (loss) per share: Basic income (loss) per share is computed by dividing consolidated net income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of stock options. The dilutive impact of dilutive potential common shares resulting from stock options is determined by applying the treasury stock method. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the three- and six month periods ended June 30, 2012 and June 25, 2011. The Company’s unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator.

A total of approximately 3.7 million potentially dilutive shares related to stock options have been excluded in the calculation of diluted net loss per share for the three- and six month periods ended June 30, 2012 and a total of approximately 4.6 million potentially dilutive shares for the three- and six periods ended June 25, 2011, as their inclusion would be anti-dilutive.

Share-based compensation
Share-based compensation: We expense the estimated fair value of share-based awards made in exchange for employee services over the requisite employee service period. Share-based compensation cost for stock options is determined at the grant date using an option pricing model; share-based compensation cost for restricted stock is determined at the grant date based on the closing price of our common stock on that date. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period.

Income taxes
Income taxes: We account for income taxes using the asset and liability approach, which requires, among other things, recognition of future tax benefits and liabilities measured at enacted rates attributable to temporary differences between financial statement and income tax bases of assets and liabilities and to tax net operating loss carryforwards to the extent that realization of these benefits is more likely than not. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year. We periodically evaluate the realizability of our net deferred tax assets; a valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. We recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits, and our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. We consider discontinued operations for purposes of determining the amount of tax benefits that result from a loss from continuing operations.

Segment information
Segment information: We currently operate in a single business segment.

Recent accounting standards
Recent accounting standards: In June 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2011-05, Presentation of Comprehensive Income. ASU 2011-05 revises the manner in which entities present comprehensive income in their financial statements. The new guidance removes the presentation options in Accounting Standards Codification 220 and requires entities to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements. ASU 2011-05 did not change the items that must be reported in other comprehensive income. The Company adopted the provisions of ASU 2011-05 in the first quarter of 2012. As the Company’s net loss was the same as comprehensive loss, the Company did not include a statement of comprehensive loss.

New accounting pronouncements
New accounting pronouncements: We have evaluated all Accounting Standards Updates through the date the financial statements were issued and believe the adoption of these will not have a material impact to our results of operations or financial position.

X

- Definition

Cash, cash equivalents and marketable securities.

+ References

No definition available.

+ Details

Name: nabi_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock

Namespace Prefix: nabi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Principles of consolidation and presentation.

+ References

No definition available.

+ Details

Name: nabi_PrinciplesOfConsolidationAndPresentationPolicyTextBlock

Namespace Prefix: nabi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Recent accounting standards.

+ References

No definition available.

+ Details

Name: nabi_RecentAccountingStandardsPolicyTextBlock

Namespace Prefix: nabi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for collaborative arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 808

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-1

-Paragraph 21

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CollaborativeArrangementAccountingPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 4, 9-15, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f(1))

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5, 6, 7, 9, 11, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CompensationRelatedCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for credit risk.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61044-112788

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number SOP94-6-1

-Paragraph 7, 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 113

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 55

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14537-108613

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 825

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6487554&loc=d3e32600-158583

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 01-6

-Paragraph 14

-Subparagraph m

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61082-112788

+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 6, 8-16, 60

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144384

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining the fair value of financial instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2155942

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 8, 10, 12, 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 06

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=7656940&loc=d3e5291-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 3

-Subparagraph (SX 210.3A-03.(b))

-URI http://asc.fasb.org/extlink&oid=6959686&loc=d3e355100-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph b

-Article 3A

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02.(b))

-URI http://asc.fasb.org/extlink&oid=6959686&loc=d3e355033-122828

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph b

-Article 3A

+ Details

Name: us-gaap_FiscalPeriod

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 48

-Paragraph 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 4

-Paragraph 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 6-34, 43, 47, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32280-109318

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144749

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144681

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of the adoption of new accounting pronouncements that may impact the entity's financial reporting.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 8, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 6

-Paragraph 5, 6, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 42

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2127266

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 11, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) (USD $)
Share data in Millions, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2012

Jun. 25, 2011

Jun. 30, 2012

Jun. 25, 2011

Basis of Presentation and Summary of Significant Accounting Policies (Textual) [Abstract]

Marketable Securities Maturities Less than 90 days

Maximum Maturity Period of Federal Deposit Insurance Corporation Backed Notes 18 months

Federal deposit insurance corporation limits $ 250,000 $ 250,000

End date of NicVAX operating agreement through December 2025

Reimbursements from government grants for research and development expenses $ 0 $ 300,000

Potential dilutive shares excluded in the calculation of diluted net income per share 3.7 4.6 3.7 4.6

Number of weeks in fiscal year 371 days

Operating period of Joint Steering Committee related to NicVAX 190 months

X

- Details

Name: nabi_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTextualAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Development arrangements, upfront payment, participation period.

+ References

No definition available.

+ Details

Name: nabi_DevelopmentArrangementsUpfrontPaymentParticipationPeriod

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Federal deposit insurance corporation limits.

+ References

No definition available.

+ Details

Name: nabi_FederalDepositInsuranceCorporationLimits

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Joint steering committee operating period.

+ References

No definition available.

+ Details

Name: nabi_JointSteeringCommitteeOperatingPeriod

Namespace Prefix: nabi_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Marketable securities maturities.

+ References

No definition available.

+ Details

Name: nabi_MarketableSecuritiesMaturities

Namespace Prefix: nabi_

Data Type: us-types:dateStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Maximum maturity period of federal deposit insurance corporation backed notes.

+ References

No definition available.

+ Details

Name: nabi_MaximumMaturityPeriodOfFederalDepositInsuranceCorporationBackedNotes

Namespace Prefix: nabi_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of weeks in fiscal year.

+ References

No definition available.

+ Details

Name: nabi_NumberOfWeeksInFiscalYear

Namespace Prefix: nabi_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Reimbursements from government grants for research and development expenses.

+ References

No definition available.

+ Details

Name: nabi_ReimbursementsFromGovernmentGrantsForResearchAndDevelopmentExpenses

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 40 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6

Treasury Stock (Details Textual) (USD $)
In Millions, except Share data, unless otherwise specified
1 Months Ended

Jul. 31, 2012

Treasury Stock (Additional Textual) [Abstract]

Number of shares repurchased 14,547,996

Total value of shares repurchased $ 24.4

Average price paid per share for repurchase $ 1.68

Minimum [Member]

Treasury Stock (Textual) [Abstract]

Common stock price per share $ 1.58

Maximum [Member]

Treasury Stock (Textual) [Abstract]

Common stock price per share $ 1.72

X

- Definition

Stock repurchase program price per share of common stock.

+ References

No definition available.

+ Details

Name: nabi_StockRepurchaseProgramPricePerShareOfCommonStock

Namespace Prefix: nabi_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: nabi_TreasuryStockAdditionalTextualAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: nabi_TreasuryStockTextualAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total cost of shares repurchased divided by the total number of shares repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7

-Subparagraph b

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_TreasuryStockAcquiredAverageCostPerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares that have been repurchased during the period and are being held in treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7

-Subparagraph b

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 41 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

Company Overview
6 Months Ended

Jun. 30, 2012

Company Overview [Abstract]

Company Overview
NOTE 1 COMPANY OVERVIEW

We are a biopharmaceutical company that has focused on the development of vaccines addressing unmet medical needs, including nicotine addiction. We have been incorporated in Delaware since 1969 and our operations are located in Rockville, Maryland. Our sole remaining product currently in development is NicVAX^® [Nicotine Conjugate Vaccine], an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. We suffered a significant setback in 2011 when NicVAX did not achieve the primary endpoint in two Phase III efficacy trials conducted in the U.S. The only remaining trial of NicVAX is the Phase IIb trial in combination with Pfizer’s varenicline being conducted in the Netherlands. If the results of the remaining trial, which are expected before year-end 2012, are positive, we believe the potential residual value of NicVAX will be enhanced. As of June 30, 2012, our remaining assets include the following: (i) $92.6 million of cash and cash equivalents, (ii) the potential residual value of NicVAX as well as any next-generation nicotine vaccine which was licensed to GlaxoSmithKline Biologicals S.A. (GSK) in 2010, (iii) the potential royalty from Phoslyra which was sold to Fresenius USA Manufacturing, Inc. (Fresenius) in 2006, and (iv) the potential value of our net operating losses (NOLs).

Merger Agreement with Biota Holdings Limited. On April 22, 2012, we entered into a merger implementation agreement (Merger Agreement) with Biota Holdings Limited, a Melbourne, Australia company (Biota), pursuant to which, among other things, Nabi and Biota will undertake a business combination under Australian corporate law such that each ordinary share of Biota capital stock will be exchanged for newly issued shares of Nabi common stock, and Biota will become a wholly-owned subsidiary of Nabi (the Merger). In connection with the Merger, Nabi will change its name to “Biota Pharmaceuticals, Inc.” but will remain listed on the NASDAQ Stock Market as its sole stock exchange listing and be headquartered in the United States.

Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger:

•
Each Biota share outstanding immediately prior to the effective time will be transferred to Nabi in exchange for 0.669212231 Nabi shares (as such amount may be adjusted pursuant to the terms of the Merger Agreement, including an adjustment for the shares purchased pursuant to the tender offer that we just completed). Immediately after the closing of the Merger, the Nabi shares issued to former Biota stockholders will represent approximately 74% of Nabi’s outstanding common stock, and the shares of common stock held by current Nabi stockholders will represent approximately 26% of Nabi’s outstanding common stock;

•
The board of directors of Nabi will consist of six Biota directors and two Nabi directors; and

•
Biota’s current Chief Executive Officer and Chief Financial Officer are expected to serve as the Chief Executive Officer and Chief Financial Officer, respectively, of Nabi until the appointment of a new U.S.-based management team.

Prior to the closing of the Merger Agreement, subject to the terms and conditions of the Merger Agreement:

•
Nabi intends to return to Nabi’s stockholders excess cash above $54 million (which is required to be delivered to the combined company), after satisfying and reserving for outstanding liabilities, through a dividend, return of capital or repurchase of outstanding Nabi shares through an issuer tender offer approved by the Board of Directors of Nabi, or a combination thereof. We currently estimate the amount of cash to be returned to Nabi stockholders to be in the range of $25 to $29 million, including the $ 24.4 million that we paid to stockholders who tendered their shares to us in our recently completed tender offer on July 30, 2012; and

•
Nabi plans to distribute to its stockholders contingent value rights providing certain payment rights arising from cash received by Nabi from a future sale, transfer, license or similar transaction involving our NicVAX program assets.

Consummation of the Merger is subject to customary conditions for a business combination of this type under Australian and Delaware corporate law, including, among others, (i) approval of the Merger by the stockholders of Biota in accordance with applicable Australian law, (ii) the affirmative vote of the holders of a majority of the issued and outstanding Nabi shares at a meeting of stockholders approving amendments to the certificate of incorporation of Nabi to (a) increase the number of authorized Nabi Shares to 200,000,000, principally to allow for the issuance of additional Nabi Shares to pay the Merger consideration, and (b) change the name of Nabi to “Biota Pharmaceuticals, Inc.,” and (iii) the affirmative vote of the holders of a majority of the votes cast at the Nabi stockholder meeting approving issuance of new Nabi shares to Biota stockholders in the Merger, as required by the rules of the NASDAQ Stock Market.

Each party’s obligation to consummate the Merger is subject to certain other conditions, including approval of the Merger by the Supreme Court of Victoria, Australia, the expiration or early termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and certain other competition laws, the absence of any injunction, restraint or governmental restriction making illegal or restraining the consummation of the transactions contemplated by the Merger Agreement, the accuracy of the other party’s representations and warranties contained in the Merger Agreement that are qualified as to materiality, the accuracy in all material respects of the other party’s representations and warranties contained in the Merger Agreement that are not qualified as to materiality, the other party’s performance in all material respects of all obligations to be performed by it under the Merger Agreement, and the absence of any effect, event, occurrence or matter that has had or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the other party of the nature specified in the Merger Agreement. In addition, Biota’s obligation to consummate the Merger is subject to receiving a certificate from Nabi showing that Nabi has a closing net cash balance of no less than $54 million, calculated in accordance with the terms of the Merger Agreement, and the appointment of specified Biota directors to the Nabi board of directors effective as of the closing of the Merger. The parties expect to close the Merger in the third quarter of 2012 subject to satisfaction of these and other closing conditions.

Tender Offer. On July 30, 2012 we completed a “modified Dutch auction” tender offer for our common stock at a price per share not less than $1.58 and not greater than $1.72 and purchased 14,547,996 shares of our common stock for approximately $24.4 million at an average costs per share of approximately $1.68. We funded the share purchases in the tender offer using available cash on hand.

In response to a preliminary proxy solicitation by Mangrove Partners indicating that they intend to oppose the merger with Biota, Nabi filed an 8-K in which our Board of Directors affirmed its belief that the Merger Agreement with Biota is in the best interest of shareholders.

NicVAX Agreement with GSK. In March 2010, we closed an exclusive worldwide option and licensing agreement with GSK for NicVAX as well as for the development of follow-on nicotine addiction vaccines. Upon closing, we received a $40 million initial payment. Under the terms of the agreement, we granted to GSK (i) an option to obtain an exclusive worldwide license to develop, commercialize and manufacture NicVAX as it currently exists, as well as certain potential alternative forms of NicVAX together with an adjuvant other than a GSK proprietary adjuvant and/or with different presentation, dosage or administration (NicVAX Alternatives), and (ii) an exclusive worldwide license to develop, commercialize and manufacture certain future generation candidate vaccines for the prevention or treatment of nicotine addiction based on our NicVAX intellectual property (other than NicVAX and NicVAX Alternatives). GSK has informed us that it does not intend to exercise the NicVAX option due to the failure of the Phase III trials to achieve their primary end points. However, GSK has not indicated that it has terminated the development of the future generation nicotine vaccine.

Notwithstanding the failure to achieve the primary endpoint in our two Phase III trials, if the future generation nicotine vaccine being developed by GSK is successful, GSK will pay us up to a total of $290 million in contingent milestone payments as follows: (i) up to $47 million based on Phase II and Phase III clinical trial-related milestones, (ii) up to $34 million based on obtaining regulatory approval in certain major market countries, and (iii) up to a total of $209 million based on tiered annual sales of future generation candidates. GSK also will pay us royalty payments on annual net sales of future generation candidates, beginning at 5% and potentially increasing on incremental sales to as high as 7%, with the increase depending on whether annual net sales of future generation candidates meet or exceed specified annual sales targets in any calendar year ranging from $300 million to $600 million. The probability of us receiving future contingent milestones or royalties is uncertain as it is based on the achievement of various success-based development and regulatory approvals contingent upon the occurrence of various future events, the occurrence of most of which have a high degree of uncertainty.

PentaStaph Sale to GSK. In November 2009, we sold our PentaStaph product candidate and related assets to GSK under an Asset Purchase Agreement for a total consideration of $46 million including a $20 million up-front payment and $26 million payable upon achievement of certain milestones, all of which we have received. We completed our work to help develop PentaStaph under contract with GSK during the second quarter of 2011.

PhosLo. In 2006, we sold certain assets related to our PhosLo operations to Fresenius. Under the sale agreement, we are entitled to additional contingent milestone payments of $2.5 million upon approval of a new indication for PhosLo and royalties of up to $65.0 million on annual sales of Phoslyra, a new formulation of PhosLo, over a base amount of $32 million for 10 years after the November 14, 2006 closing date. To date, annual sales of Phoslyra have not exceeded the base amount, and we have not recognized any royalty revenue from those sales.

X

- Details

Name: nabi_CompanyOverviewAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value Disclosures
6 Months Ended

Jun. 30, 2012

Fair Value Disclosures [Abstract]

Fair Value Disclosures
NOTE 6 FAIR VALUE DISCLOSURES

We follow a three-tier fair value hierarchy which prioritizes the inputs used in measuring the fair value of our assets and liabilities. These tiers include (i) Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; (ii) Level 2, defined as observable inputs other than Level 1 prices such as quoted prices for similar assets, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and (iii) Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. All cash and cash equivalents, as well as available-for-sale marketable securities, are recorded at fair value at June 30, 2012 and December 31, 2011. The inputs used in measuring the fair value of these instruments are considered to be Level 1 and Level 2 in accordance with the three-tier fair value hierarchy.

The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy and the fair values are based on period-end statements supplied by the various banks and brokers. The majority of our funds were deposited in institutional money market mutual funds with the remainder held in regular interest bearing and non-interest bearing depository accounts with commercial banks.

The inputs used in measuring the fair value of our available-for-sale marketable securities at December 31, 2011 (none at June 30, 2012) are considered to be Level 2 in accordance with the three-tier fair value hierarchy. These securities are valued using a multi-dimensional pricing model that includes a variety of inputs, including quoted prices for similar assets and liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. To assess the fair value of these securities, we obtain fair values from an independent third-party valuation service provider. As we are responsible for the determination of fair value, we review the values provided by the independent third-party valuation service provider for reasonableness, which could include reviewing other publicly available information.

December 31, 2011 Quoted Prices in Active
Markets for Identical
Assets Significant Other
Observable Inputs Significant
Unobservable Inputs

(In thousands)
Total Level 1 Level 2 Level 3

Government-sponsored securities
$ 993 $ — $ 993 $ —

Corporate debt securities
1,086 721 365 —

Total
$ 2,079 $ 721 $ 1,358 $ —

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share Based Compensation (Details)
6 Months Ended

Jun. 30, 2012

Summary of option activity under our stock compensation plans

Outstanding at December 31, 2011 4,053,652

Granted 1,000

Exercised

Forfeited (64,198)

Expired (325,253)

Outstanding at June 30, 2012 3,665,201

Exercisable at June 30, 2012 3,121,084

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c), d(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(g)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(f)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 48 158 1 false 14 0 false 5 false false R1.htm 00 - Document - Document and Entity Information Sheet http://nabi.com/2010-09-25/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://nabi.com/2010-09-25/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) false false R3.htm 0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://nabi.com/2010-09-25/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) false false R4.htm 0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://nabi.com/2010-09-25/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) false false R5.htm 0201 - Disclosure - Company Overview Sheet http://nabi.com/2010-09-25/role/CompanyOverview Company Overview false false R6.htm 0202 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://nabi.com/2010-09-25/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies false false R7.htm 0203 - Disclosure - Available for Sale Investments Sheet http://nabi.com/2010-09-25/role/AvailableForSaleInvestments Available for Sale Investments false false R8.htm 0204 - Disclosure - Discounted Operations Sheet http://nabi.com/role/DiscountedOperations Discounted Operations false false R9.htm 0205 - Disclosure - Income Taxes Sheet http://nabi.com/2010-09-25/role/IncomeTaxes Income Taxes false false R10.htm 0206 - Disclosure - Fair Value Disclosures Sheet http://nabi.com/2010-09-25/role/FairValueDisclosures Fair Value Disclosures false false R11.htm 0207 - Disclosure - Treasury Stock Sheet http://nabi.com/role/TreasuryStock Treasury Stock false false R12.htm 0208 - Disclosure - Share Based Compensation Sheet http://nabi.com/2010-09-25/role/ShareBasedCompensation Share Based Compensation false false R13.htm 0209 - Disclosure - Licenses and Royalty Arrangements Sheet http://nabi.com/2010-09-25/role/LicensesAndRoyaltyArrangements Licenses and Royalty Arrangements false false R14.htm 0210 - Disclosure - NOL Rights Agreement Sheet http://nabi.com/2010-09-25/role/NolRightsAgreement NOL Rights Agreement false false R15.htm 0211 - Disclosure - Commitments and Contingencies Sheet http://nabi.com/2010-09-25/role/CommitmentsAndContingencies Commitments and Contingencies false false R16.htm 0402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://nabi.com/2010-09-25/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicy Basis of Presentation and Summary of Significant Accounting Policies (Policies) false false R17.htm 0503 - Disclosure - Available for Sale Investments (Tables) Sheet http://nabi.com/2010-09-25/role/AvailableForSaleInvestmentsTables Available for Sale Investments (Tables) false false R18.htm 0506 - Disclosure - Fair Value Disclosures (Tables) Sheet http://nabi.com/2010-09-25/role/FairValueDisclosuresTables Fair Value Disclosures (Tables) false false R19.htm 0508 - Disclosure - Share Based Compensation (Tables) Sheet http://nabi.com/2010-09-25/role/ShareBasedCompensationTables Share Based Compensation (Tables) false false R20.htm 0601 - Disclosure - Company Overview (Details Textual) Sheet http://nabi.com/2010-09-25/role/CompanyOverviewDetails Company Overview (Details Textual) false false R21.htm 0602 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) Sheet http://nabi.com/2010-09-25/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) false false R22.htm 0603 - Disclosure - Available for Sale Investments (Details) Sheet http://nabi.com/2010-09-25/role/AvailableForSaleInvestmentsDetails Available for Sale Investments (Details) false false R23.htm 06031 - Disclosure - Available for Sale Investments (Details Textual) Sheet http://nabi.com/2010-09-25/role/AvailableForSaleInvestmentsDetailsTextual Available for Sale Investments (Details Textual) false false R24.htm 0604 - Disclosure - Discounted Operations (Details Textual) Sheet http://nabi.com/role/DiscountedOperationsDetailsTextual Discounted Operations (Details Textual) false false R25.htm 0606 - Disclosure - Fair Value Disclosures (Details) Sheet http://nabi.com/2010-09-25/role/FairValueDisclosuresDetails Fair Value Disclosures (Details) false false R26.htm 0607 - Disclosure - Treasury Stock (Details Textual) Sheet http://nabi.com/2010-09-25/role/TreasuryStockDetailsTextual Treasury Stock (Details Textual) false false R27.htm 0608 - Disclosure - Share Based Compensation (Details) Sheet http://nabi.com/2010-09-25/role/ShareBasedCompensationDetails Share Based Compensation (Details) false false R28.htm 06081 - Disclosure - Share Based Compensation (Details 1) Sheet http://nabi.com/2010-09-25/role/ShareBasedCompensationDetails1 Share Based Compensation (Details 1) false false R29.htm 06082 - Disclosure - Share Based Compensation (Details Textual) Sheet http://nabi.com/2010-09-25/role/ShareBasedCompensationDetailsTextual Share Based Compensation (Details Textual) false false R30.htm 0609 - Disclosure - Licenses and Royalty Arrangements (Details Textual) Sheet http://nabi.com/2010-09-25/role/LicensesAndRoyaltyArrangementsDetailsTextual Licenses and Royalty Arrangements (Details Textual) false false R31.htm 0610 - Disclosure - NOL Rights Agreement (Details) Sheet http://nabi.com/2010-09-25/role/NolRightsAgreementDetails NOL Rights Agreement (Details) false false All Reports Book All Reports Element us-gaap_CashAndCashEquivalentsAtCarryingValue had a mix of decimals attribute values: -5 -3. 'Monetary' elements on report '0601 - Disclosure - Company Overview (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Jun. 25, 2011' Process Flow-Through: Removing column 'Dec. 25, 2010' Process Flow-Through: 0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Process Flow-Through: 0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) nabi-20120630.xml nabi-20120630.xsd nabi-20120630_cal.xml nabi-20120630_def.xml nabi-20120630_lab.xml nabi-20120630_pre.xml true true XML 45 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Company Overview (Details Textual) (USD $)
1 Months Ended 6 Months Ended 6 Months Ended 1 Months Ended 12 Months Ended 6 Months Ended 6 Months Ended 6 Months Ended

Jul. 31, 2012

Jun. 30, 2012

Clinical_trial

Dec. 31, 2011

Jun. 25, 2011

Dec. 25, 2010

Jun. 30, 2012

Nabi [Member]

Jun. 30, 2012

Biota [Member]

Jun. 30, 2012

NicVAX [Member]

Clinical_trial

Jun. 30, 2012

NicVAX [Member]

Develop Next-Generation [Member]

Nov. 30, 2009

PentaStaph [Member]

Dec. 31, 2006

PhosLo [Member]

Jun. 30, 2012

Maximum [Member]

Jul. 31, 2012

Maximum [Member]

Jun. 30, 2012

Maximum [Member]

NicVAX [Member]

Jun. 30, 2012

Minimum [Member]

Jul. 31, 2012

Minimum [Member]

Jun. 30, 2012

Minimum [Member]

NicVAX [Member]

Company Overview (Textual) [Abstract]

Cash and cash equivalents $ 92,649,000 $ 94,310,000 $ 86,618,000 $ 53,564,000 $ 92,600,000

Shares Exchanged 0.669212231

Ownership Percentage 26.00% 74.00%

Amount of cash to be returned 29,000,000 25,000,000

Number of authorized Shares 200,000,000

Stock repurchase program price per share of common stock $ 1.72 $ 1.58

Initial payment received 40,000,000

Additional fee amount on exercise of options 290,000,000

Percent increase in royalty payments 7.00% 7.00% 5.00% 5.00%

Annual sales targets 600,000,000 600,000,000 300,000,000 300,000,000

Total consideration received for selling the assets of the vaccine products 46,000,000

Upfront payment received on the consideration amount 20,000,000

Amount receivable upon achievement of milestones 26,000,000

Additional contingent milestone payments 2,500,000

Royalty payments 65,000,000

Base amount 32,000,000

Period of base amount 10 years

Company Overview (Additional Textual) [Abstract]

Excess cash 54,000,000

Amount paid to shareholders tendering shares 24,400,000

Net closing cash balance 54,000,000

Number of shares repurchased 14,547,996

Total value of shares repurchased 24,400,000

Average price paid per share for repurchase $ 1.68

Number of phase III clinical trials 2 2

Payments related to trial-related milestones 47,000,000 47,000,000

Payments related to regulatory approval 34,000,000 34,000,000

Payments related to annual sales $ 209,000,000 $ 209,000,000

X

- Definition

Additional contingent milestone payments under sale agreement.

+ References

No definition available.

+ Details

Name: nabi_AdditionalContingentMilestonePaymentsUnderSaleAgreement

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount paid to shareholders tendering shares.

+ References

No definition available.

+ Details

Name: nabi_AmountPaidToShareholdersTenderingShares

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Annual sales targets.

+ References

No definition available.

+ Details

Name: nabi_AnnualSalesTargets

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Base amount of operation.

+ References

No definition available.

+ Details

Name: nabi_BaseAmountOfOperation

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: nabi_CompanyOverviewAdditionalTextualAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: nabi_CompanyOverviewTextualAbstract

Namespace Prefix: nabi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Development arrangements, consideration received.

+ References

No definition available.

+ Details

Name: nabi_DevelopmentArrangementsConsiderationReceived

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Development arrangements, contingent consideration, potential cash payment.

+ References

No definition available.

+ Details

Name: nabi_DevelopmentArrangementsContingentConsiderationPotentialCashPayment

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Development arrangements, option fee received on exercise of options.

+ References

No definition available.

+ Details

Name: nabi_DevelopmentArrangementsOptionFeeReceivedOnExerciseOfOptions

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Development arrangements, upfront non-refundable fee received.

+ References

No definition available.

+ Details

Name: nabi_DevelopmentArrangementsUpfrontNonRefundableFeeReceived

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Development arrangements, upfront payment received.

+ References

No definition available.

+ Details

Name: nabi_DevelopmentArrangementsUpfrontPaymentReceived

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Estimated cash to be returned to company.

+ References

No definition available.

+ Details

Name: nabi_EstimatedCashToBeReturnedToCompany

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Maximum amount required for satisfying and reserving for outstanding liabilities.

+ References

No definition available.

+ Details

Name: nabi_MaximumAmountRequiredForSatisfyingAndReservingForOutstandingLiabilities

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Maximum contingent amount to be received based on obtaining regulatory approval in certain major market countries.

+ References

No definition available.

+ Details

Name: nabi_MaximumContingentAmountToBeReceivedBasedOnObtainingRegulatoryApprovalInCertainMajorMarketCountries

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Maximum contingent amount to be received based on Phase II and Phase III clinical trial-related milestones.

+ References

No definition available.

+ Details

Name: nabi_MaximumContingentAmountToBeReceivedBasedOnPhaseTwoAndPhaseThreeClinicalTrialRelatedMilestones

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Maximum contingent amount to be received based on tiered annual sales of future generation candidates.

+ References

No definition available.

+ Details

Name: nabi_MaximumContingentAmountToBeReceivedBasedOnTieredAnnualSalesOfFutureGenerationCandidates

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Maximum royalty payments on annual sales of new formulation.

+ References

No definition available.

+ Details

Name: nabi_MaximumRoyaltyPaymentsOnAnnualSalesOfNewFormulation

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Minimum amount of net cash balance to consummate the Merger.

+ References

No definition available.

+ Details

Name: nabi_MinimumAmountOfNetCashBalanceToConsummateMerger

Namespace Prefix: nabi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of phase three clinical trials.

+ References

No definition available.

+ Details

Name: nabi_NumberOfPhaseThreeClinicalTrials

Namespace Prefix: nabi_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of annual net sales of future generation candidates.

+ References

No definition available.

+ Details

Name: nabi_PercentageOfAnnualNetSalesOfFutureGenerationCandidates

Namespace Prefix: nabi_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of common stock owned by shareholders.

+ References

No definition available.

+ Details

Name: nabi_PercentageOfCommonStockOwnedByShareholders

Namespace Prefix: nabi_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Period for receipts under sale agreement.

+ References

No definition available.

+ Details

Name: nabi_PeriodForReceiptsUnderSaleAgreement

Namespace Prefix: nabi_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Required number of authorized shares as per merger agreement.

+ References

No definition available.

+ Details

Name: nabi_RequiredNumberOfAuthorizedSharesAsPerMergerAgreement

Namespace Prefix: nabi_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Share exchange ratio.

+ References

No definition available.

+ Details

Name: nabi_ShareExchangeRatio

Namespace Prefix: nabi_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: instant

X

- Definition

Stock repurchase program price per share of common stock.

+ References

No definition available.

+ Details

Name: nabi_StockRepurchaseProgramPricePerShareOfCommonStock

Namespace Prefix: nabi_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total cost of shares repurchased divided by the total number of shares repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7

-Subparagraph b

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_TreasuryStockAcquiredAverageCostPerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares that have been repurchased during the period and are being held in treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7

-Subparagraph b

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Share Based Compensation (Details Textual) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 25, 2011	Jun. 30, 2012	Jun. 25, 2011
Share Based Compensation (Additional Textual) [Abstract]
Options granted to purchase			1,000
Exercise price of the options granted			$ 1.89
Average grant date fair value of options granted			$ 0.96
Share-based compensation expense	$ 0.7	$ 0.6	$ 1.6	$ 1.2
Minimum [Member]
Share Based Compensation (Textual) [Abstract]
Exercise period (in years) of options granted			1 year
Maximum [Member]
Share Based Compensation (Textual) [Abstract]
Exercise period (in years) of options granted			3 years

Share Based Compensation (Details 1)	6 Months Ended
Share Based Compensation (Details 1)	Jun. 30, 2012
Summary of Nonvested Restricted Stock Awards
Nonvested at December 31, 2011	405,977
Granted
Vested	(193,503)
Forfeited	(16,220)
Nonvested at June 30, 2012	196,254

Licenses and Royalty Arrangements (Details Textual) (USD $) In Millions, unless otherwise specified	6 Months Ended			1 Months Ended		6 Months Ended
	Jun. 30, 2012 Clinical_trial	Jun. 30, 2012 Maximum [Member]	Jun. 30, 2012 Minimum [Member]	Nov. 30, 2009 PentaStaph [Member]	Mar. 31, 2010 NicVAX [Member]	Jun. 30, 2012 NicVAX [Member] Clinical_trial	Jun. 30, 2012 NicVAX [Member] Develop Next-Generation [Member]	Jun. 30, 2012 NicVAX [Member] Maximum [Member]	Jun. 30, 2012 NicVAX [Member] Minimum [Member]
Licenses and Royalty Arrangements (Textual) [Abstract]
Total consideration received for selling the assets of the vaccine products				$ 46
Upfront payment received on the consideration amount				20
Amount receivable upon achievement of milestones				26
Initial payment received					40
Number of phase III clinical trials	2					2
Option not exercised by GSK, maximum possible milestones							290
Payments related to trial-related milestones	47					47
Payments related to regulatory approval	34					34
Payments related to annual sales	209						209
Percent increase in royalty payments		7.00%	5.00%					7.00%	5.00%
Annual sales targets		$ 600	$ 300					$ 600	$ 300
Expected continuance period of joint steering committee						190 months
End date of GSK upfront payment recognition	through December 2025					through December 2025

NOL Rights Agreement (Details)	6 Months Ended
NOL Rights Agreement (Details)	Jun. 30, 2012
NOL Rights Agreement (Additional Textual) [Abstract]
Terms of the rights agreement	Under the Rights Agreement, the Board of Directors declared a non-taxable dividend of one preferred share purchase right for each outstanding share of common stock to be distributed to stockholders of record on August 25, 2011. Concurrent with the signing of the Merger Agreement with Biota, Nabi and the rights agent amended the Rights Agreement to terminate the rights under the Rights Agreement.
Date of Adoption of stockholder Rights Agreement	Aug. 25, 2011
Preferred Stock [Member]
NOL Rights Agreement (Textual) [Abstract]
Non-Taxable Preferred Dividend Distribution, Record Date	Aug. 25, 2011

Condensed Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 92,649	$ 94,310
Marketable securities		2,079
Receivables		995
Prepaid expenses and other current assets	301	497
Total current assets	92,950	97,881
Property and equipment, net		84
Total assets	92,950	97,965
Current liabilities:
Accounts payable	75	146
Accrued expenses and other current liabilities	1,435	1,918
Deferred revenue	2,526	2,526
Liabilities of discontinued operations		1,662
Total current liabilities	4,036	6,252
Deferred revenue	31,579	32,842
Total liabilities	35,615	39,094
Stockholders' equity:
Convertible preferred stock
Common stock	6,357	6,359
Capital in excess of par value	374,792	373,157
Treasury stock	(92,567)	(92,567)
Accumulated deficit	(231,247)	(228,078)
Total stockholders' equity	57,335	58,871
Total liabilities and stockholders' equity	$ 92,950	$ 97,965

Available for Sale Investments (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Dec. 31, 2011
Estimated Fair Value of Available-for-Sale Short-Term Investments by Security Classification
Amortized Costs	$ 0	$ 2,079
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Estimated Fair Values	0	2,079
Government-sponsored securities [Member]
Estimated Fair Value of Available-for-Sale Short-Term Investments by Security Classification
Amortized Costs	0	993
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Estimated Fair Values	0	993
Corporate debt securities [Member]
Estimated Fair Value of Available-for-Sale Short-Term Investments by Security Classification
Amortized Costs	0	1,086
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Estimated Fair Values	$ 0	$ 1,086

Discounted Operations (Details Textual) (USD $) In Millions, unless otherwise specified	1 Months Ended
	Dec. 31, 2011
Discontinued Operations (Textual) [Abstract]
Estimated amounts due under pricing programs	$ 1.7

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2012	Aug. 03, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	NABI BIOPHARMACEUTICALS
Entity Central Index Key	0000072444
Document Type	10-Q
Document Period End Date	Jun. 30, 2012
Amendment Flag	false
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		28,328,389

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2012
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Principles of consolidation and presentation	Principles of consolidation: The condensed consolidated financial statements include the accounts of Nabi Biopharmaceuticals and our wholly-owned subsidiaries (referred to as “Nabi,” the “Company,” “us,” or “we” throughout this report). All significant inter-company accounts and transactions are eliminated in consolidation. All of our wholly-owned subsidiaries are dormant or are otherwise non-operative.
Accounting estimates	Accounting estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period, including such amounts related to discontinued operations. Actual results could differ from those estimates.
Fiscal year periods	Fiscal year periods: Historically, our fiscal year ended on the last Saturday of December. Consequently, we periodically had a 53-week fiscal year. In 2012, we amended our By-Laws to change our fiscal year end to a calendar basis; this prospective change did not have a material impact on our financial condition and results of operations for any periods presented.
Financial instruments	Financial instruments: The carrying amounts of financial instruments including cash equivalents, marketable securities, accounts receivable and accounts payable approximated fair value as of June 30, 2012 and December 31, 2011, because of the relatively short-term maturity of these instruments.
Cash, cash equivalents and marketable securities	Cash, cash equivalents and marketable securities: Cash equivalents consist of investments in low risk, highly liquid securities with original maturities of 90 days or less. Marketable securities consist of low risk fixed income investment instruments such as government obligations, government agency and Federal Deposit Insurance Corporation backed notes with maturities typically less than eighteen months. Marketable securities are classified as available-for-sale and recorded at fair value; unrealized gains and losses on those securities are reflected in other comprehensive income (loss). We assess the risk of impairment related to securities held in our investment portfolio on a regular basis and noted no “permanent” or “other than temporary” impairment during the first six months of 2012. Our investment policies and procedures are reviewed periodically by management and our audit committee to minimize credit risk.
Concentration of credit risk	Concentration of credit risk: Financial instruments that potentially subject us to credit and liquidity risk consist primarily of cash, marketable securities and receivables. The Company maintains cash deposits at major financial institutions with high credit quality. The Company’s operating accounts exceeded the Federal Deposit Insurance Corporation limits of $250,000. Cash equivalents primarily consist of short-term money market funds, which are deposited with reputable financial institutions. At June 30, 2012, the Company’s marketable investments consist primarily of United States government agency securities as well as corporate debt securities and commercial paper. The Company’s investment policy limits investments to only investment-grade securities with the objective to preserve principal and maintain sufficient liquidity to meet operational objectives.
Revenue recognition	Revenue recognition: Our revenue generating arrangements may include multiple elements and deliverables, including licenses, options, research and development activities, participation on joint steering committees and contract manufacturing, among other elements. When we determine that an element has stand-alone value to our customer, we allocate a portion of the total contract price to that element based on its relative selling price, determined pursuant to a selling price hierarchy, and recognize revenue for that element according to its characteristics. Revenue consists of license fees, milestone payments, and payments for contractual services. License fees received that do not have stand-alone value are initially recorded as deferred revenue, and are subsequently recognized as revenue ratably over the period of our participation on joint steering committees. The joint steering committee established in connection with our option and license agreement with GSK related to NicVAX is currently expected to operate for 190 months from the date of the agreement (or through December 2025). Our efforts under the joint steering committee established in connection with our asset purchase agreement with GSK related to PentaStaph were completed in the second quarter of 2011. For milestones that are deemed substantive, we recognize the contingent revenue when: (i) the milestones have been achieved; (ii) no further performance obligations with respect to the milestones exist; and (iii) collection is reasonably assured. A milestone is considered substantive if all of the following conditions are met: (i) the milestone is nonrefundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone appears reasonable in relation to the effort expended with the other milestones in the arrangement and the related risk associated with achievement of the milestone. If a milestone is deemed not to be substantive, the Company would recognize the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment will be deferred and recognized as revenue as the Company completes its performance obligations. Payments for contractual services are recognized as revenue when earned, typically when the services are rendered. We analyze cost reimbursable grants and contracts to determine whether we should report such reimbursements as revenue or as an offset to research and development expenses incurred.
Collaborative arrangements	Collaborative arrangements: We are an active participant with exposure to significant risks and rewards of commercialization relating to the development of NicVAX and future generation nicotine vaccines based on NicVAX technology. For costs incurred and revenues generated from third parties where we are deemed to be the principal participant, we recognize revenues and costs using the gross basis of accounting; otherwise we use the net basis of accounting.
Research and development expenses	Research and development expenses: Research and development costs are expensed as incurred; advanced payments are deferred and subsequently expensed over the period of performance. Research and development expenses include direct labor costs as well as the costs of contractors and other direct and indirect expenses (including an allocation of the costs of facilities). We expense amounts payable to third parties under collaborative product development agreements at the earlier of the milestone achievement or as payments become contractually due. In the first six months of 2011 we recorded approximately $0.3 million of cost reimbursements from government grants as an offset to research and development expenses (none during 2012).
Income (loss) per share	Income (loss) per share: Basic income (loss) per share is computed by dividing consolidated net income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of stock options. The dilutive impact of dilutive potential common shares resulting from stock options is determined by applying the treasury stock method. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the three- and six month periods ended June 30, 2012 and June 25, 2011. The Company’s unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator. A total of approximately 3.7 million potentially dilutive shares related to stock options have been excluded in the calculation of diluted net loss per share for the three- and six month periods ended June 30, 2012 and a total of approximately 4.6 million potentially dilutive shares for the three- and six periods ended June 25, 2011, as their inclusion would be anti-dilutive.
Share-based compensation	Share-based compensation: We expense the estimated fair value of share-based awards made in exchange for employee services over the requisite employee service period. Share-based compensation cost for stock options is determined at the grant date using an option pricing model; share-based compensation cost for restricted stock is determined at the grant date based on the closing price of our common stock on that date. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period.
Income taxes	Income taxes: We account for income taxes using the asset and liability approach, which requires, among other things, recognition of future tax benefits and liabilities measured at enacted rates attributable to temporary differences between financial statement and income tax bases of assets and liabilities and to tax net operating loss carryforwards to the extent that realization of these benefits is more likely than not. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year. We periodically evaluate the realizability of our net deferred tax assets; a valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. We recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits, and our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. We consider discontinued operations for purposes of determining the amount of tax benefits that result from a loss from continuing operations.
Segment information	Segment information: We currently operate in a single business segment.
Recent accounting standards	Recent accounting standards: In June 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2011-05, Presentation of Comprehensive Income. ASU 2011-05 revises the manner in which entities present comprehensive income in their financial statements. The new guidance removes the presentation options in Accounting Standards Codification 220 and requires entities to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements. ASU 2011-05 did not change the items that must be reported in other comprehensive income. The Company adopted the provisions of ASU 2011-05 in the first quarter of 2012. As the Company’s net loss was the same as comprehensive loss, the Company did not include a statement of comprehensive loss.
New accounting pronouncements	New accounting pronouncements: We have evaluated all Accounting Standards Updates through the date the financial statements were issued and believe the adoption of these will not have a material impact to our results of operations or financial position.

Treasury Stock (Details Textual) (USD $) In Millions, except Share data, unless otherwise specified	1 Months Ended
	Jul. 31, 2012
Treasury Stock (Additional Textual) [Abstract]
Number of shares repurchased	14,547,996
Total value of shares repurchased	$ 24.4
Average price paid per share for repurchase	$ 1.68
Minimum [Member]
Treasury Stock (Textual) [Abstract]
Common stock price per share	$ 1.58
Maximum [Member]
Treasury Stock (Textual) [Abstract]
Common stock price per share	$ 1.72

Share Based Compensation (Details)	6 Months Ended
Share Based Compensation (Details)	Jun. 30, 2012
Summary of option activity under our stock compensation plans
Outstanding at December 31, 2011	4,053,652
Granted	1,000
Exercised
Forfeited	(64,198)
Expired	(325,253)
Outstanding at June 30, 2012	3,665,201
Exercisable at June 30, 2012	3,121,084

Company Overview (Details Textual) (USD $)	1 Months Ended	6 Months Ended						6 Months Ended		1 Months Ended	12 Months Ended	6 Months Ended		6 Months Ended			6 Months Ended
Company Overview (Details Textual) (USD $)	Jul. 31, 2012	Jun. 30, 2012 Clinical_trial	Dec. 31, 2011	Jun. 25, 2011	Dec. 25, 2010	Jun. 30, 2012 Nabi [Member]	Jun. 30, 2012 Biota [Member]	Jun. 30, 2012 NicVAX [Member] Clinical_trial	Jun. 30, 2012 NicVAX [Member] Develop Next-Generation [Member]	Nov. 30, 2009 PentaStaph [Member]	Dec. 31, 2006 PhosLo [Member]	Jun. 30, 2012 Maximum [Member]	Jul. 31, 2012 Maximum [Member]	Jun. 30, 2012 Maximum [Member] NicVAX [Member]	Jun. 30, 2012 Minimum [Member]	Jul. 31, 2012 Minimum [Member]	Jun. 30, 2012 Minimum [Member] NicVAX [Member]
Company Overview (Textual) [Abstract]
Cash and cash equivalents		$ 92,649,000	$ 94,310,000	$ 86,618,000	$ 53,564,000			$ 92,600,000
Shares Exchanged								0.669212231
Ownership Percentage						26.00%	74.00%
Amount of cash to be returned												29,000,000			25,000,000
Number of authorized Shares						200,000,000
Stock repurchase program price per share of common stock													$ 1.72			$ 1.58
Initial payment received								40,000,000
Additional fee amount on exercise of options									290,000,000
Percent increase in royalty payments												7.00%		7.00%	5.00%		5.00%
Annual sales targets												600,000,000		600,000,000	300,000,000		300,000,000
Total consideration received for selling the assets of the vaccine products										46,000,000
Upfront payment received on the consideration amount										20,000,000
Amount receivable upon achievement of milestones										26,000,000
Additional contingent milestone payments											2,500,000
Royalty payments											65,000,000
Base amount											32,000,000
Period of base amount											10 years
Company Overview (Additional Textual) [Abstract]
Excess cash		54,000,000
Amount paid to shareholders tendering shares	24,400,000
Net closing cash balance		54,000,000
Number of shares repurchased	14,547,996
Total value of shares repurchased	24,400,000
Average price paid per share for repurchase	$ 1.68
Number of phase III clinical trials		2						2
Payments related to trial-related milestones		47,000,000						47,000,000
Payments related to regulatory approval		34,000,000						34,000,000
Payments related to annual sales		$ 209,000,000							$ 209,000,000